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SUMMARY
Chimera: (Biology) An organism consisting of at ieast two geneticaliy 
different kinds of tissue as a resuit of mutation, grafting, etc.
Coilins English Dictionary
This thesis has set out to investigate the regenerative potential of peripheral nerve 
allografting in a rodent model. In particular, the strategy of reconstructing a nerve 
defect using a novel chimeric graft of mixed antigenicity {Sandwich graft) was 
explored as an alternative to autografting or immunosuppression.
Peripheral nerve injury produces significant individual and community morbidity. 
Despite technical and surgical advances, even the results from urgent repair of 
single modality nerves are sub-optimal. This situation is compounded when nerve 
structure is lost and a bridging conduit Is required to reconstruct the defect. While 
many organic and inorganic materials have been investigated, autografting 
remains the mainstay of current clinical practice. However, suitable autografts are 
in limited supply and associated with donor site morbidity.
Like autografts, peripheral nerve allografts (PNAG) possess all the features 
required of an ideal nerve conduit, especially Schwann cells. Studies with acellular 
conduits have shown the addition of Schwann cells is advantageous to 
regeneration. However, immunological rejection of antigenic Schwann cells within 
nerve allografts renders the graft acellular, inhibiting regeneration. 
Immunosuppression preserves allogenic Schwann cells and results in regeneration 
equivalent to autografts. But immunosuppressants are associated with serious side 
effects such that their use in peripheral nerve injuries is deemed unethical.
Temporary immunosuppression has been proposed as a solution to this problem 
until the non-antigenic host axon regeneration is established. However this has 
produced conflicting results although an axonopathic process following drug 
withdrawal is acknowledged.
The aims of this project were firstly to assess the regenerative potential of non- 
immunosuppressed PNAGs. The hypothesis being that rejection would produce 
acellular grafts as donor Schwann cells were destroyed. Host Schwann cells are 
known to repopulate acellular conduits from adjacent nerve ends. By using a 
chimeric Sandwich graft, the second aim of the project was to assess whether 
augmenting host Schwann cell graft repopulation could improve axonal 
regeneration and reduce immunosuppressant requirements.
A clinically reproducible chimeric construct of a nerve allograft with an intervening 
segment of autologous nerve (a Sandwich graft) was used to bridge a standard 
traumatic nerve gap within the experimental groups. Comparisons were made 
between simple and sandwich grafts composed of autologous, isogeneic and 
allogenic nerves split into immunosuppressed and non-immunosuppressed limbs. 
Incompatible rat strains were employed using Cyclosporin (CyA) as the sole 
immunosuppressant. Qualitative and quantitative analyses of 
Immunohistochemical and conventional histological specimens, along with 
measurement of Gastrocnemius muscle mass, were used to assess the outcome 
of nerve regeneration.
Analyses were undertaken within the early and late regeneration periods of 21 
days and 32 weeks respectively. Immunohistochemistry and conventional 
histological techniques were employed, along with measurements of muscle mass 
recovery to indicate target organ reinnervation. Cyclosporin (CyA) was the sole 
immunosuppressants used.
Non-immunosuppressed PNAGs were shown to support less early axonal 
regeneration than their immunosuppressed counterparts and non-allogenic 
controls. This was associated with a reduction in Schwann cells and increased 
inflammation Indicating rejection. However, the pattern of regeneration followed 
that of the other groups and improved with time. Sandwich allografting was 
associated with improved axonal regeneration, increased Schwann cells and less 
inflammation suggesting reduced antigenicity of the sandwich construct. The 
increased neurorrhaphies compared to simple grafts did not appear deleterious.
Long-term myelinated nerve counts and target organ reinnervation produced 
similar results from all experimental groups regardless of immunosuppression. This 
work validates the use of a chimeric sandwich graft within this model. The addition 
of a depot of host Schwann cells within an allograft without immunosuppression 
produces similar regeneration to non-allogenic grafts and reduces the early delay 
period associated with rejection.
Further analysis of the formulations of CyA used indicated that although oily and 
parenteral CyA did adequately immunosuppress the allografts, the results from 
parenteral CyA were marginally better. Also, CyA use did contribute to model 
morbidity and mortality within these experiments.
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1.1 INTRODUCTION
A significant proportion of the reconstructive surgeon's workload involves dealing 
with trauma. According to The British Association of Plastic Surgeons, trauma 
comprises a third of their members’ cases, with upper limb trauma forming the 
largest proportion of this group within Plastic Surgery practice  ^ . Within this group 
there exists a population of patients who have sustained nerve injuries, either in 
isolation, or as part of a more complex destructive picture. With the addition of 
nerve injuries resulting from trauma to other body parts, whether accidental or as 
part of planned surgical resections, a sizeable source of community morbidity is 
identified.
The average number of patients with digital nerve injuries attending a Plastic 
Surgery unit serving a population of 1.2 million is between two and three hundred 
per year (Personal audit). Economically this group require specialist treatment for 
their condition and rehabilitation. Some may be permanently disabled and unable 
to work. Pathological conditions affecting the peripheral nervous system (as 
opposed to central and generalised conditions) are rarely life threatening, but are 
certainly life altering.
The peripheral nerve is a recognised anatomical structure whose physical integrity 
can be repaired, but unlike other organic conduit structures, the repaired nerve 
may not function normally afterwards despite a surgically accurate repair. 
Neurones are known to be sensitive to even minor degrees of assault . The 
most minor type of injury results in neuropraxia, or localised conduction block 
without any break in the nerve structure . This is the only type of injury where 
normal recovery of function is seen. Why this should be has been the focus of 
much research ^ .
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Since the earliest recordings of written medicine, when Galen (130-201 AD) 
recognised nerves as distinct anatomical structures, and not variants of tendons, 
their susceptibility to injury and loss of function has been noted. Early physicians 
also believed that divided nerves were incapable of uniting, and nerve injury and 
manipulation produced convulsions  ^ . Historical reports of attempts to repair 
nerves identify that suturing and agglutination were sporadically favoured ® . 
Paulus Aeginata is credited with the first recorded suture coaptation, in 
combination with agglutination in the 7^*^  century  ^ . Arabic physicians attempted 
nerve repairs by suturing in the 9^*^  and 10^  ^ centuries ® , while Roger of Parma in 
the 13^ *^  century tried egg albumin ® . The reports of Guy de Chauliac in the 14*^  ^
century observed that in cases of nerve suture in young patients: “afterwards one 
could not believe that they had been cut” ® . The superior regenerative potential of 
the young is recognised today. However for most of the last millenium there has 
been little progress in the repair of nerve injuries. Even up to the 19^  ^century it was 
commonly believed that manipulation of severed nerve ends led to convulsions 
such that repair was attempted by approximation of surrounding tissues (repair 
cum carne) . By the end of the 19^  ^ century a perceived increase of interest in 
nerve pathophyiology is evident from the available medical literature on the 
subject. The first description of repair by epineurial suture is attributed to Hueter in 
1873 . This technique, although refined, is still practiced today. Some of the
reasons for poor results from suturing in the past are recognised now as scarring at 
the coaptations, reactions to sutures and foreign bodies, infection and complication 
from poor surgical technique. Modern developments have led to improvements in 
some of these areas, however in their book of 1994, MacKinnon and Dellon 
reported that even with digital nerve repairs in the post-microsurgicai era, 89% of 
patients reported abnormal return of sensation. With more proximal injuries 
sensation and motor function showed more imperfect return . While medical 
literature is littered by reports of successful interventions improving nerve 
regeneration, the stark truth is that none produce results approaching the 
functional capabilities of intact nerve, including distal injuries in single modality 
nerves .
19
1.2 NERVE INJURY AND REGENERATION
Following nerve injury, a process of regeneration and repair is initiated. Unless the 
injury is of a Sunderland Grade I , all other degrees of damage require repair 
processes involving the many cell types which make-up an anatomical peripheral 
nerve. The most serious injury is where nerve physical continuity is broken, 
resulting in a simple laceration or loss of a portion of nerve substance. However, 
many injuries show a mixed picture of nerve structural damage.
The structural elements of peripheral nerves include the neuronal axons, Schwann 
cells and their myelin sheaths, connective tissues forming the epi-, peri- and 
endoneurium, blood vessels, lymphatics and immunocompetent cells. All of these 
elements function in concert but the relative importance of each may change after 
injury and these variations can have positive and negative effects on the 
regenerative processes.
1.2.1 Neuronal response to injury
With nerve transection, conduction is interrupted. The cell body exhibits 
chromatolysis indicating a switch of metabolic function from transmission to one of 
manufacture, with an increase in the synthesis of regeneration associated proteins 
such as tubulin and actin to facilitate regeneration and repair . However, not all 
neurons effect this transition. Significant numbers of neurons undergo cell death 
which has been reported to between 20 - 50% in studies of dorsal root ganglia 
(DRG) neurons post sciatic nerve transection . Extrapolation of this fact
indicates that post regeneration function is never going to be the same as normal 
nerve until the mechanisms surrounding apoptosis are identified and reversed.
Following nerve injury, the severed ends retract exposing vascular endothelium 
which stimulates coagulation with reduction of haemorrhage and relative ischaemia
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at both cut nerve ends. Endothelial exposure, along with axon exposure and 
axoplasm leak, compounded by recoil of the perineurial connective tissues results 
in fusing of the axonal membranes along with initiation of the acute inflammatory 
response . Local oedema results in swelling and compounds local ischaemia. 
Destruction by free radicals is facilitated by calcium ion influx into the axoplasm 
which activates the necessary proteases . The active production of cytokines 
by the intrinsic cell population signals further influx of circulating immunocompetent 
cells and amplification of the cascade reactions in progress . Macrophage 
recruitment is essential to effective Wallerian degeneration , with
degradation of the distal axon resulting from release of myelinolytic neutral 
proteases .
The distal nerve, and proximal nerve stump up to the last Node of Ranvier undergo 
Wallerian degeneration peaking at 3 days after injury and lasting for approximately 
2 weeks . Myelin is degraded after separation from the endoneurial tube and 
distal axon and phagocytosed along with axonal debris by macrophages and 
Schwann cells 4.14,31,32 yVallerian degeneration is also associated with Schwann 
cell proliferation which leaves this population aligned within the endoneurial tubes 
as bands of Büngner awaiting the regenerating axonal process 4^,31-33 y^e 
endoneurial tubes reduce their volume following clearance of axoplasm and 
myelin, and despite Schwann cell proliferation these tubes shrink if not 
reinnervated, narrowing by 80-90%, although remaining patent for some years 
. Deposition of new endoneurial collagen also affects the ability of the endoneurial 
tube to expand when reinnervated. These two factors result in axons of smaller 
diameter than in the uninjured nerve which affects conduction properties and 
function following regeneration. The parent axon and Schwann cells also influence 
this outcome .
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1.2.2 Axonal Regeneration
The axon regenerates by producing multiple sprouts . This is initiated within 
hours of the injury and established by 27 hours, although the controlling 
mechanisms are as yet unknown. Specialised growth cones are found at the 
tip of each sprout and support multiple motile filopodia , which respond to 
contact guidance cues . Cell adhesion molecules expressed by growth cones 
and Schwann cells are also important in the regeneration process . The 
neuron manufactures cell membrane proteins which axoplasmic flow delivers to the 
advancing growth cone and site of membrane addition 4^.26,31 ^^onal regeneration 
requires a suitable matrix or substrate, direction from guidance cues and the 
presence of trophic substances to support and direct regeneration. Schwann cells 
have been found to contribute in all these areas. Although the regeneration 
process is similar between species, these have different nerve regeneration rates, 
being 1-2mm per day in humans , and up to 3.5mm per day in rodents. 
Regeneration rate is also affected by scarring, distance from the cell body and age
36,42
Maturation of the axon continues behind the advancing growth cone with 
myelination of fibres and increasing axonal girth. The myelin sheath thickens with 
time, while non-myelinating axons form small groups within the folds of individual 
Schwann cells. With completion of end organ connections, a delay follows allowing 
functional maturation before conduction can be re-established 4^ -44 _
1.3 FACTORS AFFECTING REGENERATION
Rarely, injuries are simple and although regeneration has been established there 
are many variables which may affect the progress and result of nerve regeneration.
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Topographical orientation of two severed nerve ends is difficult to align accurately, 
especially if tissue has been lost. Axons are impossible to align with current 
technology, and made more difficult because of the plexus arrangement of axons 
within nerves  ^ . Also minimising surgical manipulation and thorough debridement 
of damaged tissue are all techniques known to minimise scarring in nerves as in 
other tissues .
The development of microsurgery, with its specialised instrumentation and 
magnification, has been paramount in improving the quality of neurorrhaphy 
attainable . However, it is obvious that a plateau has been reached with this 
technology while the ultimate aim of perfect nerve regeneration remains an 
unfulfilled goal.
The quality of the surgical repair certainly has a profound effect on the eventual 
outcome, possibly more important here than in other areas of reconstructive 
surgery . However as exact fascicle to fascicle coaptations are difficult, and 
certainly endoneurial tube to endoneurial tube coaptations are beyond the scope of 
current human endeavor other strategies have been assessed to improve 
regeneration.
Forssman suggested the concept of neurotrophism in1898 , while Cajal in the
1920’s suggested a neurotrophic influence played a part in the specificity of axonal 
regeneration . The first neurotrophic factor to be Isolated and defined in 1953 
was nerve growth factor (NGF) . Since then other neurotrophic factors such as 
neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-4/5) and brain derived neurotrophic 
factor (BDNF) and many more have been identified . With each, their varying 
actions in growth, regeneration and degeneration of the nervous system are being 
studied .
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1.4 NERVE GAPS AND CONDUITS
Nerve injury resulting in the loss of continuity of the structure can be repaired by a 
single coaptation. The problems of a single neurorrhaphy are multiplied when a 
portion of nerve is lost, and the gap has to be repaired using material which can 
support axonal regeneration.
The ideal conduit material should be readily available, biocompatible, 
biodegradable, supportive and protective of regeneration while also exhibiting good 
handling characteristics and be reproduceable in a variety of dimensions 
inexpensively. An internal structure to support regeneration is a desirable quality, 
as it would guide and improve regeneration.
Conduit materials can either be organic or inorganic. With increasing technology 
successive generations of scientists and surgeons have utilised and manipulated 
every conceivable material as potential nerve conduits . Lundborg has used 
silicone tubes clinically and also has found, along with other researchers, that 
the tube concept is also useful for studying regeneration and its influences ^’^ 2,55,56 
However, solid tubes block blood vessel in growth from the wound bed therefore 
they are only useful over short distances . Permeable conduit materials and 
meshes go some way to addressing these problems and are generally associated 
with improved regeneration . Synthetic tubes manufactured from biodegradable 
or organic components show more promise of fulfilling the criteria of the ideal 
conduit material. Some like RTFE (polytetrafluroethylene), polyglycoiic acid , 
PAN/PVC (acrylonitrile vinylchloride) , and PLC (poly (L-lactide-s-caprolactone) 
copolymer form hollow tubes, while others like fibronectin produce a mesh. 
Another synthetic conduit of interest is PHB (Polyhydroxybutyrate). Initial studies in 
animals have had sufficient beneficial results to initiate a clinical trial which is 
currently in progress.
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Non-neuronal glial cells migrate into the conduit material from both cut nerve ends 
supporting axon regeneration . This is therefore the limiting event as without 
the correct cell population and mix of factors provided by these cells, axonal 
development will be limited.
Organic materials have also been used as nerve conduits, including bone, arteries 
, veins , fallopian tube and muscle . The findings of cellular migration 
into acellular conduits of any type bring about the conclusion that Schwann cells 
are an essential component for axonal regeneration . For this reason, (as
well as providing a basal lamina scaffold) peripheral nerve grafts are used as the 
standard material to repair nerve gaps clinically, providing the most successful 
conduit material for the reconstruction of peripheral nerves . Nerve autografts 
are the gold standard against which all other conduits and methods to repair nerve 
gaps are measured .
1.5 NERVE AUTOGRAFTS
Interest in peripheral nerve autografting followed the clinical case reported by 
Phillpeaux and Vulpian in 1870. This case of successful regeneration following 
lingual nerve repair using a graft of hypoglassal nerve in a dog is the first attributed 
to the “modern” era of medical history . Following on from both World Wars in the 
20^  ^ century there was increasing interest in all aspects of nerve injury, repair and 
grafting . The increased use of nerve grafts during World War II, the general 
concensus was that clinical results were poor . Attempts were made to 
improve the outcome of autografting with Seddon and Sanders in the 1940s 
advocated the use of cabled nerve grafts to avoid the central necrosis observed in 
trunk nerve grafts . However, despite extensive reviews of experience over this 
period the technique remained peripheral in the management of nerve injuries . 
Since then improvements in surgical technique and magnification, along with
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greater understanding of graft physiology and non physiological tension across the 
repairs have improved the results from grafting 3,11.46-48,86.88
Studies on nerve autografts have confirmed that the structure and the presence of 
Schwann cells are required for optimal axonal regeneration across the graft 
20,34,52,75,78,89,90 graft provides an ideal structure for axonal regeneration with a 
basal lamina scaffold and extracellular matrix for contact guidance .
Schwann cells supply neurotrophic factors 33.75.92,93 along with macrophages 
19,25,27,94 prepare the endoneurial tubes for reinnervation, while cell adhesion 
molecules on the basal lamina and perineural cell surfaces aid axonal elongation 
38,39 However, the main problem associated with nerve autografts is donor site 
morbidity. There is also a finite limit to the amount of nerve any patient or surgeon 
is prepared to sacrifice to reconstruct a damaged nerve, especially when the 
results are likely to be suboptimal .
1.6 GRAFTING ACROSS IMMUNOLOGICAL BARRIERS
Interest in nerve allografting and xenografting has mirrored the historical 
developments of nerve autografting. The high demand for nerve reconstruction 
during periods of conflict, and the obvious limits of autograft supply fuelled this 
demand.
1.6.1 Xenografts
Ten years following Philipeaux and Vulpian’s autograft report, in 1880, Gluck 
claimed success following a xenograft of 3cm fowl nerve to rabbit . Follow up 
consisted of a pinch test resulting in a distal muscle twitch at 11 days. A repeat of 
the experiment by Johnson in 1919 showed that while the xenograft had joined 
with the donor, the nerve did not function at 23 days . This identifies a problem 
with historical reporting of nerve repair techniques in that more emphasis was
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placed on whether the nerve had healed than on the functional outcome . 
There was often no control limb to the experiments and variable standards of 
reporting.
The two world wars stimulated research into many experimental nerve conduits 
including encouraging previously discouraged investigators to continue 
xenografting. Early attempts to reduce the host response to the xenograft included 
fixation in alcohol storage in physiological saline and petroleum . These methods 
predated widespread knowledge of immunology, therefore it is not surprising that 
xenografts failed.
Sanders and Young in 1942 silenced xenograft research for decades when their 
experiments found no value in fresh, stored or alcohol fixed nerve xenografts. They 
concluded that xenografts were treated as foreign bodies by the host and were 
ulitmately replaced . Marmor resurrected the xenograft debate in the 1960s, 
reporting variable results in dog, rat and guinea pig models using xenografts 
pretreated by freezing and irradiation sometimes in combination with silastin or 
vascular cuffs. Variable success was also noted using azathioprine 
immunosuppression . However the poor results achieved by these
pretreatment methods in nerve allografts contributed to the halting of nerve
xenograft work except in regard to more basic areas such as Schwann cell and 
myelin responses °^3,io3
The experience with nerve xenografting should not be viewed in isolation. 
Throughout the 1960’s in the USA clinical solid organ xenografts were courting 
controversy in the full glare of a global media. Although not mentioned in the 
scientific literature, the reported cost both professionally and personally to the 
surgeons involved in these cases must have influenced research in nerve 
xenotransplantion. Nerve xenotransplantation, after all was not being advocated In
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pathological states where life was at risk to balance the ethical and moral 
dilemmas which were the Pandora's box of xenotransplantation then and now.
Recent advances in genetics have reopened the xenotransplantation debate as a 
potential source of donor organs . David White with Imutran and Alexion 
Pharmaceuticals in the USA are pioneering work with transgenic pigs to block the 
complement cascade . No work has yet been undertaken with transgenic
nerve transplants.
1.6.2 Allografts
Interest in nerve allografts has as long a history as nerve conduits and stems from 
the same reasons: significant loss of structure requiring reconstruction to restore 
continuity. Nerve allografts seem a logical step from nerve autografts in humans, 
where anatomical nerves could be replaced like for like.
Albert is credited with the first human fresh nerve allograft in 1885. He harvested 
nerves from an amputated lower limb to repair median and ulnar nerves in two 
patients . Follow up was limited but Huber reported that one graft was necrotic 
and removed at 6 days . Mayo-Robson in1889 claimed success in one patient 
who had achieved normal sensory recovery by 36 hours and motor recovery by 3 
years following a 3cm allograft . Duel in 1934 reported 6 cases of 2-4cm thin 
nerve allografts to facial nerves, all producing excellent outcomes . However the 
majority of investigators noted failures. Sander’s review of 1942 showed in the 42 
clinical cases undertaken by that time, only 8 had any improvement . By 1950 
most commentators were aware of the poor results and the pathological features of 
necrosis and cicatrization within nerve allografts such that clinical nerve allografting 
was condemned .
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Animal experimentation with peripheral nerve allografts (PNAG) continued in 
parallel with the clinical cases. Forsmann claimed PNAGs were more sucessful 
than xenografts in 1898 . In the hundred years following this, the vast majority of
investigators studying fresh PNAGs reported results of failure or rejection . Some 
successes were claimed. Huber in 1919 and 1920 reported qualitatively excellent 
results based on histological features at 83 days with rabbit allografts .
Bentley in 1936 and 1940 with cat and primate allografts noted distal regeneration 
with histological and electrophysiological assessments at up to 500 days .
Interpretation of results from allograft studies can be difficult as many experiments 
predate an understanding of immunology.
In 1915, Ingebrigsten observed an allograft lymphocyte infiltrate around 11-12 days 
and was the first investigator to attribute his findings to the host’s immune 
response . This reaction was more marked than that seen in autografts and 
caused Schwann cell destruction. Wallerian degeneration was similar in autografts 
and thin allografts, but not in thick allografts . Sanders also associated larger 
PNAGs with greater rejection , and Levinthal noted results equivalent to 
autografts with fascicular allografts but not with whole PNAGs . Zalewski 
demonstrated regeneration across short but not long allografts with minor 
histocompatibility disparity, while no regeneration occurred with MHC disparity 
despite graft length 2^2-126
Timing also seemed to be an issue. Regenerating axons were identified within 
allografts and distal host nerves but their appearance was delayed compared to 
autografts 116,117,127-129 ^ rabbit study, Gutmann (1942) blamed an early host
reaction to the allograft for the delay and subsequent poor function despite 
identification of axonal regeneration . While in 1943 he observed delayed 
regeneration in the same model but results otherwise were similar to autografts .
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Davis also noted conflicting results from two similar experiments. In 1945 he found 
consistently inferior results with allografts when compared with autografts and 
simple coaptations in a feline model, including greater fibrosis, muscle atrophy and 
trophic ulcers . His 1950 study however describes excellent results although 
central allograft necrosis was identified . The main difference between the 
studies was that the former lasted up to four months and the latter up to one year. 
Of all the studies described, despite their flaws, generally the ones showing the 
most promising allograft results were undertaken over longer time periods than the 
majority of studies showing rejection e.g. Bentley 1940 -  200 days ; Gutmann 
1942 -  500 days ; Bain and Fish 1992 -  12 months. Bain and Fish conducted 
primate studies and noted rejection at 6 months with equivalent results to 
autografts by 12 months 132,132,133
Like Gutmann, Midha demonstrated equivalent numbers of axons in PNAGs and 
autografts but poorer functional outcome . An immunological explanation was 
the most likely cause of this and the overwhelming number of failed allografts. This 
was confirmed by evidence showing superior regeneration from related donors and 
recipients. Hirasawa observed regeneration was superior in littermates and parents 
of his rabbit model than in unrelated animals . Singh matched outbred dogs and 
reported the degree of MHO difference led to PNAG rejection rather than minor 
histocompatibilty disparity 13®-137  ^ while Schaller also noted that rejection and 
quality of regeneration varied with the degree of histocompatibility disparity in an 
inbred rat model .
1.6.2.1 Immunology and graft rejection
Rejection was not understood as a concept until the immune system had been 
identified as the source of the process that destroyed “foreign” tissues. The use of 
donor tissues was viewed as a potential therapy for many life threatening 
conditions. Technically, transplantation has been achievable for many structures 
for decades. However the usual response of recipients was that they mounted an
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inflammatory-type reaction which destroyed the transplanted tissue. The host 
organism rejected it.
While investigating the use of allogenic skin in burned patients in Glasgow during 
World War II, Tom Gibson, a pioneer in Plastic Surgery, observed accelerated 
reactions following the second application of allogenic skin from the same donor. 
Working with Peter Medawar, a pioneer of immunology, Gibson and Medawar 
confirmed rejection occurred more rapidly and aggressively during this “second- 
set” reaction. This observation is generally seen as being the cornerstone of the 
development of immunology. Medawar subsequently identified that foreign tissue 
was destroyed by the host following an active systemic immune reaction, exhibiting 
both specificity and memory against the donor tissue . Following on from this, 
relatedness between host and donor was seen to be paramount to graft survival 
and culminated in the present concept that rejection is due to disparity of major 
histocompatibility (MHC) loci between the donor and recipient tissue, plus any 
tissue-specific or minor histocompatibility loci .
Allorecognition is the first stage in rejection, which can be direct or indirect. In the 
former, host T lymphocytes (CD4+) are capable of directly recognising allogeneic 
class II MHC molecules. For indirect allorecognition the host antigen presenting 
cells have to process and present donor MHC molecules Further signals
from host and donor antigen presenting cells may be required for T cell activation. 
T -ce ll mediated immune reactions (cellular immunity) are believed to feature most 
prominently in rejection but antibody-mediated reactions (humoral immunity) are 
also implicated . These two systems form the effector host response. The T cell 
sub-sets CD4+ (T helper cells) and CD8+ (cytotoxic T cells) interact with antigen 
associated with MHC class II and I respectively. Class II mechanisms are more 
readily implicated in rejection.
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Once activated, CD4+ cells secrete cytokines which initiate cascade reactions 
signalling graft infiltration by other immunocompetent cells e.g. macrophages 
Cytokines are also involved in upregulation of MHC expression amplifying the 
immune reaction further . Acute rejection is mainly mediated by cellular
immunity with the graft infiltrated by CD4+ and CD8+ cells, along with 
macrophages, and subjected to direct cytotoxic cell insults and from secondary 
mediators of inflammation . Antibodies may also be involved against blood 
group and MHC antigens. These cause complement-mediated lysis or damage via 
activation of cytotoxic macrophages and lymphocytes . Antibody reactions 
are most problematic when the graft is directly connected to the host vasculature. 
Cellular immunity directed against graft endothelial cells leads to microvascular 
occlusion with ischaemia and necrosis the final common path of allograft 
destruction.
Rejection is recognised in three forms: hyperacute occurs in minutes to hours and 
is mediated by host preformed antibodies; acute rejection occurs 5-21 days post 
grafting and is due to donor sensitization, previous sensitization produces 
accelerated rejection; and chronic rejection develops late and is caused by a 
disturbance in graft/host relationship breaking down T cell tolerance to the graft
140,143
1.6.2.2 Nerve immunogenicity
Some of the findings suggesting an immune response in nerve allografts have 
already been described. MacKinnon in 1982 in a ®^ Cr release assay used donor 
specific splenocytes to challenge graft recipients at various times post transplant to 
study the host reaction. Host recognition of nerve allograft was at day 8 in hosts 
with a MHC disparity, while delayed to day 80 where a minor difference e x i s t e d ^ .
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The inflammatory infiltrate associated with PNAG was noted to increase while 
axons and Schwann cells decreased . The inflammatory infiltrate included 
lymphocytes, macrophages and plasma cells , and was initially epineuria! 
before becoming endoneurial and associated with the microvasculature . The 
nerve architecture was disrupted with rupture of Schwann cell basal lamina tubes, 
as identified by electron microscopy , which hindered axonal regeneration. 
Allograft vascularity was also affected. Described as good at day 7, it steadily 
reduced from day 14-30. Peak cellular infiltrate assessed from aspiration of fluid 
around the graft occurred at day 9. The proportion of CD4+, and CD8+ 
lymphocytes plus cells expressing MHC class II was greater than in corresponding 
isografts . Hare also confirmed a marked infiltrate of similar lymphocytes in
allografts in an outbred ovine model, along with increased MHC class I and II 
expression on infiltrating and graft cells compared to autografts .
The source of PNAG antigenicity has been investigated partly to try to find a 
method of blocking its effects. As previously described, a nerve is made up of 
several components. The structure is of connective tissue origin containing 
collagen, elastin, reticulin, tubulin and laminin. Within this are axons, non-neuronal 
cells, largely Schwann cells, but also immunocompetent cells such as 
macrophages, blood vessels and lymphatics. The lack of a lymphatic system can 
confer a degree of immunological protection as in the cornea and some CNS sites 
, but only the endoneurium has no lymphatics in nerve.
In nerve allografts increased expression of MHC II has been noted on endothelial 
and perivascular cells within the time period of acute rejection jp cultured
endothelial cells During studies on nerve grafts. Best identified that 
revascularisation by longitudinal inosculation began around 24 hours and was 
present by 48 and 72 hours within the epineurium and endoneurium respectively 
. Therefore donor endothelium is exposed within 72 hours to the recipient’s 
circulation and immune system. Endothelium is known to be highly immunogenic in
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solid organ transplantation work and therefore is highly likely to be involved in 
nerve allograft rejection.
Perineurial cell and fibroblasts of the epineurium were also investigated as 
antigenic components of nerve as individual fascicles had been found to elicit less 
reaction that whole nerve grafts /^cellular freeze-thawed nerve allografts did
not incite an obvious immune reaction , although in experiments with
previously sensitized hosts a reaction did occur indicating weak antigenicity within 
the nerve skeleton .
The other most likely antigen presenting cell in nerve and a likely focus of 
immunoreactivity are the Schwann cells. Myelin itself was implicated but 
predegenerated allografts containing no myelin were still found to reject .
Many authors observed Schwann cells in nerve allografts were destroyed. In early 
reports this was just presumed but since the technology has existed to identify 
Schwann cells by electron microscopy and immunocytochemistry this feature has 
been confirmed 102,151,152,161,162 (jsing interferon gamma (IFNy)^® ’^^®^  and tumour 
necrosis factor beta (TNFjî)^®'  ^ , investigators have found inducible but not 
constitutive expression of MHC class II expression on Schwann cells in vitro. 
Additional experiments using specific antibody against IFNy and inhibitors of IFNy 
(hydrocortisone, cyclosporin, prostaglandin E2) have produced inhibition of 
Schwann cell MHC class II expression, further implicating IFNy in class II 
upregulation
Evidence has also been found of MHC class II on the surface of Schwann cells in 
vivo Lassner and Grochowicz identified MHC class II on Schwann cells in
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rejecting allografts but not on autografts . However others have identified this 
following simple injuries Class II expression has been identified on Schwann 
cell basement membrane and within endocytotic vesicles giving a strong indication 
that they behave as APCs (antigen presenting cells) and they are known to
be able to phagocytose myelin and axonal debris during Wallerian degeneration 
Bergsteinsdottir also reported that Schwann cells could produce interleukin-1 
(IL-1) following stimulation, and IL-1 immunolabelling was predominantly 
intracellular Wekerle caused T-cell proliferation and clustering around MHC II 
expressing Schwann cells by stimulating them with IFNy, whereafter they 
presented both exogenous and endogenous antigen to antigen-specific T-cell lines 
given further evidence suggesting Schwann cells have a role in antigen 
presentation, making them a target for rejection.
An alternative path has also been suggested by experiments but this lies contrary 
to the classical view that MHC class I and class II present endogenous and 
exogenous antigens respectively. Schwann cells could also be direct targets for 
CD8+ cells. Schwann cells have been shown to express class I antigens 
constitutively and after IFNy stimulation , and Steinhoff identified that IFNy 
class I induced Schwann cells underwent cytolysis by antigen-specific CD8+ cells 
following exposure to exogenous antigen . This alternative pattern of MHC class 
I and II function has also been noted in other systems .
It is likely from the large body of evidence that PNAG endothelium and Schwann 
cells are the major APCs and foci of the rejection response along with some minor 
antigenicity from structural elements.
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1.6.2.3 Immunosuppression
There are two available routes to reducing the immune reaction to nerve allografts: 
specific or general methods. Ideally specific methods would make this conduit 
more agreeable as the host would not require to be subjected to agents which may 
have deleterious effects on areas not concerned with the allograft.
Specific methods have included graft pretreatments, alone or in combination and 
graft ensheathment. In the latter the aim was to physically protect the allograft from 
host infiltration. Millipore and frozen/irradiated PNAG and aldehyde tanned 
collagen with lyophilised PNAG were used, but both failed.
Pretreatments were aimed at reducing the antigenicity of the allograft. Many of 
these experiments predate immunological knowledge and suffered from lack of 
experimental rigour. Methods of pretreatment include chemical storage, in situ 
predegeneration, freezing, lyophilisation (freeze-drying), freeze thawing, and 
irradiation. Some successes were claimed with these measures alone, or in 
combination, but generally the majority failed in comparison to autografts, although 
the methods may have succeeded in improving the regeneration or reducing the 
reaction compared to fresh PNAG Storing in UWCSS (University of Wisconsin 
Cold Storage Solution) showed some promise following on from the findings of 
Sanders, with reduced Schwann cell viability with time leading to reduced host 
reaction and improved regeneration through the PNAG However, Evans 
showed that inbred rat PNAG, after 3-5 weeks cold storage in UWCSS, 
regenerated similarly to fresh PNAG but less than autografts although similar 
storage in sheep had shown a reduced host lymphocyte reaction compared to 
fresh PNAG Most methods (freeze-thawing, lyophilisation) have rendered the 
PNAG acellular although preserving the endoneurial tube architecture to aid axonal 
regeneration by both mechanical and trophic support 159,181,181,182,182 However 
without Schwann cells axonal regeneration has been shown to be reduced in 
autografts and allografts, and this influences the regeneration potential of any
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conduit 76,76,158,183 Lyophilisation was observed to reduce host response but 
although regeneration occurred it was inferior to autografts 178,184,185 similar 
results were found with freeze-thawing although results in short grafts (< 4cm) 
were more promising i^o.iee ^Vith irradiation, high doses were required to reduce 
PNAG antigenicity which also led to reduced regeneration and increased fibrosis 
187,188 Irradiation was often used in combination with freezing. Some successes 
were noted but were poorly designed and controlled. Other, well controlled 
studies confirmed that freeze/irradiated PNAG supported regeneration better than 
fresh PNAG but consistently observed inferior regeneration to autografts 164,190-192
Predegeneration was also often combined with other pretreatment methods. In situ 
nerve predegenerative has no real clinical relevance and had been shown not to 
enhance regeneration within allografts or autografts i64.iei,i9i,i93 clearance of 
myelin and proliferation of Schwann cells may have been thought to be beneficial 
before the antigenicity of Schwann cells was fully appreciated, but using it along 
with a method to render the graft acellular seems counterproductive i64.iso
The major improvement in the prospects of all transplantation came with the 
advent of immunosuppressant agents. These would produce non-specific, 
generalised host immunosuppression. After their introduction it became apparent 
very quickly that these treatments offered no miracles. The immunosuppression 
they induced meant that although the graft was protected from the host, the host 
was exposed to other assaults such as infections and malignancy. Added to this 
were the unwanted drug side effects from the uncomfortable nuisance effects of 
nausea, weight gain, and itch through to the serious side effects such as liver and 
renal toxicity. Hippocrates is credited with saying that “for extreme illness, extreme 
treatments are fitting” . While this stance may be appropriate regarding life 
threatening conditions, it may not be justifiable to risk someone’s life and health to 
improve disability and morbidity. This is the case with nerve allografts. Many
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people, medical and lay, find it unethical to transplant allogenic nerves if long-term 
immunosuppression is required.
Donor specific methods of reducing rejection result in tolerance of the host towards 
the donor antigens but retained ability to respond to all other antigenic challenges. 
Zalewski induced tolerance In neonatal rats by injecting them with the relevant F1 
progeny lymphoid cells. This method has no clinical relevance, but regeneration 
and muscle reinnervation (In cases with distal coaptations) occurred. The tolerance 
was reversed using donor sensitized cells and rejection ensued, but axons were 
preserved and function recovered when host and donor had minor 
histocompatibility differences . However, without a distal repair or with major 
histocompatibility differences all was lost j^e s e  findings highlight an
important feature of nerve allografts which is different from other transplants: 
although the conduit is allogeneic, the axons are host derived therefore rejection 
long-term of the PNAG may not be so important if the axons are not permanently 
harmed by rejection.
Non-specific methods of reducing the host’s immune response also reduce the 
ability to respond to all antigens not just those in the transplant. These agents are 
usually required long term and their development and use has followed solid organ 
transplantation. The initial drugs used in PNAG experiments were the 
antimetabolites 6-mercaptopurine, actinomycine-C, and methotrexate; along with 
prednisolone, hydrocortisone, and azathioprine 69,i8s,i89,i96 was not until the 
discovery and clinical use of cyclosporin A (CyA) that organ transplanting moved 
from the laboratory to clinical reality, with a risk/benefit ratio more acceptable for 
the patient 164,197-199
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1.6.2.4 Cyclosporin A
Cyclosporin A was isolated from a Norwegian soil sample in 1970 by scientists 
working for the drug company Sandoz. It is derived from a fungus Tolypocladium 
inflatum Gams and its immunosuppressant activity was identified and developed by 
the immunologist Jean Borel The benefit of CyA over other
immunosuppressants was its selective action on T-cells _ CyA blocks IL-2
production from CD4+ (Th) cells, inhibits T-cell proliferation, binds immunophilin 
and inhibits calcineurin action Its profound inhibition of CD44- and CD8+ activity 
and promotion of suppressor T cell function make it a powerful single agent 
immunosuppressant “'67,202 CyA could immunosuppress adequately as a
single agent was of interest to workers in nerve allografting. Also, it became 
evident that if immunosuppression could succeed in protecting axonal regeneration 
through the allograft at least similar to that encountered through autografts, then as 
the axons were host derived, perhaps CyA immunosuppression would be required 
only short-term. Following axonal regeneration the allograft conduit theoretically 
could be rejected as long as regeneration sustained no irreversible deleterious 
effects.
Studies with long term CyA immunosuppression identified successful regeneration 
in comparison to non-immunosuppressed PNAGs 123,124,153.192,203-205 equivalent 
regeneration to autografts 123,134,156,192,196,206-210 histological qualitative and
quantitative assessments 129,134,207,208 well as tests of function 123,129,132,211 
Ishida also used immunological assessments to demonstrate suppression of both 
cellular and humoral immunity towards a donor-specific challenge in CyA treated 
mice with PNAGs . Only one study identified poorer regeneration with CyA. 
Ansselin used “Trembler” mice and found they rejected allografts on doses of 10- 
15mg/kg/day of CyA however assessments of electrophysiology and
morphometry were compared with normal nerve, not isografts or autografts, 
thereby enhancing any deficiencies in regeneration. The CyA had been 
administered orally. This route is associated with extremely variable bioavailability 
and low peak levels both in animals and humans . CyA is non-water soluble
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and the compound has to be emulsified in oil for administration. This is notoriously 
difficult and may add to the problems of ensuring adequate doses in small animals 
(see Chapter 2).
Investigators were aware of difficulties with CyA, and needed an easy route of 
administration for the animal models which would also ensure the desired 
immunosuppression. Bain identified the minimum effective dose required to 
prevent histologically evident rejection and immunologic reaction of sensitized 
hosts to a donor-specific antigen challenge by mixed lymphocytic culture. This is 
5mg/kg/day of CyA .
The use of temporary immunosuppression has also been investigated to test 
whether regeneration can be sustained, while withdrawing immunosuppression 
would reduce the long-term risks of it to the patient. The experimental findings 
have drawn many conflicting conclusions, some of which can be traced to the 
experimental designs. Complete rejection following immunosuppressant withdrawal 
has been observed 123,125,168.195,204  ^ has no evidence of rejection 165,190,215
groups identified intermediate reactions with incomplete loss of function and
subsequent recovery, along with weaker and delayed histological changes of 
rejection 134,192.209.211,216-223
Factors contributing to this mixed picture include: short follow-up, no distal 
neurorrhaphy, small sample size, inadequate immunosuppression, lack of 
adequate controls and quantitative outcome parameters. From experiments where 
no rejection was reported post-immunosuppression, MacKinnon did have results 
inferior to autografts at the 80-day study end-point (using azathioprine 
/hydrocortisone) and could have missed rejection within this time period , while 
Pollard employed inadequate follow-up 166,215 experiments where rejection
was shown Zalewski performed only a proximal neurorrhaphy thereby denying the
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regeneration potential of his model the proven neurotrophic benefits of the distal 
host nerve 123,125,195,204 without host axons traversing the graft to reach target 
organs the whole regenerated system would be theoretically more susceptible to 
irreversible assault.
More recent studies have indicated that a rejection reaction does occur following 
cessation of, in these cases CyA, but that the effects appear to be recoverable 
134,209-211,216,219-221 MacKlnnon and Ishida’s studies analyses were by histology
and functional assessments and immunosuppression was for 12 and 8 weeks 
respectively, with correspondent final assessments at 36 and 20 weeks 309-216 
MacKinnon’s study histology revealed evidence of remyelination at 20 weeks 
therefore it was hypothesized that the remyelination occurred secondary to 
migration of host Schwann cells into the nerve allograft following rejection of donor 
Schwann cells These two studies however suffer from the lack of autograft, 
continuously immunosuppressed allograft and non-immunosuppressed allograft 
controls. Midha redressed these problems in his study where inbred rats were 
immunosuppressed for 12 weeks to allow innervation of target organs, which was 
confirmed with functional analyses. Following CyA withdrawal demyelination 
occurred with moderate axonal loss and a decrease in walking track and 
electrophysiological parameters. Of the significant proportion of axons which 
prevailed, remyelination occurred plus regeneration of the damaged axons. Finally 
the functional and histologic parameter were similar to autograft and continuously 
immunosuppressed allografts and superior to non-immunosuppressed allografts 
controls 134-218 _
Seven reported clinical cases were undertaken between 1988-1998. CyA was the 
main immunosuppressant used although it was replaced by FK506 (tacrolimus) for 
the most recent two cases. All patients were young with large defects in major limb 
nerves, who had sustained their injuries on average four months before 
reconstruction. Cabled allografts were utilised and immunosuppression was
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maintained for 12-26 months. All but one case has shown signs of nerve 
regeneration, with sensory recovery generally exceeding that of motor function. 
Protective sensation has been universally achieved and the first two patients are 
described as being able to walk unaided and play sports. The single failed case 
was attributed to subtherapeutic CyA and rejection 217,224,225
Newer immunosuppressants are increasingly available with stronger 
immunosuppressant activity and less toxicity and side-effects. Tacrolimus (FK506) 
has been used in allograft work and has produced results similar to those seen 
with CyA. So far, none have induced tolerance despite the promise shown in some 
studies 226-230 pqj. allografting the main dilemma remains not the technical 
ability, or even the ability to achieve immunosuppression, it is the ethical matter of 
whether potentially life threatening treatments should be used in the treatment of 
non-life threatening conditions.
The recent clinical cases of composite transplantation of hands has brought these 
issues to the fore again 231-237 ^ ethics are not clear cut for these debilitating 
and cosmetically obvious disabilities, then they are even more unclear for isolated 
nerve injuries. However the fate of nerve allografting and composite grafting, 
especially of the upper limb are inextricably linked; without improvement in nerve 
allograft regeneration a major aim of the hand transplant will have failed even if it 
technically survives. This is because the role of the reconstructive surgeon is to 
restore appearance and function; if the hand is without function it is virtually 
useless and also has an obviously unusual appearance. A modern prosthesis, and 
the potential offered in this respect from microchip technology and bioengineering 
maybe more likely to provide service to the effected individual.
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1.7 HYPOTHESIS AND AIMS
At present conduits of nerve origin provide the best substrate for axonal 
regeneration. However, in nerve allograft, Schwann cells are antigenic and are 
rejected leaving weakly antigenic endoneurial tubes, which may support host axon 
regeneration. It is still unclear whether this antigenic reaction has to be 
permanently controlled with immunosuppression to obtain best regeneration 
results. However, for nerve allografts to be ethically more acceptable, the 
requirements for immunosuppression might need to be reduced while maintaining 
regeneration at least similar to autografts.
Regeneration can be improved within acellular organic and synthetic conduits by 
supplementing the availability of Schwann cells 61,62,75,238-240 the neurotrophic 
factors they produce 4,52,55,241-243 ^  simple method of achieving this was
demonstrated by Maeda and Whitworth 244,245 y^ey noted improved axonal 
regeneration through silicone tube and muscle grafts following interposition of 
autologous nerve grafts between sections of these two conduit materials (called 
stepping-stone or sandwich grafting).
It is hypothesised that similarly, a host sandwich allograft (formed from a chimeric 
structure of host and donor nerve segments sutured orthotopically together) will 
provide a depot of non-allogenic Schwann cells within a nerve allograft to provide 
neurotrophic support to regenerating host axons to compensate for the rejection of 
allogenic Schwann cells (see Chapter 2). In addition, the increased proportion of 
host Schwann cells might reduce the antigenicity of the whole graft structure. Thus 
any post-rejection axonopathy and delayed regeneration resulting from rejection 
might also be reduced, leading ultimately to reduced requirements for 
immunosuppression.
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The aims of this thesis were:
(1) To study and compare in an animal model the early time course of 
regeneration within immunosuppressed and non-immunosuppressed nerve 
allografts in comparison to nerve autografts, with particular reference to the 
progression of axonal regeneration, inflammation, vascularisation and 
Schwann cell response.
(2) To investigate the possibility of augmenting regeneration within a non- 
immunosuppressed nerve allograft by utilising a sandwich grafting 
technique, with emphasis on the effects that the autologous sandwich graft 
segment has on Schwann cells and inflammation within the early post- 
engraftment period.
(3) To assess the requirements for long-term immunosuppression by comparing 
simple and sandwich nerve allografts, along with equivalent non-allogenic 
controls. Analysis of axonal regeneration in relation to end organ 
reinnervation would be used as indication of functional recovery.
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2.1 EXPERIMENTAL PROCEDURES
2.1.1 Animal model and anaesthetic technique
Ail nerve graft experiments conducted In this project involved eight week old 
female inbred Lewis (Lew) and Dark Agouti (DA) rats. These strains are known to 
be incompatible at both major and minor histocompatibility complexes 4^6-248 
rat combination has been used by previous authors in the fields of peripheral nerve 
allografting . Also, the use of the rat allows a better comparison with the work 
of other authors, especially when investigating a new technique .
Animals were anaesthetised using inhalational induction with Enflurane [Abbott 
Laboratories Ltd, UK], followed by an intramuscular injection of Hypnorm 0.3mg/kg 
[fentanyl citrate: 0.315mg/ml and fluanisone: 10mg/ml, Janssen Pharmaceuticals 
Ltd.], and 2.5mg/kg of intraperitoneal diazepam [Phoenix Pharmaceuticals Ltd.]. All 
procedures were carried out In compliance with personal and project licenses 
issued under the Animals (Scientific Procedures) Act 1986.
2.1.2 Operative procedure
General principles of surgery were employed to avoid compromising nerve 
vascularity and to ensure atraumatic tissue handling. All microsurgical procedures 
were undertaken using an operating microscope [Wild Heerbrug Ltd., Germany], 
which also provided attachments for per-operative photography.
Experiments were carried out on the animals’ right sciatic nerves (Figure 2.1). The 
nerve was exposed through a lateral thigh incision utilising an intermuscular 
approach between the superficial gluteal and the biceps femoris muscles. A 10mm 
segment of sciatic nerve was measured by a template and removed to produce a 
standard gap size. The proximal edge of this segment lay just distal to the 
consistent vascular pedicle which the sciatic nerve receives in the upper thigh. 
Before grafting, the proximal and distal nerve stumps were mobilised for no more 
than 5mm to preserve vascularity.
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The nerve gap was repaired using one of the five graft techniques shown in Table
2.1 and Figure 2.2. These grafts form the basis of the study groups used 
throughout this project. The graft sizes are detailed in the relevant chapters.
Table 2.1 Experimental graft types under investigation
Graft Host Donor
Nerve autograft Lewis autologous Lewis
Nerve isograft Lewis isogeneic Lewis (Lew)
Nerve allograft Lewis allogeneic Dark Agouti (DA)
Nerve sandwich allograft Lewis Dark Agouti, with autologous
Lewis central segment
Nerve sandwich isograft Lewis isogeneic Lewis,with autologous
Lewis central segment
The nerve graft was obtained from a branchless portion of donor sciatic nerve. 
Epineural repairs were carried out at all neurorrhaphies using interrupted sutures of 
9/0 monofilament nylon [Ethicon Ltd., UK]. Care was taken to avoid nerve rotation, 
misalignment and axoplasm herniation. In the case of the sandwich grafts, each 
5mm segment was sutured in continuity from proximal to distal. Nerve regeneration 
in the rat is widely recognised as being more efficient than other higher species 
such that critics 62,211,250 maintained that a 10mm gap may be bridged without 
repair in this model, therefore an un-repaired 10mm gap was also undertaken as a 
control.
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Figure 2.1 Operative Series of Sandwich Graft Construction
I / '
a) Proximal nerve stump b) Nerve graft coapted. Will be halved 
before addition of host segment
c) Middle host segment in place 
with adjacent final segment
d) Whole construct in continuity
Orientation is with proximal uppermost and distal at the base of the frames.
The wounds were closed using horizontal mattress sutures of 3/0 silk [Ethicon Ltd., 
UK]. Animals receiving cyclosporin (CyA) were injected subcutaneously at the end 
of the procedure (see Section 2.2). All animals received 5ml of 0.9% saline [Baxter
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Ltd., UK] subcutaneously to prevent the likelihood of dehydration. The rats initially 
recovered in single cages in a warm room. They were returned to their six animal 
group cages within the holding facility 24 hours later. The rats were housed under 
standard conditions with free access to food and water for the duration of the 
experiments. Every effort was taken to minimalise animal distress and numbers.
Each experimental group was comprised of six animals which was the minimum 
number of animals required to allow valid statistical analysis. This number was 
established during planning of the experiments following discussion with a 
statistician (see section 2.4) and based on findings from previous work 64,245,251,252 
The experiments involved comparing the graft types mentioned previously (Table 
2.1) over time points ranging from 7 to 21 days in the short term, to 32 weeks for 
long term experiments.
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Figure 2.2 Diagram of Experimental Groups
Proximal
Nerve
^  Nerve 
Defect
Distal
Nerve
Experimental Grafts
Isograft Sandwich Allograft
Allograft Sandwich Control
Autograft
Technical errors and variation during the surgical procedures were reduced to a 
minimum as only one operator was involved, carrying out a total of more than one 
thousand microsurgical procedures. The operator had previous microsurgical 
experience ensuring that the procedures were performed in a reproducible and 
optimal manner. All the rats used were from inbred colonies, of single sex and 
similar age at the commencement of the experiments, therefore minimising any 
variation in nerve regeneration attributable to operator or model variability. All 
animals were acclimatised for two weeks prior to surgery, in accordance to Home 
Office guidelines, thus minimising any variations attributable to animal stress.
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2.1.3 Tissue harvesting and preparation
Animals were sacrificed at the end of each experiment using high dose Enflurane 
inhalation. The right sciatic nerves containing the graft segments were removed en 
bloc. These specimens were trimmed using a plastic template so that 5mm of host 
nerve was included proximal and distal to the grafts. The specimens were pinned 
to card for orientation, and to avoid shrinkage during fixation.
Preparation for immunohistochemical staining involved fixation in Zamboni’s 
solution (2% paraformaldehyde and picric acid in PBS, pH 7.4 - Appendix 1) for 6 
hours at room temperature (for fresh tissue less than 5mm thick: ratio of fixative to 
tissue at least 10:1). Afterwards, the specimens were rinsed in phosphate buffered 
saline (PBS) containing 15% (w/v) sucrose and 0.1% (w/v) sodium azide (PBS- 
sucrose - Appendix 1) at least three times over the following 3 days while the 
specimens were stored at 4°C. Rinsing was complete when the rinsing solution lost 
the yellow tinge from the Zamboni’s fixative and the tissue had sunk within its 
container. Thereafter, any sutures were removed under magnification prior to 
preparation of cryostat blocks, where liver segments were used to identify the 
proximal ends of the sciatic nerve/graft complexes. The tissues were blocked in 
OCT [Optimum Cutting Temperature compound, Tissue-Tek, Miles Inc., USA] and 
were stored at -40°C while awaiting sectioning and staining.
A section of posterior tibial nerve was collected for myelinated axon counts from 
animals belonging to long-term 32 week groups. Preparation of these specimens 
was undertaken with the assistance of Dr. Padmini Sarathchandra, Department of 
Pathology, Northwick Park Hospital NHS Trust, Harrow. A 3mm section of this 
nerve was removed 5mm distal to the distal anastomosis and immediately fixed in 
electron microscopy grade 2.5% gluteraldehyde [Agar Scientific Ltd., UK] in 0.1 M 
phosphate buffer (Appendix 1) overnight at 4'"C before rinsing twice in 0.1 M 
phosphate buffer. The specimens were fixed for 1 hour in 1% osmium tetroxide
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[Agar Scientific Ltd., UK] in 0.1 M phosphate buffer followed by washing in 
phosphate buffer (2x5minutes). Following dehydration in graded ascending 
acetones [Agar Scientific Ltd., UK], the specimens were infiltrated with an 
acetone/Araldyte mixture (ratio 1:1) [Agar Scientific Ltd., UK] overnight. Thereafter 
the specimens underwent two changes of pure resin before final Araldyte block 
polymerisation at 60°C for 18 hours. Transverse semithin (Ijim ) sections of the 
nerve were cut from the blocks and collected on glass slides. These sections were 
stained with thionin and acridine orange for analysis of myelinated fibres (Section 
2.3.4). Similar portions of contralateral unoperated posterior tibial nerves, as 
measured from the sciatic notch, were harvested and processed as above to be 
used as controls.
Gastrocnemius muscle mass was measured as an assessment of end organ 
reinnervation in the long term experimental groups . The muscles from both 
legs were approached via an extension of the original incision. The entire muscles 
were dissected cleanly and carefully under magnification and detached flush with 
bone at their origins and insertions. Each muscle was weighed to allow calculation 
of the percentage reduction in muscle mass between the operated and non­
operated legs during the experimental period.
2.2 IMMUNOSUPPRESSION
The sole immunosuppressant used was cyclosporin [Sandoz Pharmaceuticals Ltd., 
UK](also known as cyclosporine and cyclosporin A). Two preparations were used: 
the parenteral formulation available commercially (pCyA) (see Section 2.2.3), and 
cyclosporin (CyA) base powder donated by Sandoz, along with instructions for its 
preparation and administration (Section 2.2.1-2.2.2). In the rat, previous work with 
cyclosporin has led to the wide acceptance of a dose of 5mg/kg/day by 
subcutaneous injecton as suitable for immunosuppression in this model 
206,207,216 two preparations were used initially for financial reasons and
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secondly because during the course of the experiments there was concern 
regarding the bioavailability of CyA solution prepared from the base powder 
(oCyA). This became evident after some of the rats began to develop encysted 
collections of oily fluid following administration of the powder preparation in the 
subcutaneous plane around the injection sites. Further details of the different 
effects experienced with the two formulations are given in Chapter 6.
2.2.1 Cyclosporin administration
Administration of cyclosporin was by daily subcutaneous injection and commenced 
the day preceding surgery. The injection sites were varied to avoid morbidity and 
maintain bioavailability. The dose each animal received was altered according to 
weekly weights . A depot effect can occur when using this method of 
administration especially over prolonged periods 5^4,206 also borne out by
these experiments (see above and Chapter 6). Accordingly, CyA was administered 
on alternate days after the first twelve weeks of any long term experiments. Full 
precautions, in keeping with Health and Safety requirements were employed when 
preparing and handling these solutions.
2.2.2 Parenteral cyclosporin (pCyA)[Sandimmun]
Commercially produced vials of pCyA at 50mg/ml (in solution with 650mg 
polyethoxylated castor oil and 33% ethanol by volume) were diluted using 0.9% 
saline [Baxter, UK] to produce a solution of lOmg/ml as per the manufacturer’s 
instructions (Sandoz Pharmaceuticals Ltd., UK; Ishida et al., 1993).
2.2.3 Oily cyclosporin preparation (oCyA)
Pure cyclosporin is a non-water soluble fine white powder. To achieve the best 
solution for in vivo administration, Sandoz instructed the preparation of a solution 
as follows: lOOmg CyA dissolved in 165mg/ml of ethanol absolut, followed by 
350mg/ml of corn oil and 385mg/ml of Labrafil M2125 CS [Gattefosse, France].
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This is a derivatized vegetable oil comprising unsaturated polyglycolysed 
glycerides, donated by Alfa Chemicals Ltd., UK. These quantities (900mg) 
correspond to 1 ml of primary solution. To this a further 9ml of corn oil was added to 
produce a final solution of CyA with a concentration of 10mg/ml.
2.2.4 Animal care during cyclosporin administration
Cyclosporin is a toxic agent associated with many side effects 253.255,256  ^ Plainly 
related to hepato- and nephrotoxicity. One sensitive indicator of CyA toxicity in rats 
relates to weight, either failure to gain weight or weight loss 253.254 /\pjrp,^|g vvere 
weighed weekly and were observed for signs of ill health on a daily basis. 
Generally, the animals were observed for changes to their limbs, skin and 
behaviour (see also Chapter 6). Dehydration can precipitate CyA toxicity, therefore 
efforts were made to minimise the likelihood of this occurring, especially 
peroperatively.
2-2.5 Cyclosporin monitoring
Circulating cyclosporin levels were measured from whole blood samples taken by 
venepuncture of the tail veins or by intra-cardiac puncture following terminal 
anaesthesia. Samples were collected in paediatric EDTA and lithium heparin 
coated tubes. Analysis for creatinine, alkaline phosphatase, alanine transaminase 
(ALT) and aspartate aminotransferase (AST) were undertaken as tests of hepatic 
and renal function Cyclosporin was measured from whole blood using
fluorescence polarization immunoassay (FPIA) technology [Tdx Cyclosporine 
Monoclonal Whole Blood Assay, Abbot Laboratories, USA]. This system is capable 
of detecting concentrations with 95% confidence for samples containing greater 
than, or equal to 25ng/ml of cyclosporin. Mr. Mark Dunsford and colleagues, 
Department of Chemistry, Guy’s Hospital, London carried out these biochemical 
analyses.
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2.3 MORPHOLOGICAL ASSESSMENT
2.3.1 Cutting techniques
Specimens of the host nerve/graft complex were cut in 15pm longitudinal sections. 
To ensure that a similar representative portion of the nerve/graft complex was 
examined in all samples, initially one specimen was sectioned completely and 
stained. From this it was determined that at least 15 sections needed to be cut 
before the core within the nerve/graft complex was reached (Figure 2.3). Once 
reached, the core sections to be stained were collected sequentially on alternate 
Vectabond [Vector, UK] coated slides (Appendix 2), each slide was subsequently 
processed for immunostaining. For each antiserum, or histological stain, two slides 
with three sections each were utilised. Sections were allowed to dry for 4-6 hours 
at room temperature to reduce section loss during the immunostaining.
Figure 2.3 Diagram explaining the graft complex cutting technique
15tim • 
sections
Proximal
Neuroritiaphy
Distal
Neurorrtiaphy
• / .  .A_________ \
\m m y  y
Proximal
Nerve
Graft
Segment
Distal
Nerve
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2.3.2 Immunohistochemical staining
The various staining techniques employed were carried out using a routine 
protocol. Analysis of coded samples by Dr. Giorgio Terenghi, Reader in Surgical 
Sciences (Blond Mclndoe Centre, University College London) confirmed the 
consistency of staining. All analyses were conducted on coded slides which gave 
no indication of the tissue of origin. The image analysis of immunohistochemical 
staining is an established method of quantitative analysis. All analyses were 
carried out by the author and results were found to be consistent with co-workers 
using similar tissues and techniques known positive control was included
in each staining batch to confirm the reliability of the technique .
2.3.2.1 Indirect immunofluorescence method
Indirect immunofluorescence was used to stain the longitudinal nerve/graft sections 
as this technique was found to give optimal contrast and allowed the best definition 
of regenerating axons within the grafts.
After drying, the area around the sections was marked using a hydrophobic pen 
[DAKO Ltd., UK] to contain the antiserum when applied. The sections were then 
immersed in PBS containing 0.2% Triton-X [BDH,UK] (Appendix 1) for one hour at 
room temperature to achieve tissue permeability. This was followed by rinsing in 
PBS (3x3 minutes) before application of the primary antibody (Section 2.3.3) within 
a humid chamber. Incubation was overnight (16-20 hours) at 4°G. The low 
temperature incubation used here maximises specific binding while minimising 
non-specific background staining.
On sections where fluoroscein isothiocyanate (FITC) conjugated antibodies were 
used as the second layer (see Section 2.3,3), additional counterstaining with 
pontamine sky blue was carried out for thirty minutes at room temperature 
following Triton-X permeabilisation, in order to reduce background fluorescence.
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Additional PBS rinses (3x3 minutes) were also carried out before application of the 
primary antibody.
On day two, sections were washed in PBS (3x5 minutes) prior to incubation with 
the secondary antibody (1 hour at room temperature). During this time the humid 
chambers were protected from external light to preserve the fluorescent markers. 
Final rinses in PBS followed (3x5 minutes) with the addition of a penultimate rinse 
in Tween (1/4000) in PBS for one minute to remove any excess unbound 
secondary antibody. Slides were mounted using PBS/glycerol (Appendix 1) 
containing 2.55 (w/v) 1,4-diazabicyclo (2.2.2) octane [Aldrich Chemicals, UK] as an 
anti-fading agent. Slides were stored in darkness at 4°C ready for viewing.
2.3.3 Antibodies
Antibodies to several peptides and proteins were used to detect regenerating 
axons, Schwann cells, macrophages and blood vessels within the host nerve/graft 
complex.
The antisera used in this study and their target antigens are specified below:
1. Panaxonal marker of neurofilaments (PamNF); a cocktail of antibodies to 
heavy molecular weight phosphorylated neurofilament proteins which 
localise large and small calibre axons. PamNF acts as a general axonal 
marker which defines functioning axonal material and was used to assess 
axonal regeneration in the various nerve grafts employed in this project .
2. S-100; a specific Schwann cell cytoplasmic antigen . This antisera
identifies the presence and progression of Schwann cells within the grafts, 
although it does not distinguish their origin.
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3. ED-1; a specific marker for rat macrophages. This antiserum was used to 
assess macrophage invasion into each graft as an indication of the degree 
of inflammation elicited .
4. von Willebrand factor (vWF); a specific endothelial cell surface antigen. This 
antiserum was used to identify blood vessels and the pattern of graft 
vascularisation .
The specific dilutions of the antisera and their suppliers are detailed in Table 2.2. 
All primary antibodies were diluted with a PBS solution (Appendix 1) containing
0.03% Triton-X [BDH, UK], 0.1% bovine serum albumin [Sigma Chemicals Ltd., 
UK], and 0.1% sodium azide [BDH, UK]. Second layer antibodies were all diluted 
with PBS only.
Table 2.2 Antisera specifications
Primary antibody
PamNF
(mouse monoclonal) 
S-100
(rabbit polyclonal) 
ED-1
(mouse monoclonal) 
vWF
(rabbit polyclonal)
Dilution Identifies
1/2000 axons
1/800
Source
Affiniti, UK
1/1200 Schwann cells DAKO, Denmark
macrophages Serotec Ltd., UK
1/1200 endothelial cells DAKO, Denmark
Secondary antibody Dilution
Goat anti-mouse 1 /100
Goat anti- rabbit 1/100
Conjugate
Cyanine-3 (red)
FITC (green)
Source
Amersham, UK
T.C.S. Biologicals, 
UK
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2.3.4 Thionin-Acridine Orange staining
Semithin (1 }xm) sections from the posterior tibia! nerve distal to the graft segments 
were treated with thionin blue and counterstained with acridine orange (Appendix 
3) to stain myelin sheaths around the regenerated nerve fibres. Myelin stains dark 
blue. From these, number of myelinated fibres, their size and myelin thickness 
could be measured (Section 2.3.5). Three slides, with a minimum of six sections on 
each, were prepared and stained from each animal.
Following fixation as already described, sections were collected on plain glass 
slides to be stained. The underside of the slides was flamed briefly ten to twelve 
times to provide section adherence before staining. Fresh thionin was applied to 
the sections (60 seconds) at 70°C on a hotplate. After washing with distilled water, 
fresh acridine orange was applied to the slides (30 seconds) again at 70°C on a 
hotplate. Following final rinsing in distilled water, the slides were heat dried before 
mounting in DPX.
2.3.5 Computerised image analysis
Quantification of staining of the experimental specimens was undertaken using a 
computerised image analysis system [Seescan Analytical Services, Cambridge, 
UK]. This system comprises: a microscope [ORTHOLUX II, Leitz Wetzler, 
Germany] mounted with a CCD camera [Sony Inc., Japan], which is connected to a 
dedicated computer terminal and software.
For immunofluorescence staining, illumination of the specimens was by a UV 
source emitting at a constant level, in conjunction with separate filter blocks for 
cyanine-3 (red staining, peak emission wavelength 570nm) and FITC (green 
staining, peak emission wavelength 520nm). For viewing sections stained with
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thionin/acridine orange, a bright light was used, whose current was stabilised to a 
constant level via a transformer.
The CCD camera allows capture of the section image under view. These images 
are digitised within the computer and stored on 128MB 90mm optical laser disks 
[3M, USA]. An automatic pattern recognition programme permits the capture of 
adjacent images without overlapping. Before analysis, the captured images are 
edited to improve contrast and facilitate quantification. This involves automatic 
background subtraction, resulting in the images being further automatically 
enhanced by reduction of “binary noise". The removal of images less than 3 pixels 
in size further reduced binary interference while manual editing removed artefacts 
due to background staining. The image of the staining was finally thresholded, with 
levels being kept within constant limits for each experiment. The edited image was 
then quantified according to defined parameters (see below). Following 
quantification, the data was downloaded onto a 2MB floppy disc [3M, USA] and 
transferred to a PC for data processing and analysis.
For each animal and each antibody, measurements were made from two sections 
and the results averaged. Reproducibility was verified by repeat blind analysis of 
the coded specimen. The measuring parameters used in this project are 
summarised below.
1. Area of immunostaining
The amount of axonal regeneration, Schwann cell density, and macrophage 
infiltration within the nerve/graft complexes was indicated by the 
measurement of total stained area within the specimens at selected fixed 
points. These include an area (one screen width wide), 2mm from the 
proximal anastomosis within the graft tissue (Area G); 2mm distal to the 
distal anastomosis (Area D); and for sandwich grafts, 2mm within the 
autograft segment (Area M), all under x25 objective magnification. The total 
area of staining across the full width of the graft was calculated by summing 
the measurements from adjacent fields (Figure 2.4). The total area of
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staining across the graft can then be expressed as a percentage of the area 
of nerve that was analysed.
2. Myelinated axon counts
Under x40 objective magnification, three random fields within the posterior 
tibial nerve were measured for each section, with a minimum of two sections 
analysed from each nerve. The images were automatically thresholded and 
manually edited to remove artifacts and non-axonal components of the 
nerve e.g. blood vessels and Schwann cell bodies. The number of normal 
fibres was automatically counted from each captured image. The internal 
and external perimeters of the myelin sheaths were also measured, and the 
myelin thickness, fibre and axonal diameters calculated from these. The 
image of the whole posterior tibial nerve was also captured from the 
semithin transverse sections under x4 objective magnification.
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Figure 2.4 Diagram of a longitudinai histological section.
The distances along the nerve/graft complex, measured from the proximal (PN) and distal (DN) 
neurorrhaphies is given in millimetres (mm). Each small rectangle represents a microscope field. 
The total area of staining was calculated by summating adjacent fields.
a) For Simple grafts: quantification of staining took place within the graft 2mm from the proximal 
neurorrhaphy (Area G) and 2mm distal to the distal neurorrhaphy (Area D).
PN
Area
G DN
Area
D
2mm 2mm
Simple Graft 
15mm
b) For Sandwich Graft: Quantification of staining took place in areas G and D as with simple 
grafts, with the addition of an area 2mm within the autograft segment of the sandwich graft 
construct (Area M).
PN
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G
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M DN
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D
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Autograft 
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2.3.6 Axonal regeneration distance
This was the distance reached into the graft tissues by regenerating axons from 
the host proximal nerve. Specimens were inspected for identification of the farthest 
travelled axon and this penetration distance was measured from the proximal 
neurorraphy (Figure 2.5) using a calibrated graticule at x10 objective magnification.
The proximal neurorrhaphy was identified by the presence of suture holes and by a 
small area of randomly orientated axons, on either side of which axons were 
organised parallel to the long axis of the specimen. In specimens more than 
fourteen days post surgery, this feature was still present although less distinct.
Figure 2.5 Measurement of axonal regeneration distance
Diagram showing measurement of maximum axonal regeneration distance into the experimental 
grafts at 7 days (PN = Proximal neurorrhaphy, DN = Distal neurorrhaphy).
PN DN
Distance 
- penetrated by - 
farthest axon (mm)
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2.3.7 Photography
All microscopic images were photographed on an Olympus BH2 microscope 
mounted with a dedicated Olympus camera and connected to an automatic 
exposure meter [Olympus Optical Co. Ltd., UK]. Immunofiuorescent images were 
visualised using filter blocks for cyanine-3 and FITC as already mentioned (see 
Section 2.3.5). Fluorescent UV photography was carried out using Kodak Elite 400 
film [Kodak, UK].
Bright light colour photography was carried out with Kodak 160T slide film [Kodak, 
UK]. Per-operative photographs were taken using a microscope mounted camera 
and Kodak 160T film as before. Unless otherwise stated, photographs illustrated 
within this document have been presented in a proximal to distal orientation from 
left to right.
2.4 STATISTICAL ANALYSIS
Statistical analysis was carried out in collaboration with Mrs. Caroline Dore, Senior 
Medical Statistician at the Royal Postgraduate Medical School, Hammersmith 
Hospital, London. Prior to commencement of the experimental work, the minimum 
number of animals likely to allow a valid statistical outcome (six in each group) was 
estimated from previous work and following discussion with Mrs. Dore. 
Commercially available software packages were used to carry out the statistical 
analyses including STATA [STATA Corporation, Texas USA] and SIGMASTAT 
[Jandel Scientific, Germany]. The normality assumptions for all data were checked 
using Shapiro-Francia’s W  test, while Bartlett’s test was used to check the 
assumption of equal variances. In some case (detailed in text), logarithmic 
transformation of data from measurements of area of staining improves the validity 
of the assumption of equal variance. Other test methods when variances are not 
equal include assessments based on ranks e.g. Kruskal-Wallis One Way Analysis 
of Variance (ANOVA). When required, relevant pairwise multiple comparison
64
procedures were undertaken for each individual analysis as identified in the 
relevant chapters.
Generally, a three way analysis of variance (ANOVA) was used to compare the 
results from staining of axons, macrophages and Schwann cells in relation to graft 
type, presence of immunosuppression, and time course. A further one way ANOVA 
was used to compare all groups at each time point. Multiple comparison 
procedures were then used to compare every possible pair of group means at each 
time point. For each group, the mean and 95% confidence interval were calculated. 
The confidence interval was the pooled estimate of the standard deviation from the 
one way ANOVA performed at each time period. If logarithmic transformation had 
been undertaken then the means and 95% confidence intervals were transformed 
back to the original scale of measurement for reporting.
All graphical representations throughout this work are of group means presented 
with standard error bars.
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3.1 INTRODUCTION
Experimentally, long nerve allografts of up to 5cm in rat, rabbit 123,205,211,215 
primate models 129,132,185 regenerated to a similar degree to autografts when 
fully immunosuppressed. However, immunosuppression for non-life threatening 
conditions using drugs capable of life-threatening consequences is still generally 
perceived to be unethical. Temporary immunosuppression would seem feasible as 
the regenerating axons are host derived and much experimental time has been 
devoted to investigating this possibility. Unfortunately, while all investigators agree 
that a rejection reaction takes place, some note subsequent recovery with ultimate 
regeneration similar to non-allogeneic controls, 124,185,196,216,262 others find that 
subsequent regeneration is not as good and do not feel that temporary 
immunosuppression has a place in current clinical practice 125,204,247,263 Respite 
the advent of hand transplantation opening up the debate, the balance of opinion 
regarding non-essential allotransplantation is one of caution . This is also 
expressed in standard textbooks of reconstructive surgery regarding the role of 
nerve allografts in the future .
With immunological rejection the non-neuronal cells are destroyed 121,221,247,264  ^
leaving an essentially acellular conduit. Rejection in a peripheral nerve allograft 
model becomes evident around 4 days post-transplantation, peaking around 9-14 
days and lasting up to six weeks, depending on the ferocity of the immunological 
response 129,209,247,265 jherefore graft cellularity may not be deleted in a sudden 
immunological reaction. A more likely staged response might allow enough host 
Schwann cells to migrate into the rejecting nerve allograft to repopulate them, in 
the same manner as acellular conduits are repopulated 23,76,151,266 more
positive results from temporary immunosuppression would suggest that this does 
occur 134,216,220,267 Howevor, while many experiments using cyclosporin (CyA) 
treated nerve allografts concentrate on durations in terms of months with high 
powered morphological assessments on largely transverse histological sections 
97,134,250,268  ^ jjmjted data exists as to events occurring within the grafted nerve
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in the early regeneration period in immunosuppressed and non- 
immunosuppressed animals. There is also often a lack of comparative data with 
suitable control groups 125,204,210.211,216 yging longitudinal histological sections 
instead of transverse ones will also allow analysis of regeneration as it progresses 
through the graft with time. As CyA has been associated with a degree of central 
neurotoxicity 225,256 jg ^|qq important to assess the effects of CyA on standard 
non-allogenic grafts .
3.2 AIMS
The aims of this experiment were to quantify and assess the pattern and progress 
of early axonal regeneration within a nerve allograft model during the time period 
when immunological rejection was most likely to occur. Immunosuppressed and 
non-immunosuppressed groups were compared to assess their respective 
regenerative potential.
The effects of any potential genetic disparity were assessed by comparing 
allogeneic, isogeneic and autogenous nerve grafts. This combination would also 
provide the opportunity to assess any differences in regeneration potentially 
attributable to CyA treatment.
3.3 EXPERIMENTAL PROTOCOL
The surgical and anaesthetic techniques employed in this study are described in 
Section 2.1. Inbred adult Lewis (Lew) rats were the primary host animals and 
provided their own autografts, and isografts for identical litter mates. Adult Dark 
Agouti (DA) rats provided the allograft nerves. A 10mm section of sciatic nerve was 
removed to create a standard nerve defect. This section was then transplanted 
orthotopically as either an autograft, allograft, or isograft. The autograft group 
allows comparison with current accepted clinical practice and the isograft group
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should produce similar results to the autografts if the animals are a representative 
inbred population i.e. they show no genetic disparity between individuals. These 
groups were further divided according to whether or not they were 
immunosuppressed (Table 3.1). The sole immunosuppressant used was 
cyclosporin A (CyA). This was delivered subcutaneously in a dose of 5mg/kg/day, 
and in these experiments was made up from parenteral formulation cyclosporin (25 
mg/ml) (Chapter 2.3). The CyA was administered from the day preceding surgery 
for the complete period of each experiment.
Table 3.1 Experimental Groups (n=6)
Group Code CyA Duration CyA (
Allograft (Allo+CyA) yes 7 14 21
Allograft (Allo-CyA) no 7 14 21
Autograft (Auto+CyA) yes 7 14 21
Autograft (Auto-CyA) no 7 14 21
Isograft (Iso+CyA) yes 7 14 21
Isograft (Iso-CyA) no 7 14 21
Longitudinal nerve/graft specimens were harvested at 7, 14 and 21 days post- 
operatively, to assess the nerve graft morphology over time. These times 
corresponded to the duration of CyA administration in each group. Details of the 
techniques for tissue fixation and staining are given in Chapter 2. Indirect 
immunofluorescence was utilised to identify the elements under investigation in this 
experiment which were: Schwann cells, macrophages, vascular endothelium and 
neural axons. Staining in the graft sections was quantified within an area 2mm into 
the graft (Chapter 2) as measured from the proximal neurorraphy (termed Area G). 
This area was one frame wide and extended across the width of the nerve/graft 
complex. Assessment of axonal penetration into the graft tissue was undertaken at 
7 days only and is also described In Chapter 2.
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3,4 RESULTS
3.4.1 Macroscopic features
Grafts were inspected on retrieval for differences in colour, texture, integrity, 
surface vascularity and condition of the anastomoses and wound bed (Figure 3.1).
At 7 days, there was minimal fascial condensation and scarring within the zone of 
surgery for all groups. Correspondingly, the nerve/graft complexes were easy to 
remove. All operated nerves were mildly swollen in comparison with unoperated 
contralateral sciatic nerves. Oedema was especially prominent within all graft 
segments which were less supple than adjacent host nerve. There were prominent 
vascular markings running along the epineurial surfaces of the grafts giving them a 
slightly hyperaemic appearance. These vessels were continuous with host nerve 
vessels.
Figure 3.1 Macroscopic appearance of a non-immunosuppressed allograft 
(Allo-CyA) at 21 days
Note the colour difference, which differentiates the allogenic graft from the host nerve 
proximally and distally (Proximal to the LEFT).
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Grafts in all groups, except those of the Allo-CyA group, were similar in 
appearance to one another. At 7 days, Allo-CyA grafts were yellowish in colour, 
with a matt, opaque appearance compared to the shiny ivory, more translucent 
grafts within the other groups. These external features became progressively more 
evident with time. By 21 days, there was a generalised increase in the degree of 
fascial adherence and scarring associated with the grafts which was most obvious 
in the Allo-CyA group. Nevertheless, this did not hamper removal of the 
specimens. The hyperaemic appearance was reduced in all grafts while still being 
noticeable within the Allo-CyA group. Here the colour and texture of the grafts 
remained conspicuously different from the other groups.
3.4.2 Morphological features of axonal regeneration
At day 7, in all groups immunostained regenerating axons were seen crossing the 
proximal neurorrhaphy. Local to this point the regeneration was haphazard, before 
orientated axons aligned parallel to the long axis of the graft, running preferentially 
along the periphery of the graft (Figure 3.2). The maximum distances penetrated 
through the graft sections were achieved by more advanced axons. These were in 
advance of the main axonal regeneration front (Section 3.4.3), which generally, at 
7 days, was within the proximal third of the graft segments and contained the 
majority of stained fibres. The non-immunosuppressed allograft (Allo-CyA) group 
exhibited the poorest regeneration (Figure 3.3). Within the graft, swollen and 
fragmented axonal remnants were also stained and were a prominent feature in all 
specimens at this time point. However, it was easy to distinguish the morphology 
between brightly stained regenerating axons and these dull axonal remnants.
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Figure 3.2 Regenerating axons at 7 days
Fig. 3.2a Auto-CyA x 20 (Proximal neurorrhaphy)
Fig. 3.2b Auto-CyA X 20 (Area G)
PamNF staining of regenerating axons in the autograft group showing: a) the disorganized 
pattern of axons crossing the proximal neurorrhaphy, then b) having a more parallel and 
peripheral orientation as the main graft segment is traversed.
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Similar morphological features were seen in each group at 14 and 21 days. In 
particular there were greater amounts of stained parallel, well orientated, fine 
axons extending across the whole graft width, progressing with time (Figure 3.4). 
By 14 days a number of axons had reached the distal stump, with the main 
regeneration front seen to reach the distal third of the graft (Figure 3.5). By 21 
days, the main regeneration front had crossed into the distal nerve. However, in 
the Allo-CyA group there was a time lag so that the 21 day findings were similar to 
the 14 day findings of the other groups, with a more sparse distribution of axons 
within the core of the graft and residual stained axonal remnants indicating delayed 
regeneration.
Figure 3.3 Non-immunosuppressed allograft at 7 days
PamNF staining of Allo-CyA x 20 (Area G) showing regenerating axon with axonal remnants
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Figure 3.4 PamNF staining of axonal regeneration at 21 days
Auto+CyA X 20 (Area G) Allo+CyA X 20 (Area G)
Allo-CyA x20 (Area G)
Staining is reduced in the non-immunosuppressed allograft group. Regeneration is similar 
to that identified in the other groups, following a peripheral and parallel course from 
proximal to distal.
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Figure 3.5 PamNF staining comparing allografts at 14 days
Fig. 3.5a
Allo+CvA X 10 (Area G
Axons extend across the whole graft width in the Allo+CyA group, but remain peripheral in 
the Allo-CyA group.
Fig. 3.5b
Allo+CyA X 10 (Distal neurorrhaphy) Allo-CyA X 10 (Distal neurorrhaphy)
Axons crossing into distal nerve across the whole graft width in the Allo+CyA group, while 
only a few are reaching it in the Allo-CyA group, and are following a peripheral course there.
3.4.3 Quantification of axonal regeneration 
Maximum Axonal penetration Distance
The maximum penetration distance of regenerating axons in each experimental 
group was measured at 7 days (Table 3.2). At later times, the majority of groups 
possessed a number of axons that had crossed into the distal nerve, and it was 
therefore impossible to determine accurately the exact distance of penetration. The 
non-immunosuppressed autograft group (Auto-CyA) showed the fastest 
regeneration, with the furthest axons having nearly reached the distal coaptation by
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7 days. However, this result was not statistically different from the results obtained 
from the isograft groups, or the immunosuppressed autograft (Auto+CyA) and 
allograft groups (Alio+CyA).The non-immunosuppressed allograft group (Allo-CyA) 
produced the poorest regeneration, which was significantly lower than all the other 
groups (p<0.05).
Table 3.2
Maximum axonal penetration at 7 days (mm) - Mean (+/-SD), n=6
+CyA
Allograft
8.62
(+/-3.42)
Autograft
7.85
(+/-1.03)
Isograft
8.11
(+/-2.03)
-CyA 4.19"
(+/-0.77)
9.43
(+/-1.10)
8.30
(+/-0.72)
* p<0.05 Allograft -  CyA vs All other groups
One way ANOVA to compare all 6 groups, Scheffé multiple comparison
procedure to compare every pair of group means.
Table 3.3
7 day Percentage area of axonal staining -  
Mean (+/- S.D.), n=6
Proximal Graft
Allograft Autograft Isograft
+CyA 1.31
(+/-0.99)
1.30
(+/-1.11)
0.78
(+/-1.06)
-CyA 0.13"^""
(+/-0.25)
4.40"
(+/-4.03)
2.07
(+/-1.48)
* p=0.002 Allograft -  CyA vs Autograft - CyA
** p=0.025 Allograft -  CyA vs Isograft -  CyA
One way AN OVA to compare all 6 groups (p=0.0009), Scheffé multiple comparison procedure to 
compare every pair of group means. Analysis undertaken on log transformed data to satisfy 
assumption of homogeneous variances. Data presented in original scale of measurement.
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Proportion of Axonal Staining
An estimate of the amount of axonal regeneration was indicated by the 
quantification of the total area of neurofilament staining across a constant width of 
each graft (Area G), which was measured at each time point.
At day 7 (Table 3.3), the Auto-CyA group exhibited the highest level of 
immunostaining, which was not significantly different from all the other groups, 
except the Allo-CyA group (p=0.002), confirming the findings from the 
measurements of axonal penetration. The Allo-CyA group supported less axonal 
regeneration than the other groups, but because of variation within the 
immunosuppressed groups it was significantly different only in comparison with 
other non-immunosuppressed groups.
By 14 days (Table 3.4) the difference in axonal regeneration between the Allo+CyA 
and the Allo-CyA groups had become significant (p< 0.001).
Table 3.4 14 day Percentage area of axonal staining -  Proximal Graft
Mean (+/- S.D.), n=6
Allograft
+CyA 13.86
(+/-4.00)
-CyA 5.80 "
(+/-0.86)
* p< 0.001 Allograft -  CyA vs Allograft + CyA
One way ANOVA to compare groups (p=0.0004), Scheffé multiple comparison procedure to 
compare every pair of group means. Analysis undertaken on log transformed data to satisfy 
assumption of homogeneous variances. Data presented in original scale of measurement.
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At 21 days post-ope rati vely (Table 3.5), all the groups showed an increased 
amount of neurofilament staining corroborating the morphological findings. The 
results from both isograft (lso+/-CyA) groups and the Auto+/-CyA groups were 
similar. Axonal regeneration in the Allo+CyA group remained significantly greater 
than in the Allo-CyA group (p=0.027) and was similar to the control groups with or 
without CyA administration. The Allo-CyA group produced significantly poorer 
results than the Auto-CyA group and either of the isograft groups (p<0.002). These 
results show that the Allo-CyA group does not support as much regeneration as 
the other groups, although it does support some regeneration and that this 
improves over time in a similar manner to the others. Statistical analysis comparing 
results obtained at 7 and 21 days (Fig.3.5) confirms that axonal staining has 
increased significantly in all groups (p<0.004).
Table 3.5 
21 day Percentage area of axonal staining -  Proximal Graft 
Mean (+/- S.D.), n=6
Allograft Autograft Isograft
+CyA 19.66 18.37 25.88
(+/-1.79) (+Z-2.78) (+7-3.24)
-CyA 11.89*/** 28.84 24.07
(+7-4.66) (+7-2.68) (+7-7.04)
* p=0.027 Allograft -  CyA vs Allograft + CyA
**p<0.002 Allograft ~ CyA vs Autograft -  CyA ; Isograft +/- CyA
One way ANOVA to compare groups (p=0.000), Scheffé multiple comparison procedure to compare 
every pair of group means. Analysis undertaken on log transformed data to satisfy assumption of 
homogeneous variances. Data presented in original scale of measurement.
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Figure 3.6 Comparing axonal staining at 7 and 21 days
Axonal Staining at 7 and 21 days (%
35 -I
30 -
25 -
20 -
15 -
10
I
& I Î
7 day results 21 day results
Experimental Groups
Statistical analysis comparing results in each group between 7 and 21 days showed that 
regeneration had improved significantly in all groups (p<0.004). t-tests were used to compare 
groups Allo+CyA, Auto-Cya, Auto +Cya. The other groups failed the test for equal variances, 
therefore the Mann-Whitney Rank Sum test was used.
3.4.4 Morphological assessment of macrophage staining
In all groups, the unaffected proximal nerve furthest away from the proximal 
neurorrhaphy showed scattered small, EDI stained macrophages aligned within 
the nerve structure. These features were identical to those seen in unoperated 
control nerves (Figure 3.7) where discreet positive staining showed a constitutive 
population of macrophages. These cells lie along the long axis of the nerve and
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have an elongated appearance with dappled cytoplasm and more obvious granular 
nuclei, with the cell being “squashed” between axonal fascicles within the 
perineurium. The features noted here are in keeping with the findings of other 
authors .
Figure 3.7 ED1 staining of normal unoperated nerve x 20
Staining of scant constitutive macrophage population
Within the experimental groups, the cell density, size and shape varied 
considerably from that seen in unoperated sciatic nerve throughout the 21 day 
period of assessment. The most marked difference was the rise in macrophage 
density, extending throughout the grafts and into both nerve stumps in all groups. 
Cell numbers appeared greatest around each neurorrhaphy in all groups. The 
macrophages were mainly large, bulky cells with granular to foamy cytoplasm 
containing obvious vesicles and inclusions of debris (Figure 3.8). There were also 
large numbers of macrophages within the epineurium and in and around blood
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vessels. These latter macrophages tended to be smaller, whose morphological 
features indicated their possible monocyte origins.
The size and features of the macrophages were similar in all groups, except in the 
Allo-CyA group. Here the macrophages appeared more strongly stained and more 
extensively distributed than in any other graft groups. The cells appeared 
clumped together, with exaggerated individual morphological features. Individual 
cells were difficult to distinguish (Figure 3.9). The large amount of stained 
macrophages present within the Allo-CyA group did not appreciably alter over the 
21 day period, while in all other groups there appeared to be an increase of stained 
cells over the 21 day period as confirmed by quantification analysis.
Figure 3.8 EDI staining within graft segments
Fig. 3.8a Auto -CyA x 20 Fig. 3.8b Auto -CyA x 40
EDI staining showing the morphological features of macrophages within: a) the graft 
segment of an Auto-CyA section, and b) identifying small un reactive macrophages within a 
blood vessel near the distal neurorrhaphy.
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Figure 3.9 ED1 staining of allografts at 14 days
Allo+CyA (Area G) x 10
Allo-CyA (Area G) x 10
EDI staining within allografts sections showing the difference in quantity and features of 
macrophages. Other non-antigenic groups were similar to the Allo+CyA group.
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3.4.5 Quantification of macrophage staining
Macrophage quantification was undertaken within the same Area G of the proximal 
graft as used for other immunohistochemical staining. Measurement 
of staining gives a semi-quantitative assessment of the relative amounts of 
macrophages present within each experimental scenario allowing comparisons to 
be made between experimental groups .
At 7 days (Table 3.6), the Allo-CyA group had significantly greater ED1 staining 
than all other groups (p<0.01), a pattern maintained at 21 days (Table 3.7). There 
was no significant difference between the Allo+CyA, and isograft or autograft 
groups regardless of immunosuppression.
Table 3.6
7 day Percentage area of ED1 staining - Proximal graft 
Mean (+/-S.D.), n=6
Allograft Autograft Isograft Normal
+Cya 9.35 11.58 11.87
(+/-1.99) (+/-3.55) (+7-3.27)
-CyA 27.12* 13.27 7.37 0.79**
(+7-5.47) (+7-3.16) (+7-1.82) (+7-0.27)
* p< 0.01 Allograft - CyA vs All other groups
**p<0.001 Normal unoperated nerve vs All other groups
One way ANOVA to compare groups (p=0.000), Scheffé multiple comparison procedure to compare 
every pair of group means. Analysis undertaken on log transformed data to satisfy assumption of 
homogeneous variances. Data presented in original scale of measurement.
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As there was no statistical difference within either the isograft or autograft paired 
groups at 7 or 21 days, only the allograft groups were analysed at 14 days (Table 
3.7). Here there had been an increase in macrophage staining from 7 days within 
the Allo+CyA group which was not significant. The amount of staining within the 
Allo-CyA group remained relatively unchanged, although the results between the 
two groups were consistently significantly different at all time points (p<0.004).
Table 3.7 
Percentage area of EDI staining in Allografts -  Proximal Graft 
Mean (+/-S.D.), n=6
7 days 14 days 21 days
Allograft + Cya 9.35* 12.80* 17.11 *
(+/-1.99) (+/-2.81) (+/-4.60)
Allograft - CyA 27.12 27.88 30.26
(+7-5.47) (+7-7.02) (+7-2.99)
* p < 0.004 Allograft + CyA vs Allograft -CyA at every time point
Two way ANOVA to comparing factors time with CyA, significant interaction between CyA and time 
(p=0.04). One way ANOVA to compare groups, Scheffé multiple comparison procedure to compare 
every pair of group means. Analysis undertaken on log transformed data to satisfy assumption of 
homogeneous variances. Data presented in original scale of measurement as represented above.
At 21 days (Table 3.8) there was no within-group difference for the autografts or 
isografts. Only the Iso+CyA group was significantly lower than the Auto-CyA group 
(p<0.04). Comparisons between groups containing allogeneic grafts at 21 days 
showed that the Allo-CyA group had the greatest macrophage staining at 30.26% 
which was significantly greater than the corresponding immunosupressed group 
(p=D.022).
Table 3.8
21 day Percentage area of EDI staining -  Proximal graft
Mean (+/-S.D.), n=6
+CyA
Allograft Autograft Isograft
17.11
(+/-4.60)
18.95
(+/-6.37)
12.35 ** 
(+/-2.19)
Normal
-CyA 30.26 * 
(+/-3.00)
21.30
(+Z-2.66)
15.80
(+A2.39)
0.79 *** 
(+/-0.27)
* p < 0.05 Allograft - CyA vs Allograft + CyA, Autograft + CyA, lsograft+/-CyA
**p < 0.04 Isograft + CyA vs Autograft -  CyA
***p < 0.001 Normal unoperated nerve vs All other groups
One way ANOVA to compare groups (p=0.000), Scheffé multiple comparison procedure to compare 
every pair of group means. Analysis undertaken on log transformed data to satisfy assumption of 
homogeneous variances. Data presented In original scale of measurement.
Comparison of data within each group at 7 and 21 days (Table 3.9) mirrored 
morphological findings, showing non-significant increases within the Allo-CyA 
group but significant changes within the Allo+CyA group (p<0.005). The autograft 
groups and the Iso-CyA group also exhibited significantly increased staining 
between 7 and 21 days (p<0.04) although the Iso+CyA group did not. Generally, in 
the majority of groups staining levels were lower in the CyA treated groups, 
although not necessarily significantly.
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Table 3.9
7 and 21 day Percentage area of Macrophage staining -  Proximal Grafts.
Mean (+/-SD), n=6
Autograft
Isograft
Allograft
p < 0.04
* p < 0.001
^**p < 0.005
7 days 
21 days
7 days 
21 days
7 days 
21 days
+CyA
11.58
(+/-3.55)
18.95*
(+/-6.73)
11.87
(+7-3.27)
12.35
(+7-2.19)
9.34
(+7-1.99)
17.11 *** 
(+7-4.60)
-CyA
13.27
(+7-3.16)
21.30**
(+7-2.66)
7.37
(+7-1.81)
15.80**
(+7-2.39)
27.12
(+7-5.47)
30.26
(+7-3.00)
Autograft + CyA between 7 and 21 days
Autograft - CyA and Isograft - CyA between 7 and 21 days
Allograft + CyA between 7 and 21 days
Comparison of each within-group mean by f - te s t
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Figure 3.10 SI DO staining of Schwann cells within grafts at 7 days
a)Auto+CyA x 20
b) Allo+CyA x20 c) Allo-CyA x20
Features of Wallerlan degeneration are displayed, although note the more irregular and 
“moth-eaten” appearance of the non-immunosuppressed group suggesting a process in 
excess of Wallerian degeneration is occurring.
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3.4.6 Morphological assessment of Schwann cell staining
All the grafts In these experiments contained constitutive Schwann cells, which 
underwent the changes of Wallerian degeneration related to nerve injury.
Within the proximal nerves the features exhibited by stained Schwann cells were 
similar in all groups at all time points; appearing well preserved, tightly packed, and 
longitudinally orientated with occasional vacuolation. At the proximal neurorrhaphy 
(PN), thinner elongated immunoreactive Schwann cells appeared to cross into the 
graft segment in a disorganised manner. A more parallel orientation was resumed 
as they penetrated further into the graft similar to the findings with neurofilament 
staining.
At 7 days (Figure 3.10), within the grafts of all groups, the Schwann cells were 
large and more rounded in shape with overall parallel orientation, but containing 
many vacuoles and debris filled vesicles; features typical of Wallerian 
degeneration. At the distal neurorrhaphy, Schwann cells had similar normal 
features to those at the proximal neurorrhaphy and also gave the appearance of 
reaching into the graft (Figure 3.11). By 21 days (Figure 3.12), the grafts of all 
groups showed a general reduction in degenerating constitutive Schwann cells, 
with fewer vacuoles, and less marked features than at 7 days. More spindle 
shaped immunostained cells with more obvious normal features of nuclei and 
defined orientation forming bands of Büngner were noted within and penetrating 
into the grafts from both nerve stumps by 21 days.
Figure 3.11 S I00 staining of Schwann cell at Distal neurorrhaphy
Auto-CyA X 40
Schwann cell appearing to cross into distal graft from distal nerve
Figure 3.12 SI 00 staining of Schwann cells in grafts at 21 days
Allo+CyA X 20
Appearances were similar in all non-allogenic groups (including the immunosuppressed 
allografts). Schwann cells aligned into bands of Büngner.
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In the Allo-CyA group, at 7 days the amount of positive stained cells in the nerve 
stumps and adjacent graft appeared similar to the other groups. However, by 14 
days (Figure 3.13) there was a noticeable reduction in the amount of SI 00 staining 
within the graft segment with more evident signs of degeneration. The central 
portion of the graft was generally the most severely affected with numerous faintly 
stained, indistinct cells with occasional large vacuolations (Figure 3.13). At 21 
days, the relative amounts of normal looking stained cells appeared to have 
increased within the grafts, with morphological features similar to those from the 
other groups. These findings are suggestive of a rejection process becoming 
maximal between 7 to 21 days, and affecting particularly non-immunosuppressed 
allografted Schwann cells. It also appears that at 21 days there are a significant 
amount of Schwann cells projecting into the grafts from the distal and proximal host 
nerves.
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Figure 3.13 SI 00 staining within Allograft groups at 14 days
Allo+CyA
Proximal Neurorrhaphy x 10
Allo-CyA
Proximal Neurorrhaphy x 10
Area G x 20 Area G x 10
Distal neurorrhaphy x 10Distal neurorrhaohv x 10
Schwann cell density Is reduced within the non-immunosuppressed group. Note the pattern 
of staining Is similar to that described In the other groups although more advanced here In 
the Immunosuppressed group, with Schwann cells evident throughout the whole graft 
structure. Schwann cells appear to be crossing both neurorrhaphies, seen more clearly In 
the non-immunosuppressed group.
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3.4.7 Quantification of Schwann cell staining
As with ED1 staining of macrophages, 8100 will stain all Schwann cells regardless 
of their morphological condition. This means that measurement of the amount of 
8100 staining will give only an indicative assessment of Schwann cell numbers. 
The size and features of cells varies throughout the period of Wallerian 
degeneration and, as the amount of Schwann cell debris was more prominent at 7 
days, Schwann cell quantification was only carried out at 14 and 21 days. As 
allogenic Schwann cells become destroyed by rejection, cell density tended to be 
reduced in non-immunosuppressed allografts at 14 days, before showing some 
recovery at 21 days.
Only the allograft groups were quantified at 14 days as the results of morphology 
and quantification with the other stains has shown the immunosuppressed allograft 
to be similar to controls, and this was corroborated by the qualitative analysis of 
Schwann cells. At 14 days (Table 3.10), the amount of 8100 stained cells was 
significantly lower within the Allo-CyA group compared to the Allo+CyA group 
(p<0.001), which confirms the morphological observation.
Table 3.10 
14 days Percentage area of Schwann cell staining - Proximal graft 
Mean (+/-S.D.), n=6
Allograft + Cya 29.88
(+/-3.90)
Allograft -  CyA 8.08 *
(+Z-2.22)
* p < 0.001 Alio + CyA vs Alio - CyA
One Way ANOVA to compare groups. Analysis undertaken on log transformed data to satisfy 
assumption of homogeneous variances. Data presented in original scale of measurement.
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Table 3.11
21 day Percentage area of Schwann cell staining -  Proximal Grafts
Mean (+/-S.D.), n=6
Allograft Autograft Isograft
+CyA 40.92 39.26 38.46
(+7-9.69) (+7-4.99) (+7-5.27)
-CyA 8.30* 45.77 47.71
(+7-4.55) (+7-3.77) (+7-4.52)
* p < 0.05 Allograft -- CyA vs All other groups
One Way ANOVA between groups (p< 0.001), Tu key test within each group.
At 21 days the results of quantification for the Allo-CyA group remained 
significantly different from the Allo+CyA group, and were also significantly different 
from the autograft and isograft control groups regardless of immunosuppression. 
There was no statistical difference between these controls and the Allo+CyA group 
(Table 3.11).
3.4.8 Morphological assessment of endothelial cell staining
Von Willebrand's factor (vWF) was used to stain endothelial cells, in order to 
identify the vascular pattern following grafting and any areas of poor 
vascularisation and relative ischaemia. At 7 days, multiple small calibre vessels 
were found around both neurorrhaphies, with more extensive vascularisation within 
the grafts than in unoperated nerve (Figure 3.14a). Vessels were also seen to 
penetrate the grafts from the surrounding tissue (Figure 3.14d). Subjectively, the 
vessels appeared smaller in diameter in the Allo-CyA group than in other groups 
(Figure 3.14c). From day 14, all groups, except the Allo-CyA group, had clear 
patterns of moderate to large branching blood vessels traversing the entire grafts 
(Figure 3.14b). In the Allo-CyA group small calibre vessels persisted within the
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graft and around each neurorrhaphy (Figure 3.14c, 3.14d). By 21 days, blood 
vessel pattern and density were similar in all experimental groups. These findings 
suggest that, following grafting, in the Allo-CyA group there is a longer relative 
ischaemic period than in the other groups, a further contributing factor leading to 
poorer central core regeneration.
Figure 3.14 Endothelial staining with vWF in Area G
a) Normal nerve x 10 b) Allo+CvA at 21 davs x 10
c) Allo-CyA at 14 days x 10
Following graft insertion, multiple small vessels were seen around both neurorrhaphies and 
within the grafts. By 21 days, staining identified larger caliber, more mature looking vessels, 
appearing more like those in normal nerve (3.14a, 3.14b). Vessels were less distinct within 
non-immunosuppressed groups compared to the other groups (3.14b, 3.14c). Similar to 
axons and Schwann cells, vessels were identified in peripheral sites during earlier time 
periods. Some vessels were seen penetrating the grafts from the wound bed (3.14d).
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3.5 DISCUSSION
This study has investigated the early post-engraftment period comparing both 
immunosuppressed and non-immunosppressed peripheral nerve allografts using 
four separate but integrally related features: axonal regeneration, macrophage 
infiltrate, Schwann cell morphology and vascularisation. By using longitudinal nerve 
sections events occuring within the proximal and distal host nerve ends can be 
compared directly to events within the allograft at each time point under 
investigation. We have shown that axonal regeneration will occur to a limited extent 
within a nerve allograft without immunosuppression and that its advancement 
follows the same pattern as its immunosuppressed counterpart and relevant 
control groups. Rejection of allogenic ceils does occur but they seem to be 
replaced gradually, allowing axonal regeneration to increase slowly.
Cyclosporin has been extensively used in the investigation of peripheral nerve 
allografting . It has been shown to be an extremely effective single agent 
immunosuppressant 1 1^7,199,202  ^ ^nd since its discovery in the 1970’s it has 
revolutionised transplantation medicine, it has been shown to have relatively little 
toxicity in the rat within the time scale of these experiments 206,213,253 
Administration by the subcutaneous route provides good drug bioavailability while 
being less stressful on the animal models when compared with other possible 
methods 206,213,254 used the parenteral formulation of CyA in the well-
documented dose of 5mg/kg/day 200,209 dose has been reported to prevent
rejection and allow axonal regeneration comparable to autograft and isograft 
controls 207,216,254 _
Axonal regeneration is widely accepted to occur at an average rate of 1mm per day 
. Although, depending on the site and local factors, rates of 1.0 - 8.5mm per day 
have been quoted . The results from this study indicate a good rate of 
regeneration for a proximal mixed nerve, with the maximum Auto-CyA group
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axonal regeneration distance reaching 9.43mm from the proximal neurorrhaphy 
over 7 days. Only the Allo-CyA group produced a maximum penetration distance 
less than that expected, at 4.19 mm over the same period. However this compares 
favourably with results extrapolated from experiments where fibronectin, PHB 
(poly-3-hydroxybutyrate) and frozen thawed muscle conduits were assessed 
. Comparing the results of axonal penetration with the features noted 
morphologically, it is apparent that the most advanced axons in all groups were 
mainly evident close to the periphery of the grafts. With time, each graft core 
became filled with regenerating axons.
From the results of macrophage staining all groups exhibited results greater than 
normal nerve. The constitutive population of macrophages is reported at between 
1 -4 % , which is in keeping with the result for normal nerve quoted here, with
similar density of macrophages being noted in rat and human peripheral nerves 
. The greatest inflammatory infiltrate was associated with the Allo-CyA group. This 
might contribute to the reduced axonal regeneration seen in this group by providing 
a degree of physical Impedance to the advancing axons similar to that seen in 
fresh muscle grafts where the basal lamina tubes contain cells and debris , and 
also because of the associated disruption to nerve architecture . However it also 
suggests that an inflammatory reaction in excess of that normally seen following 
nerve injury was occurring. This process is likely to be immunological rejection, 
with its concomitant destruction of antigenic Schwann cells, resulting in poorer 
regeneration.
Although acute rejection is most associated with a lymphocyte infiltrate, a 
mononuclear/macrophage infiltrate is also occurring as both cell lines are intimately 
involved in the rejection process 145,273,274 studies of cardiac and renal 
allotransplantation the degree of macrophage infiltration has correlated with the 
occurrence and severity of allograft rejection . This occurs within a few days 
of antigen exposure, once aliorecognition and antigen presentation to
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im m u n o c o m p e te n t  c e lls  h a s  o c c u r re d  145,247,263 th e  n e rv e  a llo g ra ft  m o d e l  
re je c tio n  a p p e a r s  to  b e c o m e  m a x im a l a ro u n d  1 4  d a y s  p o s t -o p e  ra ti v e ly  a n d  to  
e x te n d  fo r  a  v a r ia b le  t im e  p o in t th e re a f te r ,  d e p e n d in g  o n  th e  a n t ig e n ic  lo a d  
209,247,277,278 “fh o s e  o b s o rv a t io n s  a r e  c o n s is te n t w ith  th e  m a s s iv e  a n d  s u s ta in e d  
m a c r o p h a g e  in filtra te  re p o r te d  in th e s e  e x p e r im e n ts .
Macrophages are integral to Wallerian degeneration 20,22,25,144,279  ^ ^^hich accounts 
for the infiltrate seen in the other experimental groups. They phagocytose axonal 
and myelin debris 1 -^20,27  ^ t”ecycle cholesterol for myelin resynthesis i^ ®-273 and 
produce cytokines which promote axonal regeneration directly and indirectly 
through Schwann cell stimulation to produce neurotrophic factors 25,92,94,230 
Schwann ceils also phagocytose debris and can synthesise myelin without 
recycled components although these processes are prolonged in the absence of 
macrophages 19.94,173,273 Macrophages are also one of the major antigen 
presenting cell in allografts i4o.i4s,i46 although Schwann cells can also participate in 
this in nerve allografts i 5i . i 63, i68,170,281
Schwann cells are the major non-neuronal, endoneural cell type, being nine times 
more common than fibroblasts , and they are highly immunogenic 102.170,264,231 
They are essential to optimum nerve regeneration, as has been shown by many 
commentators comparing cellular and acellular conduits ^2,02,75,233  ^ they have 
the ability to migrate from both proximal and distal nerve ends into bridging 
conduits 102.151,245,247 /Although we did not attempt to track the two populations of 
Schwann cells (host and donor) in these experiments, histological findings 
suggested that Schwann cell migration was occurring from the host nerve stumps. 
This was especially evident within the Allo-CyA group at 14 days where the greater 
cellular degeneration highlighted the presence of Schwann cells extending across 
the coaptation zone. This would be consistent with evidence from axonal 
regeneration results and macrophage infiltration indicating that reduction of donor 
Schwann cell staining was secondary to antigenic cell destruction by rejection,
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thereby producing poorer axonal regeneration. However, the maximum rejection 
phase appeared to be limited, as morphological assessment indicated increased 
Schwann cell density within the allograft by 21 days with spindle shaped elongated 
cells noted across the whole graft width. Although this finding was not borne out by 
the results of Schwann cell quantification, the progressive improvement with time 
of axonal regeneration, both morphologically and quantitatively, provide additional 
evidence to indicate that an environment more conducive to axonal regeneration 
was being established in the Allo-CyA group. It should also be emphasised that in 
a nerve undergoing Wallerian degeneration a variety of Schwann cell sizes are 
present depending on the stage of dedifferentiation of the individual cells. For this 
reason the quantification of SI 00 staining cannot relate in a direct way to cell 
numbers but, as shown here, the amount of staining can be used to identify trends 
and provide additional evidence of events observed morphologically.
Experimental findings for the Alio+CyA group and the control groups were not 
significantly different. The results of this study would indicate that short-term 
immunosuppression with CyA prevented rejection of antigenic glial and endoneural 
cell components. Therefore, antigenic host Schwann cells were undergoing 
Wallerian degeneration at a similar rater as neighbouring host Schwann cells, 
hence supporting better host axonal regeneration. Other groups have also 
identified this. Lassner used staining of Schwann cell MHC expression to 
identify the allograft cells as being of donor origin, while Midha determined 
Schwann cell phenotype using a mutant mouse strain in an allograft model lacking 
myelin basic protein so that host and donor could be differentiated .
Restoration of circulation to an avascular graft requires contributions from the 
wound bed and either cut nerve end 52,156,259.283,284 pi-Q^ious work in our laboratory 
using double immunostaining has shown in an acellular conduit, that regenerating 
blood vessels from the proximal nerve end travel in association with regenerating 
axons, and the more correctly orientated the blood vessels, the more efficient the
axonal regeneration . Also improvements in establishing the circulation are 
accompanied by associated improvements in regeneration . The investigation of 
the relative contributions of inosculation and neovascularisation involved in nerve 
grafting is beyond the scope of the experiments reported here, except to say that 
the topic remains under debate . However, the finding of small calibre vessels at 
7 days, becoming larger with time and appearing similar to the pattern of vessel 
alignment noted in the proximal and distal nerves indicates that an active 
revascularisation process is occurring and maturing with time. The pattern of 
Schwann cell and axonal distribution supports this, with both elements preferring 
peripheral, oxygenated sites instead of the relative ischaemia of the graft core. As 
the blood supply to the graft becomes more established, so Schwann cells and 
axons are distributed throughout the grafts. Grochowicz, in a microangiographic 
study observed a similar pattern of nerve graft revascularisation as identified here, 
with longitudinal orientated vessels within the graft and smaller calibre vessels 
around the neurorrhaphies in immunosuppressed allografts and autografts . 
Findings in the experiments reported here suggest that both inosculation and 
neovascularisation are involved in revascularisation of these grafts.
Identification of multiple small calibre blood vessels at 3 weeks within the Allo-CyA 
group suggests a more immature blood supply. Vascular endothelial cells are also 
highly immunogenic 4^6,148,286 part of the rejection reaction circulation will be 
disrupted with the prolongation of ischaemia directly contributing to the poorer 
regeneration seen in the Allo-CyA group, and also indirectly through the effects of 
ischaemia on Schwann cells.
The general results from isograft and autograft groups were not significantly 
different from each other, supporting the assumption that within these inbred 
groups there was no significant genetic disparity between animals. Wallerian 
degeneration and axonal regeneration were found to proceed in similar manners 
within the control groups. However the presence of macrophages and the
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cytokines they produce, most notably interleukin 1 (IL-1), are beneficial to the 
efficient progression of Wallerian degeneration and regeneration 22,25,92,144,287 
Cyclosporin is known to exert most of its immunosuppressant effects by inhibiting T 
lymphocyte production of lymphokines, but by effecting T cells, CyA also has 
indirect effects on macrophages , which if sufficient could affect the progress 
of Wallerian degeneration. CyA also effects the non specific effector mechanisms 
of rejection of which the monocyte/macrophage system is integral . In these 
experiments the administration of CyA has produced a slight, but not significant 
deleterious effect on the responses of non-allogenic control grafts. Neurotoxicity 
has been reported with CyA, usually with prolonged usage and being identified by 
more central effects . Within the time frame of these experiments CyA did not 
appear to hinder axonal regeneration. This is in keeping with studies using CyA 
and the immunosuppressants FK506 and 15-deoxysperguelin where administration 
of the immunosuppressant improved axonal regeneration 134,227,228,288
In view of the inherent problems associated with autografting and the often 
suboptimal results produced by this management strategy 41.48,289  ^ selected 
cases peripheral nerve allografting remains an attractive proposition. MacKinnon’s 
group have undertaken reported successful immunosuppressed clinical cadaveric 
nerve allografts 217.224,225 results of this study provides further evidence to
suggest that the nerve allograft is a viable alternative and that manipulation of the 
microenvironment may improve the conditions for nerve regeneration without, or 
with reduced immunosuppressant requirements.
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Morphological Assessment of the effects of an 
Allogenic/Autologous Nerve Sandwich Graft on 
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4.1 INTRODUCTION
Researchers studying acellular or inorganic conduits have noticed that inclusion of 
Schwann ceils 62,75.76,238,239,290,291  ^ neurotrophic factors 4.52,65,241-243 ji^^proves
axonal regeneration through these conduits. Enhanced regeneration has been 
achieved using cultured Schwann cells 61,62,77,162,238,240 portions of nerve 
interposed between portions of conduit 69.244,245,292,293 latter technique has
been called “stepping stone” grafting , or “sandwich grafting” 4^5,292 
technique introduces extra neurorrhaphies but requires no special facilities or 
expertise other than the skills of a competent microsurgeon. This technique has not 
been investigated with nerve allografts.
As seen in previous chapters allografts already possess most of the factors 
associated with an ideal conduit , but they also contain Schwann cells. It is 
possession of these antigenic cellular factors which limit the nerve allograft, as 
peripheral nerve tissue is not immunologically privileged. All of the components 
within peripheral nerve express antigenic markers. Basal lamina in studies using 
acellular nerve appears to have little antigenicity 77,92,1 S8, i 59,18o , i86,294-296  ^ however in 
an experiment involving submaxillary glands Darcy showed a second-set reaction 
occurred to basal lamina . A higher degree of antigenicity has been reported for 
vascuiar endothelium 146,148,151,297,298 Schwann cells 162,151,152,162,264
express the constitutive and inducible M.H.C. (Major histocompatibility complex) 
class I and II antigens 1 s i,  162,167-170,281
It would seem rational to hypothesise that if a depot of Schwann cells will 
repopulate other acellular conduits, then a depot of autologous Schwann cells will 
repopulate a nerve allograft following rejection. As indicated by other work using 
the same technique 69,245,292,299  ^ axonal regeneration within the nerve aliograft 
should be improved by addition of a Schwann cell depot, but peculiar to allogenic 
grafts, increasing the host celi compiement within the allograft may remove or 
reduce requirements for immunosuppressants. The sandwich graft construct,
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formed from both allogenic and non-allogenic elements would therefore represent 
a chimeric structure. In other organ systems chimeric states have been found to 
improve host tolerance to allogenic tissue 165,300-303
4.2 AIMS
The purpose of this study was, firstly, to investigate the effect of inclusion of a 
depot of host Schwann cells on the axonal regenerative potential within an allograft 
model. Secondly, to assess the effect the depot of host Schwann cells had on 
immunosuppressant requirements by comparing immunosuppressed and non- 
immunosuppressed groups.
Qualitative and quantitative assessment of regenerating axons and Schwann cells 
were carried out to determine the relationship of these components within the 
sandwich graft model. Macrophage and endothelial ceil staining were also 
undertaken to assess the effect of the sandwich allograft on inflammation and 
vascularity. Further comparisons were made between allogenic sandwich grafts 
and a non-allogenic control sandwich graft composed of isogenic and autologous 
nerve, as well as with simple nerve allografts and isografts (see Chapter 3).
4.3 EXPERIMENTAL PROTOCOL
The animal models, surgical and anaesthetic techniques employed in this study are 
described in Chapter 2.1. The parenteral formulation of cyclosporin A (CyA) was 
the sole immunosuppressant used (Chapter 2). This was delivered subcutaneously 
in a dose of 5mg/kg/day, beginning the day preceding surgery and continuing for 
the 21 day duration of the experiment.
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Table 4.1
Experimental Groups
Graft Host Donor CyA Duration Number
SandAllo Lew DA/Lew Yes 21 days 6
+ CyA
SandAllo Lew DA/Lew No 21 days 6
- CyA
SandCon Lew Lew/Lew No 21 days 6
-CyA
Sandwich allografts (SandAllo) were constructed as per Chapter 2.1.2., and were 
composed of two 5mm sections of DA sciatic nerve with a central 5mm portion of 
host Lewis nerve. Similarly, sandwich control (SandCon) grafts comprised two 
5mm portions of isogeneic nerve with a central 5mm Lewis autologous segment. 
For a summary of all the groups involved see Table 4.1. An immunosuppressed 
control sandwich graft group was not used in this experiment as the findings from 
non-aliogenic control groups in Chapter 3 had not noted any significant differences 
between isografts or autografts related to immunosuppression.
Details of techniques for tissue fixation and staining are given in Chapter 2.1.3- 
2.2.3. The technique of indirect immunofluorescence was employed using the 
following antisera: Pan-axonal marker of neurofilaments (Pam-NF), S I00, EDI and 
Von Willebrands factor as per Chapter 3. Morphological assessments for 
qualitative analysis (Chapter 2.2), along with computer assisted image analysis for 
quantification of area of staining were utilised (Chapter 2.2.5). Three separate 
areas were measured to quantify staining area. These were: an area 2mm into the 
proximal graft as measured from the proximal neurorrhaphy (Area G), an area 
2mm into the middle autologous graft segment as measured from its neurorrhaphy
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with the proximal graft (Area M), and an area 12mm distal to the proximal 
neurorraphy (Area D) (Figure 4.1).
4.4 RESULTS
4.4.1 Macroscopic
All of the sandwich grafts used in this experiment had healed well by 21 days, and 
all were easily removed at harvest. However, there were conspicuous differences 
noted between the allogenic and autologous graft segments especially within the 
non-immunosuppressed sandwich graft group. The features were similar to those 
described for simple grafts in Chapter 3, with oedema of all the graft segments and 
relative hyperaemia of the epineurial surface of the grafts. These features were 
much more marked within the allogenic segments of the non-immunosuppressed 
sandwich allografts, due to their juxtaposition between segments of autologous 
nerve. The yellow toned colour difference previously noted with simple allografts 
was also evident within the allogenic sections of the non-immunosuppressed 
sandwich grafts (Figure 4.2).
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Figure 4.1
Diagram of quantification areas G, M, and D within sandwich and simple
grafts.
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Figure 4.2 Sandwich graft at 21 days
Macroscopic appearance at 21 days of a Sandwich allograft + CyA. Proximal is uppermost.
4.4.2 Morphological features of axonal regeneration
Sandwich grafts were oniy assessed at 21 days. This time point was noted in 
experiments comparing simple non-allogenic and allogenic graft models (Chapter 
3) to produce axonal regeneration in the former groups across 10mm grafts and 
into distal nerve. However regeneration within the non-immunosuppressed allograft 
group exhibited delayed and poorer regeneration, associated with reduced 
amounts of Schwann ceil staining. Based on these observations, expectations of 
the situation within the sandwich grafts were that by 21 days the peak of 
immunological rejection would be passed, although probably still ongoing, and 
allogenic Schwann celi numbers would be maximally depleted. Therefore at this 
time point, any benefits from the host depot of Schwann ceils within the sandwich 
grafts would be more easily observed. Comparison with the results in Chapter 3
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would also identify any gross differences in behaviour between the various types of 
graft sections employed.
In the sandwich grafts, features of axonal regeneration within the allogenic and 
non-allogenic graft segments were similar to those described in Chapter 3. The 
majority of axons had reached the distal graft segment with the most advanced 
fibres extending into the distal nerves. The sandwich grafts all appeared to have 
produced regeneration similar to that identified within the non-allogenic grafts in 
Chapter 3, and certainly much better than the non-lmunosuppressed simple 
allograft group.
The pattern of regeneration again indicated that axons regenerated from an initially 
preferred course along the periphery of the nerve grafts gradually extending to 
include the whole width of the nerve graft sections with time. This was indicated by 
the progressive reduction in the amount of regenerating axons from proximal to 
distal, and peripheral to central along the sandwich graft structure. Also, at 21 days 
there was minimal disorganisation of fibres associated with the most proximal 
neurorrhaphy. However, with successively more distal neurorrhaphies the stained 
axons crossing the coaptations became more obviously disorganisation and similar 
to those noted In the early time periods observed within Chapter 3. There was no 
obvious difference in the amount of axonal regeneration observed within either the 
immunosuppressed or non-immunosuppressed sandwich allografts, or the 
sandwich control group (Figure 4.3).
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Figure 4.3 Sandwich graft axonal regeneration at 21 days
SandAllo+CyA SandAlio-CyA
Area G x 10 Area G x 10
Area M x 10 Area M x 10
Area D x 10 Area D x 10
Pam-NF stained axons showing regeneration as It proceeds from proximal to distal through 
the sandwich grafts. Features In the control group were similar to those In the Allo+CyA 
group.
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4.4.3 Quantification of axonal regeneration
The sandwich grafts used in this experiment measured 15mm in length and were 
used to repair a 10mm nerve defect. As qualitative assessment had indicated 
many axons were present within the distal graft sections, quantification of axonal 
staining was undertaken within the proximal and distal graft areas (Figure 4.1-Area 
G and D) at this 21 day time point. The aim of the two measurements was to help 
establish a more accurate interpretation of regeneration within the different models, 
especially as theoretically the increased number of coaptations may influence 
regeneration.
Table 4.2
21 day Percentage area of axonal staining -  Sandwich Grafts 
Mean (+/-SD)
Proximal Distal
graft (Area G) graft (Area D)
SandAllo 14.94 6.01
+ CyA (+/-1.47) (-f/-2.87)
SandAllo 14.84 7.54
- CyA (+/-2.18) (+/-3.16)
SandCon 10.75 * 4.91
- CyA (+Z-2.46) (+/-1.13)
Area G
* p<0.05 SandCon vs SandAllo +/- CyA
One way ANOVA comparing groups (p=0.005). All pairwise multiple comparison procedures 
Tu key test
Area D
One way ANOVA comparing groups (p=0.233). No significant difference between groups.
Quantification of the sandwich allografts within the proximal allograft segments 
confirms the findings from morphological assessment (Table 4.2), with no statistical 
difference identified between the amounts of stained axons present within these
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groups regardless of immunosuppression. There was, however, a statistical 
difference found on comparison with the sandwich control group (p<0.05). This 
difference was not noted when axonal staining was quantified within the distal area 
of analysis. Here there were no statistical differences noted between any of the 
sandwich graft groups.
Comparison of quantification within the proximal grafts between the sandwich 
grafts and the simpie grafts from Chapter 3 produces a much more complex picture 
(Table 4.3), A One Way ANOVA was undertaken on ranks which uses median 
values for each group, therefore some of the results differ from those given in 
Chapter 3.
Table 4.3 
21 day Percentage area of axonal staining -  Proximal Graft 
Median (25-75%)
SandAllo SandCon Allograft Isograft
+CyA 14.45* n/a 19.70** 25.10*
(13.70-16.30) (18.40-20.30) (24.30-27.70)
-CyA 14.85* 10.21 10.55 23.95"
(12.50-17.10) (8.61-12.50) (9.81-12.80) (22.90-29.50)
* p<0.05 SandAllo+ACyAvs All other groups
**p<0.05 Allograft + CyA vs All other groups
’ p<0.05 Isograft + CyA vs All other groups
"p<0.05 Isograft -  CyA vs All other groups
Kruskal-Wallis One Way ANOVA on ranks as data failed equal variance test (p<0.001). All pairwise 
multiple comparison procedures -  Student-Newman-Keuls method.
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The isograft and immunosuppressed allograft groups have produced the greatest 
axonal regeneration, with all the sandwich grafts exhibiting statistically poorer 
regeneration by comparison (p<0.05). However, both aliogenic sandwich grafts 
showed significantly better axonal regeneration than the non-immunosupressed 
simple allograft (p<0.05). The results from the sandwich control group were the 
poorest overall. This was an unexpected result as measurements were taken 
within an isogenic graft portion and were expected to mirror the results produced 
by the other isogenic groups. Again, when results from all groups were compared 
within the distal area of quantification (Area D), no statistical differences were 
noted (Table 4.4).
Taken together, qualitative and quantitative findings from the proximal and distal 
assessment areas indicate a potential benefit conferred by the sandwich allograft 
composition. However, the results from the sandwich control group infer that where 
no benefit is expected i.e. the graft is not allogenic, then the structure may 
compromise eariy regeneration although appearing to even out with time.
Table 4.4 
21 day Percentage area of axonal staining -  Distal Quantification Area 
Mean (+/-SD)
SandAllo SandCon Allograft Isograft
+CyA 6.01 n/a 5.62 4.47
(+/-2.87) (+/-2.61) (W-2.85)
-CyA 7.54 4.91 3.69 6.66
(+/-3.16) (+/-1.13) (+/-1.49) (+/-3.14)
One way ANOVA to compare groups (p=0.186). No statistical difference between groups.
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4.4.4 Morphological assessment of Schwann cell staining
As in the simple grafts (see Chapter 3), Schwann cells within the proximal nerve 
stumps were well organised, longitudinally orientated and exhibited some 
vacuolation. Within the sandwich grafts there were less obvious distinctions 
between any of the groups (Figure 4.4). Generally, there were well orientated 
longitudinal rows of elongated, normal looking Schwann cells within the grafts and 
the distal nerve stump. The core areas of the graft sections were where deficient 
staining, if any, occurred. This was not such a prominent feature as that noted 
within the simple non-immunosuppressed allograft group presented in Chapter 3. 
At each of the coaptations, Schwann cells and their processes were seen to extend 
across these more disorganised zones giving the indication of migration across 
these areas as noted within the simple grafts. This disorganised appearance was 
more obvious at the more distal coaptations mirroring the appearance of axonal 
staining.
4.4.5 Quantification of Schwann cell staining
As mentioned within the experimental protocol, quantification of immunostaining 
was undertaken within the proximal graft, middle autologous graft and distal grafts 
of the sandwich grafts: areas G, M and D respectively, (or distal nerve in the case 
of simple grafts). When comparisons were made with results of similar staining 
within Chapter 3, only the proximal and distal areas were compared as there was 
no area corresponding to the central autologous graft within the simple models.
Quantification of Schwann cell staining within the proximal graft sections of 
sandwich grafts at 21 days indicated that there was significantly less Schwann cell 
staining within the non-immunosuppressed group compared to the control 
sandwich graft group (p<0.05), but no difference with regard to the 
immunosuppressed sandwich allograft (Table 4.5).
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Figure 4.4 Sandwich graft Schwann cell staining at 21 days
SandAllo+CyA 
Area G x 40
SandAllo-CyA 
Area G x 40
Area D x 20 Area D x 10
S I00 staining of Schwann cells within allogenic sandwich grafts. Schwann cells in both 
groups are aligning into bands of Büngner. There are some cells still exhibiting vacuolation. 
Schwann cells are present throughout both graft types, in all areas.
Comparison of these results with the simple graft groups (Table 4.6) shows that all 
of the sandwich graft groups have produced greater Schwann celi staining than the 
non-immunosuppressed ailograft group (p<0.05). This is especially important in the 
case of the non-immunosuppressed sandwich aliograft group.
14
Table 4.5
21 day Percentage area of Schwann cell staining - 
Mean (+/-SD)
- Proximal Graft
SandAllo SandCon
+ CyA 31.45 n/a 
(+/-5.70)
- CyA 28.04 * 41.16 
(+/-8.62) (+/-6.6Q)
* p<0.05 SandAllo -  CyA v SandCon
One Way ANOVA comparing groups (p=0.016). All pairwise multiple comparison procedures -  
Tukey Test.
Table 4.6
21 day Percentage area of Schwann cell staining - 
Mean (+/-SD)
- Proximal Graft
SandAllo SandCon Aliograft Isograft
+CyA 31.45 ** n/a 40.92 
(+/-5.70) (+/-9.69)
38.46
(+/-5.27)
-CyA 28.04 *** 41.16 8.30 * 
(+/-8.62) (+/-6.69) (+/-4.55)
47.71
(+/-4.52)
* p<0.05 ** p<0.05 
*** p<0.05
Allograft -  CyA vs All other groups 
SandAllo + CyA vs Isograft -CyA
SandAllo -  CyA vs Isograft -  CyA, SandCon, Allograft + CyA
One Way ANOVA (p< 0.001). All pairwise multiple comparison procedures -  Tukey Test.
Both of the sandwich aliograft groups had significantly poorer staining than non- 
immunosupressed isograft group, which had the best results. As it was expected, 
the isograft section measured within the control sandwich graft exhibited similar 
staining to the simple isografts. Similarly, there was no difference noted within the 
proximal quantification areas of both the immunosuppressed sandwich and simple
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allograft groups. The immunosuppressed simple ailograft did however show 
greater staining than the non-immunosuppressed sandwich allograft but staining 
was equivalent within both sandwich ailograft groups.
Table 4.7
21 day Percentage area of Schwann cell staining -  Middle Autograft Section 
Mean (+/-SD)
SandAllo SandCon
+ CyA 28.41 * n/a
(+/-5.32)
- CyA 31.45 38.69
(+/-3.42) (+/-7.15)
* p=0.02 SandAllo + CyA v SandCon
One Way ANOVA to compare groups (p=0.019), Scheffé multiple comparison procedure to 
compare every pair of group means. Analysis undertaken on log transformed data to satisfy 
assumption of homogeneous variances. Data presented in original scale of measurement.
Schwann cell staining within the middle autologous graft section of the sandwich 
grafts (Table 4.7) identified an unexpected result. No differences were predicted 
within this area as it was autologous in all groups. However, staining within the 
immunosuppressed sandwich allograft was significantly poorer than that noted 
within the control group (p=0.02). There was no significant difference detected 
between either of the sandwich allograft groups.
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Table 4.8
21 day Percentage area of Schwann cell staining -  Distal area
Mean (+/-SD)
SandAllo SandCon
+ CyA 17.59 * n/a
(+/-7.64)
-CyA 31.36 38.02
(+/-7.55) (+/-11.99)
* p<0.05 SandAllo + CyA V SandCon
One Way ANOVA to compare groups (p=0.005). All pairwise multiple comparison procedures 
Tukey Test.
Regarding the distal area of quantification, another unexpected result was 
identified within the immunosuppressed sandwich ailograft group (Table 4.8). 
Schwann cell staining in this group was significantly poorer than both the non- 
immunosuppressed sandwich allograft and control groups (p<0.05). This did not 
agree with the findings of morphological assessment. This finding also affected the 
results when comparisons were made with the simple graft results (Table 4.9). 
Here the only group showing significantly different staining from the other groups 
was the immunosuppressed sandwich allograft group, although it was not different 
from either the immunosuppressed isograft or non-immunosuppressed sandwich 
aliograft groups. However, it should be remembered that the quantification area D 
(12mm from proximal neurorrhaphy in all groups) is within the distal graft segment 
of the sandwich grafts, while it is within the distal host nerve of the simple grafts. 
This means that the measurements undertaken from the sandwich ailograft groups 
were the only from allogenic areas.
Generally, these results indicate that the appearance of greater Schwann cell! 
staining within the non-immunosuppressed sandwich aliograft group can be 
attributed to its non-allogenic component.
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Table 4.9
21 day Percentage area of Schwann cell staining -  Distal Quantification Area 
Mean (+/-SD)
Sand.allo Sand/con Allograft Isograft
+CyA 17.59 * 
(+/-7.64)
n/a 35.10
(+/-9.29)
31.16
(+/-9.29)
CyA 31.36
(+/-7.55)
38.02
(+/-11.99)
38.46
(+/-6.82)
36.73
(+/-3.20)
* p<0.05 SandAllo + CyA vs SandCon, Allograft +/- CyA, Isograft -  CyA
One Way ANOVA (p<0.001). All pairwise multiple comparison procedures-Tukey Test.
4.4.6 Morphological assessment of macrophage staining
The morphological features exhibited within the sandwich grafts were similar to 
those described within the simple grafts in Chapter 3. The most exaggerated 
macrophage forms, with large cells containing vesicles and granular cytoplasm 
were found within the allograft sections of the non-immunosuppressed sandwich 
ailograft group (Figure 4.5). Features within the autograft sections were similar to 
the features noted within all other sandwich graft groups. In all groups, smaller EDI 
stained cells were found within the epineurium compared to the macrophages 
within the grafts. This was consistent with findings within the simple grafts. Other 
consistent features were the increased numbers of stained cells associated with 
each neurorrhaphy and within the central areas of the non-immunosupressed 
allograft sections especially.
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Figure 4.5 Sandwich graft Macrophage staining at 21 days
SandAllo+CyA 
Area G x 10
SandAllo-CyA 
Area G x 10
Area M x 10 Area M x 10
Features of EDI staining of macrophages in immunosuppressed and non- 
immunosuppressed sandwich allografts. There are less stained macrophages within the 
SandAllo-CyA group than were noted within the simple Allo-CyA groups in Chapter 3. The 
morphological features of the macrophages are also less bizarre. Macrophage staining is 
similar within the autologous segments of both groups.
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4.4.7 Quantification of macrophage staining
Macrophage staining was quantified within the proximal graft, middle autologous 
section and distal areas of the sandwich grafts, as per Schwann cell quantification.
Not unexpectedly, there were larger amounts of stained macrophages quantified 
within the proximal allograft section of the non-immunosuppressed sandwich 
allograft group (Table 4.10) compared to the other sandwich groups (p=0.03). This 
is consistent with the morphological findings.
Table 4.10 
21 day Percentage area of Macrophage staining -  Proximal Graft 
Median (25-75%)
SandAllo SandCon
+ CyA 10.70 n/a
(10.29-11.06)
CyA 17.97 * 10.87
(16.87-20.14) (10.29-13.79)
p<0.05 SandAllo-CyA vs SandAllo + CyA, SandCon
Kruskal-Wallls One Way ANOVA on ranks as data failed equal variance test (p=0.03). All pairwise 
multiple comparison procedures -  Student-Newman-Keuls method.
When compared to the simple grafts at the same time point (Table 4.11), the 
simple non-immunosuppressed allografts show the greatest amount of staining. 
This is significantly greater than the staining within all the other groups. The lowest 
staining was measured within the immunosuppressed sandwich allograft and 
isograft groups, and sandwich control group. These were all similar. Staining within 
the non-immunosuppressed sandwich allograft and isograft groups plus the
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immunosuppressed simple allograft groups were also similar of intermediate 
quantity.
Table 4.11
21 day Percentage area of Macrophage staining -  Proximal Graft 
Median (25-75%)
+CyA
-CyA
SandAllo
10.70
(10.29-11.06)
SandCon
n/a
Allograft Isograft
16.51** 11.65
(13.04-19.09) (11.13-12.21)
17.97* 10.87 30.61* 16.35***
(16.87-20.14) (10.29-13.79) (27.39-32.86) (13.13-18.11)
* p<0.05 Allograft -  CyA vs All other groups
** p<0.05 Allograft + CyA vs SandAllo+CyA, SandCon, Isograft+CyA
***p<0.05 Isograft -  CyA vs SandAllo+CyA, SandCon, Isograft+CyA
* p<0.05 SandAllo-CyA vs SandAllo+CyA, SandCon, Isograft+CyA
Kruskal-Wallls One Way ANOVA on ranks as data failed normality test (p<0.001). All pairwise 
multiple comparison procedures: Student-Newman-Keuls method.
Macrophage staining quantified within the middle and distal areas of the sandwich 
grafts showed no significant differences between sandwich groups within either 
area (Tables 4.12 and 4.13)
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Table 4.12
21 day Percentage area of Macrophage staining - Middle Autograft Section
Mean (+/-SD)
SandAllo SandCon
+ CyA 11.94 n/a
(+/-3.04)
-CyA 11.12 12.52
(+/-2.76) (+/-1.36)
One way ANOVA to compare groups (p=0.629). No statistical difference between groups.
Table 4.13 
21 day Percentage area of Macrophage staining -  Distal Area 
Mean (+/-SD)
SandAllo SandCon
+ CyA 8.13 n/a
(+/-2.21)
-CyA 10.39 8.52
(+/-2.34) (+/-1.47)
One way ANOVA to compare groups (p=0.157). No statistical difference between groups.
When compared to the other simple graft groups, results of macrophage staining 
within the distal quantification area show that only the simple non- 
immunosuppressed allograft group features significantly greater staining than all of 
the other groups (Table 4.14). These results of macrophage quantification indicate 
that the sandwich allograft construct is associated with less inflammation than a 
simple allograft model containing an equal antigenic load.
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4.4.8 Morphological assessment of endothelial cell staining
Features of Von Willebrands factor staining of endothelial cells were similar to the 
findings in Chapter 3. Smaller calibre vessels were associated with the areas 
around the neurorrhaphies in all groups and also within the allograft sections of the 
non-immunosuppressed sandwich allograft group (Figure 4.6). More mature 
vascular patterns were noted within the segments forming the other groups. 
Although the relatively small size of each individual graft segment making up the 
sandwich grafts meant that the distinctions between regions such as the 
neurorrhaphy and the graft cores was not always as clear as within the simple graft 
groups.
Table 4.14
21 day Percentage area of Macrophage staining -  Distal Quantification Area 
Median (25-75%)
SandAllo SandCon Allograft Isograft
+CyA 8.63 n/a 15.93 8.44
(6.40-9.32) (8.56-21.83) (5.77-11.09)
-CyA 11.13 8.70 16.54* 9.98
(9.16-11.76) (7.01 -8.92) (15.10-17.40) (9.45-11.20)
* p<0.05 Allograft -  CyA vs All other groups
Kruskal-Wallis One Way ANOVA on ranks as data failed equal variance test (p=0.005). All pairwise 
multiple comparison procedures -  Student-Newman-Keuls method.
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Figure 4.6 Sandwich Allograft -CyA Endothelial cell staining
Area G x 10 staining with vWF showing multiple small calibre vessels within the allograft.
4.5 DISCUSSION
The best regeneration possible following nerve transection is when the two cut 
ends are coapted quickly, accurately, and without non-physiological tension 
4,16.46,48,87,88,304 sconaho howovor does not guarantee perfect restoration of
function even in distal single modality nerves . |f any degree of nerve
structure is lost, unless very small and undertaken before structural inherent 
elasticity is lost, repair will require the use of a nerve graft. Autologous nerve 
grafting has been established as the best available technique for restoration of 
continuity across a nerve gap since Seddon popularised it over fifty years ago .
The benefits of autografting sit uncomfortably with the detrimental effects of its use. 
There are limited amounts of expendable nerve for this purpose, and with it, 
sacrifice of a normal functioning nerve is inevitable. The morbidity associated with 
the use of autologous nerve grafts is well documented 41,52,289,305 not
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inconsequential, especially when the result is two imperfectly functioning nerve 
territories. This, along with the desire for a more surgically efficient alternative has 
fuelled research into developing an ideal “off-the-shelf” conduit.
The single feature shared by all synthetic conduits is the absence of endoneural 
cells, and Schwann cells in particular. Schwann cells are crucial to nerve 
regeneration . Although Schwann cells will migrate and survive without axons, 
the converse is less true 32,75,181,242  ^ mitogens inhibiting Schwann cell 
proliferation will also negatively influence axonal regeneration . Bunge has 
remarked on the broad repertoire of functions Schwann cells have in promoting 
axonal regeneration ^  . This includes the production of neurotrophic factors 
24,40,89,92-94,306  ^ providing an ideal substrate for axonal elongation, even in the 
form of their basal lamina alone, and connection with adhesion molecules 
33,39,181,307,308 Ressarchers have endeavoured to mimic this by adding Schwann 
cell cultures 61,62,77,238,309 various neurotrophic factors 4.52,65,241-243 acellular 
conduit materials. While these may have improved regeneration they are some 
way from clinical practice and technically demanding or difficult to maintain.
The use of a depot of Schwann cells in the form of a sandwich graft within an 
acellular conduit has been shown to improve regeneration within conduits of vein 
, silicone and muscle 345,292 ultimate aim of these studies was to try 
to improve regeneration over larger defects. In the rat, regeneration is 
compromised with defects greater than 10mm 4,55,72,245,292,310
Calder successfully bridged a 1.5cm defect in rat sciatic nerve using an acellular 
muscle/nerve sandwich graft . Whitworth extended the technique in a rabbit 
model using 3 nerve sandwiches between acellular muscle grafts to bridge a 5cm 
defect . Results from both experiments show regeneration similar to autograft or 
isograft controls, and superior to muscle grafts alone. Smahel also noted improved
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regeneration following the insertion of a 2mm nerve segment within a 14mm vein 
graft in rats, and using three nerve segments within 40-45mm vein grafts in rabbits 
69,311 However Maeda, although finding superior regeneration within a sandwich 
graft of nerve and silicone conduit compared to an equivalent sized simple silicone 
conduit (18mm) noted regeneration to be inferior to isograft controls . This 
difference in outcomes can be explained by the fact that Calder and Whitworth 
used a basal lamina conduit of acellular muscle, while Maeda used an inert 
conduit. Organic conduits of nerve and muscle are more suitable substrates for 
axonal regeneration than silicone as they allow more efficient revascularisation, 
orientation and support by way of adhesion molecules 62.72,73,312,313 y^eda also 
found that regeneration was poorer in a 24mm double sandwich graft of three 
silicone conduits and two nerve segments. Orientation of the tiny nerve segments 
may have been difficult in this model, plus their were 5/10 infection or extrusions 
associated with the model and 2/10 in the 24mm group failed to regenerate at all 
. It is unclear whether these were taken into account when statistically analysing 
his results.
As allogenic Schwann cells are known to be destroyed during immunological 
rejection 161,156,162,221,314  ^ |s  therefore hypothesised that restoration of the 
Schwann cell population will improve axonal regeneration similar to that described 
in other experimental sandwich grafts. Also, replacing allogenic Schwann cells with 
autologous ones will decrease or halt further rejection removing or reducing the 
requirements for immunosuppression.
In the experiments described here, a sandwich allograft model has been fashioned 
along with a composite isogenic/autogenic control sandwich group. The autologous 
segments were obtained from the nerve resected to form the 1cm defect to be 
repaired. It should be pointed out here that the nerve defect is not necessarily the 
same as a nerve gap. Millesi has stressed the difference of these two factors 
especially as they can lead to confusion with interpretation and comparison of
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studies . Nerves are elastic therefore resection of a measurable amount of 
nerve, or a simple division will produce a larger gap than the defect, while the 
resected segment appears to shrink. The amount of recoil is individual and position 
dependant. Therefore, a nerve graft has to be sufficient to overcome the defect and 
any additional loss of elasticity and non-physiological tension which may have 
occurred with injury and fibrosis. The size of the graft then represents the gap 
between the two transected nerve ends. Therefore, the only reproducible 
parameters when comparing models are the grafts and resection sizes.
Sandwich allografts have been shown here to support axonal regeneration. The 
pattern of regeneration was similar to that described within simple graft models and 
morphologically appeared to be as successful as the non-allogenic simple grafts. 
Axonal regeneration in peripheral graft areas was preferred to the central zones 
initially. In the sandwich grafts these features were more conspicuous in the distal 
graft segments, while in the proximal areas excellent regeneration was visible 
across the whole graft including good axonal organisation across the 
neurorrhaphies. Axonal remnants and suggestions of axon oedema were not 
features identified within any of the sandwich groups. As in the other reported 
examples of sandwich grafting, comparisons with simple conduits of the parent 
material showed that regeneration was improved by the addition of a nerve 
segment 244,245,292 However, important for this experiment was that regeneration 
was improved regardless of immunosuppression in the sandwich allograft and was 
superior to that seen within the simple allograft. Regeneration progresses from 
proximal to distal, therefore at this early time point less regeneration was measured 
within the distal area where no statistical differences were noted between all 
groups. These axons represent some of the most efficient to regenerate such that 
conditions can be assumed to be ideal in their locale. However, the variability of 
result proximally is a reminder that regeneration within these models is still in 
evolution, and a final analysis depends on longer term studies.
127
The sandwich control group exhibited the poorest regeneration overall. This was 
not predicted as the particular area of quantification was in an isograft segment 
and therefore regeneration closer to that measured in the simple isografts was 
expected. There may be several reasons for this but no comparison can be made 
with available literature as no other author has included an equivalent control group 
in their experiments 244,245,292 increased number of neurorrhaphies would be 
expected as potential areas limiting regeneration. However, it has generally been 
found that improving regeneration from that seen in the acellular parent graft has 
outweighed any deficiencies associated with the suture lines 244,245,292 
benefit would be expected from a composite non-allogenic graft such as the 
sandwich control graft, the deficient regeneration in this case may have been 
influenced by the increased scarring . The other potential source of 
irregularities within the results may be due to the technical constraints. The length 
of the graft complexes and their limited flexibility, meant that it was sometimes 
difficult to get all areas lying flat enough to ensure longitudinal sections were cut at 
the same depth through the long axis of the sections. While an arrangement of 
serial cutting was devised to ensure each staining batch contained representative 
sections from the widest portion of the graft (Chapter 2) it would not have been 
enough to ensure equal section depths in all areas. This is another reason why 
multiple areas were quantified. However, the similarity of results measured within 
the distal quantification areas of all grafts indicates that overall regeneration was 
not inhibited. Longer term studies are required to fully evaluate this issue.
If the hypothesis that supplying host Schwann cells will improve regeneration in an 
allograft similar to that experienced within acellular grafts is true, then an 
improvement in Schwann cell staining would be expected within the non- 
immunosuppressed sandwich allograft. This was indeed the case. When compared 
to simple non-immunosuppressed allografts, all groups including the non- 
immunosuppressed sandwich allograft has significantly greater amounts of 
Schwann cell staining. The results were comparable between sandwich allografts, 
and the immunosuppressed sandwich allograft was similar to its equivalent simple
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allograft. The results within the sandwich allografts were less than that within the 
isograft groups which mirrors the findings from axonal staining, however it should 
be remembered that proximally the area of quantification was within an allogenic 
segment for the allografts and an non-allogenic segment for the isografts such that 
a difference would be anticipated.
The standard deviation values show that there was some variability within the 
groups regarding the quantification of Schwann cell staining. This and the reasons 
already suggested for variable results may have influenced the lower values 
measured for the immunosuppressed sandwich allograft within the middle and 
distal grafts. The middle graft is autologous therefore all groups were expected to 
be similar. Within the distal quantification area measurements were taken within 
allogenic segments of the sandwich allografts and non-allogenic segments within 
all the other groups. The poorer results within the immunosuppressed sandwich 
allograft group may be spurious and related to group size and the technical 
considerations given earlier, as axonal regeneration was similar between groups 
within this area.
Schwann cells are known to migrate from transected nerve into conduits 
33,63,102,151,252,277 j^Q y  yyj|[ migrate further in environments more conducive to their 
survival and function. Therefore they migrate more effectively from the proximal 
nerve stump in association with axons, as interactions between these two cells are 
synergystic 33,63,242,252 noted proximal Schwann cell migration to be double
that of distal migration , while Whitworth noted a greater improvement in distal 
migration following addition of a sandwich autograft graft within a muscle conduit 
. Schwann cells in both of these studies were also noted to migrate from the 
sandwich host depot. However, as Schwann cells have a limit to their capacity to 
repopulate acellular structures from adjacent nerve, the distance between nerve 
segments was important for regeneration. The use of acellular conduits, because 
they are devoid of cells makes it easier to attribute the presence of any cells found
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within them to the adjacent structures. Serial analyses at early time points can 
track Schwann cells from the host nerve portions. The situation within nerve 
allografts where reduction and subsequent improvement in Schwann cell staining, 
along with the morphological features identified would also indicate that host 
Schwann cells were replacing the destroyed allogenic Schwann cells in a similar 
manner. In Whitworth’s study using 2.2cm sandwich muscle grafts, at 20 days the 
whole structure contained Schwann cells . The sandwich grafts here appeared 
well populated with Schwann cells at 21 days in a similar rodent model.
The technology now exists to label Schwann cells genetically , or to identify cell 
origin as host or donor based on their MHC or sex chromosomes . These 
experiments have confirmed in acellular conduits that allogenic donor cells are 
rejected and host Schwann cells are responsible for conduit repopulation ^^ 1,162 
Atchabahian confirmed this by producing rejection when a host repopulated 
conduit was transplanted back into the original donor .
No immunological tests for rejection were undertaken in this experiment. Findings 
in Chapter 3 for the non-immunosuppressed allograft with poor axonal 
regeneration associated with reduced Schwann cell staining and increased 
macrophage staining indicate that an immunological destruction of Schwann cells 
was most likely taking place. Schwann cells have been identified along with 
vascular endothelium as the most significantly allogenic endoneurial cells 
102,148,151,152,162,264,297,298 ||. jg clestructîon, along with graft ischaemia which
delays regeneration within nerve allografts 6i,is6,i62,264,284 jj^jg ^ ^ s  noted
within the progression of regeneration described in Chapter 3. Delay in establishing 
end organ/neuronal connections can have profound implications for restoring nerve 
function 3.16,27,289,317,318  ^ therefore methods to shorten the delay period are to be 
encouraged. The longer the graft to be bridged, the longer the delay, and with 
acellular conduits the less likely that Schwann cells will repopulate the whole graft 
seriously compromising axonal regeneration 290,310,319,320 provision of
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additional Schwann cell depots with their neurotrophic benefits will therefore help 
reduce any delay period. Morphologically, this was suggested by the results of this 
experiment, as regeneration was similar within the distal graft and distal nerve in 
the sandwich groups compared to the simple grafts.
Histologically, the pattern of macrophage staining was similar to that within simple 
grafts. Comparing sandwich grafts, morphologically there was more intense 
staining and more exaggerated macrophage features within the non- 
immunosuppressed sandwich allografts. This was borne out by the findings of 
quantification where there was greater macrophage staining within the proximal 
graft sections. However, comparison with the non-immunosuppressed simple 
allografts showed that macrophage staining was significantly reduced. This simple 
allograft produced the greatest staining proximally. As mentioned in Chapter 3, the 
addition of CyA would be expected to influence macrophage recruitment indirectly 
through T-cell effects as both cells have many interactions in cell mediated 
immunity 168,263,274,279 y^e  higher levels of macrophage staining mirror the 
reduced levels of Schwann cell staining in the non-immunosuppressed alloenic 
groups indicating a likely association between these features. The fact that levels 
are not as high within the non-immunosuppressed sandwich allograft indicates the 
reduced allogenicity of this structure as it becomes populated with host derived 
axons and Schwann cells, as has been hypothesised.
Not surprisingly the middle autologous segment showed no significant difference 
regarding macrophage staining within the sandwich grafts. The picture within the 
distal grafts was similar despite the allogenic nature of this segment in the 
sandwich allografts. Again this may represent efficient graft rejection and 
repopulation with host cells. Calder found Schwann cell migration from an 
autologous nerve segment within a muscle sandwich graft to be equal to the rate of 
migration from distal nerve . Comparison between all groups in the distal 
quantification area show that only the non-immunosuppressed allograft had
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significantly greater staining than the other groups. This measurement was taken 
within the host distal nerve, 2mm from the adjacent allogenic segment. However, 
from the findings in Chapter 3, the appearance of this particular group following 
ED1 staining showed a structure overwhelmed with stained cells, therefore this 
quantification value is consistent with the morphological findings.
Staining of endothelium confirmed the presence of a vascular structure within the 
sandwich grafts. Generally the features were similar to those found within Chapter 
3 although there were more small vessels related to the increased neurorrhaphies. 
The non-immunosuppressed sandwich allograft, like its simple counterpart, 
showed larger amounts of small calibre vessels especially within the allogenic 
sections. This may represent a more immature system developing in the face of a 
rejection process. As in Chapter 3, regeneration and Schwann cell repopulation 
were likely to be poorest, if identified, within the graft cores. Although there were no 
areas identified as devoid of blood vessels within the sandwich grafts, unlike within 
the simple non-immunosuppressed allograft, the delayed activity within the graft 
cores may represent a combination of later revascularisation than the periphery 
and reduced Wallerian degeneration secondary to this. Restoration of blood 
supply, particularly proximally from inosculation is essential to satisfactory axonal 
regeneration 166,259,284,321 vessel and axon progression mirror each other and 
are most effective in a well ordered environment. Revascularisation also occurs 
from the wound bed and the diameter of the graft is known to affect this 3.81,283,322
In conclusion, sandwich allografts behave in a similar manner to sandwich grafts 
constructed from other acellular conduits. Generally they improve regeneration 
from that seen within grafts composed of their parent material here and within the 
literature. In this study, at an early time point, the results indicate that there may be 
potential for regeneration to Increase with time. Or at least, when regeneration was 
still evolving for the delay period to be reduced. As hypothesised, the role of the 
Schwann cell was essential to regeneration. Results indicate that host Schwann
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ceils repopulated the rejecting nerve allograft and that the additional depot of 
autologous nerve in the sandwich graft construct proved beneficial in this regard 
and non-immunosuppressed led to the improvement in regeneration measured 
within the non-immunosuppressed sandwich allograft compared to its simple 
equivalent.
Other investigators have concentrated on the benefits this technique confers on 
achieving greater bridging distances 69,244,245,292,293 this remains valid, the
potential benefits of reducing the requirements for immunosuppression were of 
greater interest in this model. Results confirm the hypothesis that within a 
sandwich allograft without immunosuppression regeneration can be significantly 
improved. The related reduction in macrophage staining adds further evidence of 
the reduced antigenicity of this graft type compared to a standard allograft. This 
suggests that the detrimental effects of immunosuppesslon withdrawal 
151,221,247,266,268 QQuld also be reduced by this technique.
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5.1 INTRODUCTION
Previous experiments In Chapters 3 and 4 have shown that without 
immunosuppression regeneration is poorer in an allograft model although axons 
which do regenerate show similar regenerative behaviour to that within non- 
allogenic grafts. The addition of a depot of host Schwann cells to the allograft 
model as a Sandwich graft improved short term regeneration (see Chapter 4). This 
introduced the possibility of being able to reduce or abandon immunosuppression 
use in this allograft model. The depot of Schwann cells appeared to improve 
regeneration by increasing the efficiency of host Schwann cell repopulation of a 
rejecting allograft where the donor Schwann cells have been destroyed.
The aim of this experiment was to test whether the short-term advantage conferred 
by the sandwich allograft model was maintained over a longer time period. Factors 
affecting long term axonal survival include the satisfactory reinnervation of nerve 
distal to the level of injury and the re-establishment of appropriate target organ and 
central connections "^’342.323 q-g improve the likelihood of this happening many 
axonal growth cones are produced from axon sprouts which search for conducive 
substrates 14,30,31,34,39,52,324 once correctly associated with target organs, any 
unsuitable connections are severed, and the axonal sprouts are pruned 1 "^ '62,325,325 
Therefore, the length of time for long-term experiments should be sufficient to allow 
these processes to take place such that the remaining axons are truly mature and 
representative.
in the rat sciatic nerve model target organ reinnervation can be established by 12 
weeks, and by six months it is more mature although not necessarily fully 
completed 14,158,215,238,325,327 However, as allografts have been shown to have 
slower regeneration potential, these experiments were conducted over 8 months to 
ensure pruning from all models was essentially complete.
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5.2 AIMS
The aim of this investigation was to assess the long-term regeneration potential of 
non-immunosuppressed nerve allografts to determine whether the addition of a 
depot of autologous Schwann cells within the construct of a Sandwich allograft 
could improve regeneration within this allogenic model. Assessments involved 
morphological analysis of myelinated axons within the posterior tibial nerve distal to 
the nerve graft, while gastrocnemius muscle mass was measured as an indicator 
of motor reinnervation and recovery.
5.3 EXPERIMENTAL PROTOCOL
The host and donor animals, along with the operative procedures for graft insertion 
and specimen retrieval and fixation are detailed In Chapter 2.1. These long-term 
experiments lasted 32 weeks (Table 5.1). In view of the recognised depot effect 
which can occur with prolonged subcutaneous administration of CyA , CyA was 
administered daily up to 12 weeks and on alternate days subsequently. Reports of 
rejection continuing to a maximum of 9 weeks have been described . In view of 
this and also that distal end organ reinnervation was predicted to be occurring by 
12 weeks (based on the standard regeneration rate of 1 mm/day), this time was 
chosen as the period at which to reduce CyA administration. As in the short-term 
experiments already described, CyA administration was commenced the evening 
before surgery.
Oily CyA (oCyA) was used and is made up from base powder CyA donated by 
Sandoz Pharmaceuticals Ltd., UK. The formulation was prepared and was 
administered as detailed in Chapter 2.2. The dose used was 5mg/kg/day.
Myelinated nerve fibre analysis was undertaken on thionin blue and acridlne 
orange stained semithin transverse sections of the posterior tibial nerve 5mm distal
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to the nerve graft. Analysis was by computerised image analysis as described in 
Chapter 2.3.4-2.S.5. Gastrocnemius muscle was resected and weighed as in 
Chapter 2.1.3. Mass was compared between the operated and unoperated muscle 
and results expressed as a percentage of the normal muscle mass.
Table 5.1 Experimental Groups
Group Host Donor CyA Numbers
Simple grafts
Allograft (Allo+oCyA) Lew Da yes n=6
Allograft (Allo-CyA) Lew Da no n=6
Isograft (Iso+oCyA) Lew Lew yes n=5
Isograft (Iso-CyA) Lew Lew no n=5
Sandwich grafts
SandAllo (SAIIo+oCyA) Lew Da yes n=5
SandAllo (SAIIo-CyA) Lew Da no n=6
SandControl (SCon+oCyA) Lew Lew yes n=6
SandControl (SCon-CyA) Lew Lew no n=6
Controls
Normal Lew no n=6
Unrepaired Lew no n=5
Allograft {Allo+vehicle) Lew Da no n=6
5.4 RESULTS
5.4.1 Myelinated fibre analysis
Analysis of semithin sections stained for myelinated axons yielded results from 
several parameters such as: axon number, size distribution, axon and fibre 
diameters from which myelin thickness and G-ratio were calculated, along with the 
measure of laciness. Unequal group numbers evident within the results relate to
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technical loss of sections during processing or loss of the animal model within the 
experimental group (see also Chapter 6).
Table 5.2
Total Axon Counts in Posterior Tibial Nerve -  Median values
Simple Grafts n CyA Type No. Axons (25-75 Gentiles)
Allograft 6 yes oCyA 1137 (1068-1508)
Allograft 6 no 1235 (931-1583)
Isograft 5 yes oCyA 1035 (929-1205)
Isograft 5 no 932 (721-1104)
Sandwich Grafts n CyA Type No. Axons (25-75 centiles)
SandAllo 5 yes oCyA 1125 (801-1222)
SandAllo 6 no 1221 (1069-1760)
SandCon 6 yes oCyA 926 (755-1138)
SandCon 6 no 1184 (1087-1216)
Controls n CyA Type No. Axons (25-75 centiles)
Normal 6 no 526* (474-593)
Unrepaired 5 no 11 (8-15)
Allo+vehicle 6 no 1129 (896-1664)
*p < 0.05 Normal vs Allograft+oCyA, Allograft-Cya, SandAllo-CyA, SandControl-CyA.
Comparing the Normal control to all other groups (except Unrepaired), results were not normally 
distributed. Kruskal-Wallis ANOVA on ranks executed (p=0.001). Dunn’s multiple comparison 
procedure as groups contain unequal numbers.
Results from Unrepaired nerve and AII0+ vehicle were omitted from statistical analysis as gross 
difference and variability skewed analyses, results included in table for comparison.
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The number of regenerated axons were counted as per the description in Chapter
2.3.5 from randomly chosen frames using the image analyser and have been 
expressed as the median total number of axons (Table 5.2). The frame area was 
1.764x10'^jim. The number of axons counted is greater within the experimental 
groups than the numbers identified within the normal, unoperated nerve. Statistical 
analysis identified that this was only significant when comparing the normal group 
with the non-immunosuppressed sandwich allograft and sandwich control group, 
plus the simple allograft groups regardless of immunosuppression. All of these 
groups had counts in the higher ranges for these experiments. The unrepaired 
group showed the poorest results, which were highly variable. This was a 
consistent finding when comparing the other parameters under investigation. The 
nature of the unrepaired group's results affected the statistical analyses especially 
with regard to their variability, such that this group often skewed the results of 
analysis. To make more reliable statistical conclusions this group was omitted from 
formal analysis.
It was surprising to see any evidence of axonal regeneration within the unrepaired 
group as at specimen retrieval the separated nerve ends were mainly fixed by 
fibrous tissue onto the muscular bed. Any connection between the neuromas was 
by fine, tenuous, flimsy connective tissue bands extending between the divided 
nerve ends across the muscle surfaces. These findings suggest that any 
neurotisation may have occurred from the muscle rather than the proximal nerve 
stump (Figure 5.1).
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Figure 5.1 Unrepaired nerve at 32 weeks
Distal nerve stump without proximal attachments and tethered to muscular bed.
Results from the control group testing the oil-based vehicle used in the preparation 
of CyA for injection (Allo+vehicle) also caused problems during statistical analysis. 
The high variability within this group and also the non-immunosuppressed isograft 
group produced skewed results. Using the Kruskall-Wallis ANOVA on ranks, 
statistical analysis produced the same outcome as a One way ANOVA but without 
the need to omit these latter two groups to improve equal variances.
The results from analysis of frequency distribution of fibre diameters (Table 5.3) 
show for normal nerve greater amounts of medium and large diameter fibres than 
the experimental groups. For analysis and presentation, results from the normal 
group were divided into roughly three equal groups with ranges as shown, allowing 
easier comparison between the relevant groups.
All experimental groups showed significantly greater amounts of small fibres than 
normal nerve. The unrepaired group exhibits the highest proportion of small 
diameter fibres with no contribution within the large diameter range. However, 
despite this, all experimental groups show no statistical differences.
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Table 5.3
Frequency Distribution of Fibre Diameters -  Mean Percentage (+/- SD)
Groups
Simple Grafts
CyA Type % Small % Medium % Large
1-7|Lim 8-10|xm 11-20+jxm
Allograft yes oCyA 87.77
(+/-2.73)
9.42
(+/-2.04)
2.80
(+/-0.84)
Allograft no 90.76
(+/-5.66)
7.63
(+/-4.22)
1.61
(+/-1.47)
Isograft yes oCyA 87.00
(+/-7.08)
9.98
(+/-4.65)
3.03
(+/-2.81)
Isograft no 90.13
(+A3.73)
8.15
(+/-2.90)
1.72
(+/-0.85)
Sandwich Grafts
SandAllo yes oCyA 86.51
(+/-5.03)
10.23
(+/-3.15)
3.27
(+/-2.14)
SandAllo no 87.48
(+/-4.47)
9.55
(+/-2.91)
2.97 
(+/-1.63)
SandCon yes oCyA 87.87
(+/-2.87)
9.24
(+/-1.97)
2.89 
(+/-1.49)
SandCon no 88.32
(+/-4.95)
9.26
(+/-2.98)
2.42
(+/-2.09)
Controls
Normal no 33.39 * 
(+A4.35)
31.56 * 
(+/-5.12)
35.05 "  
(+Z-9.33)
Unrepaired no 98.00 ** 
(+M.47)
2.00
(+A4.47)
0.00
(+/-0.00)
Allo+vehicle no 90.30
(+/-5.17)
8.06
(+A3.85)
1.64 
(+/-1.36)
Comparing % Small One way ANOVA (p<0.001), Scheffé multiple comparison procedure, *p<0.001 
Normal vs All groups.
Comparing % Medium One way ANOVA (p<0.001), Scheffé multiple comparison procedure, 
*p<0.001 Normal vs All groups.
Comparing % Large One way ANOVA {p<0.001), Scheffé multiple comparison procedure, 
” p<0.001 Normal vs All groups.
Omitting the Normal group. One way ANOVA, p=0,049 showing no significant difference between 
the remaining groups.
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For the medium and large fibre diameter ranges, the normal nerve group shows 
greater distribution here than all the other groups, which is significant. Repeating 
the analysis without the normal group showed no statistical difference between the 
experimental groups within either of these ranges. The results for groups receiving 
CyA show better, although non-significant, fibre distribution within the mid-high 
diameter ranges, as does the sandwich allograft without immunosuppression. 
These results suggest that both immunosuppression and the sandwich graft are 
beneficial.
Tables 5.4 -  5.6 show the results from measurement of axon and fibre diameter, 
myelin thickness, G-ratio and laciness. These measurements represent the mean 
results from 3 random frames of analysis from at least two section per animal, from 
which the group’s descriptive statistics were calculated.
Table 5.4 Myelinated Nerve Morphology -  Mean +/- SD
Group
Simple Grafts
n CyA Type Axon Diameter 
pm
Fibre Diameter 
pm
Allograft 6 yes oCyA 1.78 (+/-0.14) 4.47 (+/-0.25)
Allograft 6 no 1.76 (+/-0.37) 4.21 (+/-0.44)
Isograft 5 yes oCyA 1.99 (+/-0.39) 4.55 (+/-0.54)
Isograft 5 
Sandwich Grafts
no 1.69 (+/-0.26) 4.29 (+/-0.37)
SandAllo 5 yes oCyA 1.97 (+/-0.26) 4.42 (+/-0.32)
SandAllo 6 no 1.75 (+/-0.20) 4.42 (+/-0.29)
SandCon 6 yes oCyA 1.72 (+/-0.26) 4.28 (+/-0.26)
SandCon 6 no 1.63 (+/-0.20) 4.38 (+/-0.38)
Controls
Normal 6 no 4.70 (+/-0.48) * 8.39 (+/-0.62) *
Unrepaired 5 no 1.24 (+/-0.27) 3.13(+/-0.34) "
Allo+vehicle 6 no 1.87 (+/-0.35) 4.29 (+/-0.51)
Comparing Axon diameters One way ANOVA (p<0.001), Scheffé multiple comparison procedure, 
*p<0.001 Normal vs All groups.
Comparing Fibre diameters One Way ANOVA (p<0.001), Scheffé multiple comparison procedure, 
*p<0.001 Normal vs All groups; "p<0.04 Unrepaired vs Allograft+oCyA, Isograft+oCyA, SandAllo- 
CyA.
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The measurement of fibre diameter reflects the degree of fibre myelination (Table
5.4). The normal group’s results were significantly better than all other groups. The 
unrepaired group, although poorest, is only significantly different from the groups 
with some of the highest values namely the immunosuppressed simple allograft 
and isograft, and the sandwich allograft without immunosuppression. Results 
comparing the unrepaired group with the immunosuppressed sandwich allograft 
and the non-immunosuppressed sandwich control group were equivocal with p 
values of 0.059 and 0.052 respectively. The interpretation of measurements from 
the unrepaired group tends to indicate superior regeneration to that indicated by 
the appearance of the nerve sections from this group and the raw data (Figure
5.2). This highlights the fact that although statistics provides a valuable tool for 
describing and comparing data, it is only one factor while the overall picture still 
has to be appreciated in the interpretation.
Regarding axon diameter (Table 5.4), the normal nerve shows significantly the 
largest mean value, while the unrepaired group shows the lowest value. However, 
none of the experimental groups’ results show any significant differences for axon 
or fibre diameters.
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Figure 5.2 Semithin sections of distal myelinated nerve x 40
Normal nerve Unrepaired distal nerve stump
Allo+oCyA Allo-CyA
SandAllo+oCyA SandAllo-CyA
D
n .
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Table 5.5 Myelinated Nerve Morphology -  Mean +/- SD
Group n CyA Type Myelin Thickness G-ratiopm
Simple Grafts
Allograft 6 yes oCyA 1.35 (+/-0.10) 0.34 (+/-0.03)
Allograft 6 no 1.22 (+/-0.08) 0.36 (+/-0.04)
Isograft 5 yes oCyA 1.28 (+/-0.12) 0.38 (+/-0.04)
Isograft 5 no 1.30 (+/-0.06) 0.34 (+/-0.03)
Sandwich Grafts
SandAllo 5 yes oCyA 1.23 (+/-0.06) 0.37 (+/-0.02)
SandAllo 6 no 1.34 (+/-0.09) 0.33 (+/-0.03)
SandCon 6 yes oCyA 1.28 (+/-0.05) 0.34 (+/-0.03)
SandCon 6 no 1.38 (+/-0.12) 0.32 (+/-0.03)
Controls
Normal 6 no 1.85 (+/-0.09) * 0.50 (+/-0.01 ) **
Unrepaired 5 no 0.58 (+/-0.48) 0.26 (+/-0.22)
Allo+vehicle 6 no 1.21 {+/-0.14) 0.39 (+/-0.05)
Comparing Myelin Thickness One way ANOVA {p<0.001), Scheffé multiple comparison 
procedure, *p<0.001 Normal vs All groups.
Comparing G-ratIo One way ANOVA (p<0.001), Scheffé multiple comparison procedure, **p<0.002 
Normal vs all groups. Unrepaired group omitted from statistical analysis in view of gross difference 
and high variability, results included in table to indicate this.
Thinner myelination of fibres would be expected in the experimental groups 
compared to the normal nerve, and analysis of the results confirms this (Table 5.5), 
with the normal nerve exhibiting statistically greater myelination than all the 
operated groups. The unrepaired group has obviously inferior results than the 
others and was omitted form statistical analyses for reasons expressed previously.
The G-ratio is calculated as the proportion of the axon diameter to the myelinated 
fibre diameter, and therefore it reflects the degree of myelination. There is some 
disagreement within the literature as to the relationship between myelin thickness 
and fibre diameters between normal and regenerated nerves. Some report a 
parabolic relationship where the smallest fibres exhibit low (<0.4) G-ratios , 
while others show a linear relationship, or no appreciable relationship at all . 
The normal group results here are statistically superior to the other groups. The
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lower G-ratios associated with the regenerated axons in the experimental groups 
support the parabolic argument where the increased proportion of smaller fibres 
within the nerve skews the mean G-ratio. This is because very small fibres often 
have proportionally thicker myelin in an attempt to restore their conductive 
properties . In this format (Table 5.5), the exact relationship between G-ratio and 
fibre dimensions are obscure, but it serves to identify the difference between 
normal and regenerated nerves.
Table 5.6 Myelinated Nerve Morphology -  Mean +/- SD
Group n CyA Type Laciness SD
Simple Grafts
Allograft 6 yes oCyA 0.82 (+/-0.01)
Allograft 6 no 0.84 (+/-0.03)
Isograft 5 yes oCyA 0.84 (+/-0.02)
Isograft 5 no 0.82 (+/-0.03)
Sandwich Grafts
SandAllo 5 yes oCyA 0.84 (+/-0.03)
SandAllo 6 no 0.79 (+/-0.01)
SandCon 6 yes oCyA 0.83 (+/-0.02)
SandCon 6 no 0.83 (+/-0.03)
Controls
Normal 6 no 0.85 (+/-0.02)
Unrepaired 5 no 0.51 (+/-0.42)
Allo+vehicle 6 no 0.80 (+/-0.03)
One way ANOVA no significant difference between experimental groups
Unrepaired group omitted from statistical analysis In view of gross difference and high variability, 
results Included In table to Indicate this.
Laciness relates to the shape of the fibres (Table 5.6). A value of 1 indicates a 
perfect circle with smaller values indicating more irregular shapes due to fibre 
damage or imperfect regeneration. The unrepaired group gives the poorest value 
but was omitted from analysis because of its high variability. Otherwise, most 
groups including the normal group show no significant difference.
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5.4.2 Target Reinnervation
For target organ reinnervation, motor reinnervation of gastrocnemius muscle was 
assessed by comparing the mass of the muscle on the operated side with that of 
the normal muscle. Each animal therefore contributed its own control (Table 5.7).
Table 5.7 Gastrocnemius muscle mass -  % operated side / normal
Simple n CyA Type Median % 25-75 centiles
Grafts
Allograft 6 yes oCyA 64.24 (53.98-70.90)
Allograft 6 no 68.21 (59.05-72.93)
Isograft 5 yes oCyA 58.91 (52.27-63.52)
Isograft 5 no 49.29 (35.62-59.40)
Sandwich
Grafts
SandAllo 5 yes oCyA 65.00 (61.37-65.67)
SandAllo 6 no 72.39 (69.91-74.69)
SandCon 6 yes oCyA 68.20 (60.23-75.42)
SandCon 6 no 67.75 (65.63-68.61)
Controis
Unrepaired 5 no 11.68 7** (9.69-13.11)
Allo+vehicle 6 no 66.56 (51.83-74.68)
Results not normally distributed therefore Kruskal-Wallis One way ANOVA on ranks executed using 
Median values.
Comparing Unrepaired to Simple grafts (Including Allograft+vehicle), K-W ANOVA, p=0.002. 
Dunnett's multiple comparison procedure, *p<0.05 Unrepaired vs All groups.
Comparing Unrepaired to Sandwich grafts, K-W ANOVA, p=0.001. Dunnett’s multiple comparison 
procedure, **p<0.05 Unrepaired vs All groups.
Omitting Unrepaired group, K-W ANOVA shows no significant difference between the remaining 
groups, p=0.061.
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The unrepaired group shows significant muscle atrophy and highly variable results 
as experienced within the other assessment modes. All experimental groups had 
significantly greater muscle mass than the unrepaired group being around two- 
thirds the mass of normal muscle. There was no significant difference noted 
comparing the experimental groups although the best muscle weight was recorded 
in the non-immunosuppressed sandwich allograft group, while the standard isograft 
control groups had the lowest results.
Analysis of mass of Gastrocnemius muscle harvested from experimental groups 
within the early regeneration period (Chapter 3), show a steady reduction in muscle 
mass following denervation from 7-21 days (Figure 5.3). There were no significant 
differences found between groups at any time point.
Figure 5.3 Gastrocnemius muscle mass following denervation
Percentage Gastrocnemius Muscle Loss
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The rat, despite having a major nerve trunk injury, continues to take weight on its 
affected hind limb throughout the experimental period. The limb also contributes to 
ambulation although the gait is altered through changes to ankle, knee and foot 
contribution. Therefore, although the uninjured limb will undertake compensatory 
work following the injury, all of the rats were similarly affected. The muscle was 
undisturbed by the initial surgery and on removal all muscles appeared normal and 
healthy, with no evidence of abnormal fibrotic or adipose tissue which could have 
contributed to their mass (Figure 5.4).
Overall, these results indicate that regardless of immunosuppression, in this animal 
model, simple allografts and sandwich allografts exhibit similar regeneration 
profiles to the isograft groups which represent current clinical practice. The use of a 
sandwich graft did not confer any statistically significant benefit, or deficit, although 
across some parameters it did exhibit results closer to normal values than other 
experimental groups.
149
Figure 5.4 Gastrocnemius muscle at 32 weeks
Unrepaired
Control Operated
Allo+oCyA Allo-CyA
Control Operated Control Operated
SandAllo+oCyA
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SandAllo-CyA
Operated Control Operated
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5.5 DISCUSSION
Following nerve Injury and repair we have previously shown that axonal 
regeneration is established in non-allogenic nerve grafts by three weeks. 
Regenerating axons have to regenerate to reach target organs and form 
appropriate connections. It is understood that axons regenerate at an average of 
1mm per day . However this rate varies from 1-8.5mm/day, being inversely 
proportional to the distance the injury is from the neurone . Regeneration 
sufficient to reestablish target organ connections within 12 weeks has been noted 
in the rat. The mechanism whereby axons regenerate leads to the production of 
more axon sprouts than required 14,30,31,34,52,324 process improves the
likelihood of an axon finding a suitable substrate for regeneration, thereby 
reestablishing appropriate innervation with Schwann cells en route and finally 
connecting the correct neurone with its target organ 14,34,33,39 once the primary 
neuronal unit has been reestablished, any superfluous axons with inappropriate 
connections die back through the process of pruning. Pruning can occur at any 
point and can last for some time. However, as serial tests of function up to a year 
following sciatic nerve repair have shown a plateau is reached around 12 weeks, 
the peak of pruning is likely to be largely complete by around this point 216,325,327 
As our previous work has identified that regeneration In an allogenic model is 
delayed by comparison with non-allogenic models the longer time period of 8 
months was chosen to ensure mature axonal regeneration in these experiments.
The final outcome of nerve repair depends on the correct connection between the 
central nervous system, peripheral neurone and target organ where signals can 
pass in an antegrade and retrograde manner 4.242,323 p^nctional assessments are 
notorious for their subjectivity, qualitative nature and difficulties with interpretation 
192,332,333 there are no “routine” functional tests experimentally or clinically
where there is uniform agreement regarding the relative merits of one test over 
another.
151
In this experiment, analysis of myelinated nerves present within the posterior tibial 
nerve distal to the experimental nerve graft was undertaken. This morphological 
technique gives quantitative information related to the maturity and success of 
nerve regeneration within the distal nerve. Although not testing function, 
measurements of axonal size and myelin thickness are known to correlate with 
electrophysiological functional assessments 2,210,219  ^ |g because of the 
relationship between axon diameter, myelin thickness and the internode distance
52,331
Muscle atrophies when denervated, which is reversible in a time dependant 
manner if innervation is reestablished. Hence the return of muscle bulk indicates 
the return of innervation and with this, functional potential . However, prolonged 
denervation atrophy is associated with connective tissue fibrosis, impeding the 
establishment of end-plate formation and nerve regrowth . Sterne used 
gastrocnemius muscle mass as an end-point indicator of reinnervation after using 
fibronectin conduits impregnated with the neurotrophic factor, Neurotrophin 3 (NT- 
3) in comparison to autograft controls . Initial muscle atrophy was followed for 30 
days post engraftment showing that the results here at 21 days do not represent 
the lowest mass reached. At 34 weeks autografts had attained 71 % of their control 
muscle mass , producing similar results to those shown here. Other authors 
have also found recovery of different muscle mass to reach approximately 70% of 
control muscle mass following nerve repair 209.334,335
From the results obtained from these experiments it can be seen both functionally 
and morphologically that the results from grafted and regenerated nerves fall short 
of normality. However, the similar values across the experimental groups are 
indicators that regeneration has reached a stable phase, especially in relation to 
the isograft groups, and the morphological features as shown in the figures (Figure
5.2).
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Statistical analysis has shown that some of the groups are similar to the normal 
nerve in terms of myelinated axon numbers, although the absolute axon number is 
not always the most useful parameter. The experimental groups have a higher 
number of axons than the normal nerve as nerve pruning may still be taking place 
14,52,325,326 jherefore other variables must be considered. As there is no significant 
difference between measures of axon, fibre diameter, myelin thickness or when 
considering the qualitative features of the experimental groups or muscle mass, 
then the lower values values for axon counts in the isograft groups, the 
immunosuppressed sandwich allograft and sandwich control groups appear to 
suggest the lower numbers indicate more appropriate axonal connections.
It is recognized that axons regenerating post injury are smaller and with thinner 
myelin than that noted in normal nerve ^2.330,330 alteration in these parameters
is evident from the results shown here. As conduction velocity correlates to axon 
and myelin dimensions 2,210,219  ^ the reduced function related to these 
dimensions can be appreciated without electophysiological testing. The recovery of 
muscle mass indicates the reinervation of muscle fibres but not up to normal levels, 
although significantly better than in the unrepaired group.
Comparing the distribution of fibre diameters, there were no statistical differences 
between experimental groups, although there were fewer numbers of medium and 
large fibres within the non-immunosuppressed allografts group which suggests a 
possible benefit being conferred by GyA and the host section within the sandwich 
allograft.
Following nerve injury, the restoration of normal function is the exception rather 
than the rule 11-36.41,48,289,337 this reason, autografting, as the usual method of 
nerve reconstruction is the standard by which all other techniques are compared. 
The IsoG-CyA group represents the standard non-allogenic graft technique in
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these experiments. For all of the assessments here there are no significant 
differences determined between experimental groups. The use of the sandwich 
grafting technique, where a graft of host nerve is transplanted orthotopically within 
an allogenic graft model forming a chimeric structure. Is validated by these 
experiments.
The use of a sandwich control group was to determine whether the extra 
neurorrhaphies were deleterious. Using autologous muscle grafts Whitworth 
showed that over short (2.2cm), and long (5cm) graft distances the effect of the 
sandwich graft was beneficial 245,315 however, Maeda found a 5 segment silicone 
/nerve sandwich model (24mm) did appear to hinder regeneration, but not an 
18mm model . In the sandwich graft model the addition of a depot of cellular 
nerve can outweigh the potential deficit of an extra neurorrhaphy where the host 
Schwann cells have repopulated acellular muscle , silicone conduits , vein 
69,293,311 now rejected nerve allograft to aid axonal regeneration.
These experiments show that in a non-immunosuppressed allogenic model, where 
donor Schwann cells are reduced (see Chapter 3.4.6-3.4.7), the addition of a host 
nerve segment containing its complement of Schwann cells aids regeneration of 
host axons through the graft construct. Results in Chapter 3 and 4 show that over 
short gaps of 1 and 1.5cm respectively, axonal regeneration does occur within the 
simple non-immunosupressed allograft. However the extent of regeneration within 
the early time points is much reduced compared to non-allogenic groups. As 
predicted from other work 76,151,221,247.263,264,268 the evidence of reduced 
Schwann cell staining here, rejection is occurring, but regeneration progresses in a 
similar fashion to the non-allogenic models as shown by examination of 
longitudinal histological sections.
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In our experiments we have shown that a sandwich graft technique conferred a 
benefit on regeneration through a non-immunosuppressed allograft up to 21 days. 
It was also evident that the benefits continued to be observed up to 32 weeks, as 
no difference was seen between groups regardless of immunosuppression. These 
results are at odds with other investigators. The majority of opinion would indicate 
that nerve allografts are poorer than auto or isografts unless immunosuppressed 
78,97,124,153,204,209,268 ^/^ith Immunosuppression, results from allografts however are 
comparable to non-allogenic grafts 153,206,211,216,223,247 |,^ the experiments
described here no such differences were noticed long term. The reasons for the 
differences may be that the model is too efficient at regenerating, that the gap 
distance is too small, that the immunosuppression was inadequate, or that 
insufficient genetic disparity existed between the rat strains.
The rat is a commonly used experimental model. The strains used here have been 
used before in transplantation experiments 151,162,220,230,247,338 known to
have a mismatch at both major and minor histocompatability loci 220,246,248 
previous experiments on simple allografts (see Chapter 3.4) we have shown by 
qualitative and quantitative morphological assessment of Schwann cell and 
macrophage staining that immunological rejection had occurred. The use of CyA at 
the recommended dose (5mg/kg/day) 206,254,262 produced improved axonal 
regeneration, along with reduced macrophaged infiltration and greater Schwann 
cell numbers. Hence, there would appear to be sufficient genetic disparity between 
the rat strains.
Nerve regeneration in the rat is generally faster than in higher mammals , and 
one could argue that the use of a short gap of less than 1.5cm in a rat is insufficient 
to hinder regeneration 52.55,192,211,250,340 3 ^0 ^ short gaps can allegedly be bridged 
successfully without grafting or repair. However, we have shown that regeneration 
in unrepaired controls was not successful. Such innervation as was observed was 
minimal and very variable, consequently many statistical comparisons between
155
groups were impossible. All myelinated axons were of small diameter, and 
generally the fibres showed poorer evidence of regeneration across all parameters. 
Morphologically the nerve sections were smaller and more fibrotic than the other 
groups. At retrieval, any neurotisation which had occurred did not appear to 
emanate from the proximal nerve stumps.
Results from Chapters 3 and 4 along with evidence of work using acellular conduits 
of organic, inorganic or synthetic material indicate that host Schwann cells will 
repopulate the acellular structures and improve regeneration 
62,69,75,76.238,239.244,245,290-293 addition of host Schwann colls within the sandwich
allograft had obvious early benefits. While these remained evident in the non- 
immunosuppressed sandwich group at the 32 weeks assessment the benefit over 
the simple non-immunosuppressed allograft group was obscure. Even this group at 
the end of the experiment had regenerated similarly to the other experimental 
groups. This may relate to the size of the nerve gap. It is recognised that the longer 
the bridging conduit the poorer the regeneration 2^.68,319 been attributed
to the reduced gradient of positive regeneration influences the further the 
regenerating axon front is from the distal nerve 40,52,55,68 yyhn@ nerve tissue 
69,245,293  ^ Schwann cells 61.62,77,162,238,240  ^ g,. addition of neurotrophic factors 
4,52,65,241-243 ^ j] |  jmp|-Qve regeneration distances, as yet the distance regeneration 
has to proceed along remains a major factor in determining outcome. Proximal 
injuries fair worse than distal for this reason, but also because there are more 
nerve branches within proximal nerve trunks which have to be negotiated by the 
regenerating axons on their route distally ®>45-34i y^jg provides many opportunities 
for incorrect innervation which despite the arrangement of the growth cone, 
neurotrophic, neurotropic and contact guidance cues does not ensure ideal 
regeneration.
We have already indicated that the dose of CyA administered was associated with 
the prevention of the negative effects of allografting shown in Chapters 3 and 4
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such as increased macrophage infiltration and reduced Schwann cell staining. The 
difference between the formulations used was that for the long term experiments a 
less expensive but still frequently used oily preparation was employed and 
recommended by the manufacturer (Sandoz) 210,213,251,253,254 depot effect of 
oily CyA and risk of infection in injection sites are known from the work of Bain and 
Midha 205,254,252 for these reasons the injection site was varied as
recommended and the dose of CyA was reduced by alternating the days of 
injection. To minimise any effect on regeneration we waited until target organ 
reinnervation was likely to be underway at 12 weeks before altering the CyA 
regime. The addition of a control group using the vehicle used to prepare the CyA 
for injection was to verify that no additional benefit was incurred by administration 
of this solution. The results for the AlloG+vehicle group are similar to the Allo-CyA 
group and all the other groups for the reasons given previously.
Investigations of temporary immunosuppression for peripheral nerve allografting 
have produced some controversial results. However, the differences in outcome 
can often be related to study design, such as the absence of a distal coaptation 
123,125,195,204  ^ Insufficient immunosuppression to allow target reinnervation , 
and lack of appropriate controls 210,211,216 MacKinnon and collaborators are 
probably the strongest advocates of temporary immunosuppression and although 
they noted an axonopathic process morphologically, electrophyslologically and 
functionally, this was reversible with time 134,207,215,218 jy\ey have investigated 
peripheral nerve allografting in primates 129,133 ^^d have gone on to undertake it in 
humans. MacKinnon has reported 7 clinical cases of nerve allotransplantation 
using CyA, Fk506, azathioprine and prednisolone between 1988 and 1998 
217,224,225 has Combined alio- and autografting but as parallel unconnected
cables rather than in series, as here. This was explained as a fail-safe strategy if 
the nerve allograft failed, and also to decrease the antigenic load of the combined 
cable graft structure .
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As noted in Chapter 3 there did appear to be a small benefit conferred by CyA 
administration to non-allogenic and allograft groups alike. This difference was not 
significant. Work with CyA 1^4,228,288 FK506 226,227,342,343 shown that
immunosupressant administration can improve regeneration in allografts and 
autografts. FK506 is a more potent immunosupressant such that more beneficial 
regeneration in allografts has been noted with it than with CyA 226,227,344 
parenteral CyA was used in the experiments in Chapters 3 and 4 and in view of the 
similarity of results among the experimental groups here we have performed the 
same experiments again using parenteral CyA and have repeated the early 
experiments using oily CyA. These results are reported in Chapter 6.
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CHAPTER SIX
Assessment of the effects of Cyclosporin 
preparations on Axonal Regeneration and on Well­
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6.1 INTRODUCTION
Since the establishment of allotransplantation and the development of Cyclosporin 
(CyA) and the newer generation immunosuppressants, researchers have 
concentrated efforts towards testing hypotheses and techniques which may reduce 
immunosuppressant requirements ios,154,168,192,301,302,333,345-350  ^ Unlike in clinical
practice, CyA was shown to be a useful single agent immunosuppressant for nerve 
allografting in rats . This has made comparison and reproducibility of 
experiments much simpler. Experience with CyA and knowledge of its toxicity has 
made the establishment of safe dosage regimes essential. Several factors are 
known to interplay in relating drug dose to action. These include: route of 
administration, bioavailability, phamacokinetics and pharmacodynamics of the 
agent 202,213,256 compliance is an important issue in human practice, with ease of 
administration to ensure correct dose delivery being a similar factor in veterinary 
practice.
CyA is not water soluble 1 5^,200,202 Sandoz have developed a parenteral 
formulation which can be diluted in physiological fluids and have also altered their 
oral preparation to improve its bioavailability 214.255,351 However, for nerve allograft 
research many investigators have used base powder CyA from Sandoz, which 
needs to be dissolved in an oil and alcohol mixture (see Chapter 2) 202,206,213,253.262 
From experience of preparing solutions of CyA, it would be expected that 
parenteral CyA would have greater bioavailability than oily CyA.
Some of the issues involved in the pharmacokinetics of CyA administration in the 
rat have been already examined, especially regarding an optimal route of 
administration 213,262 Comparing oral, intramuscular, intraperitoneal and 
subcutaneous routes of administration of an oil based preparation, Wasseff found 
that although the subcutaneous route did not produce the greatest bioavailability, it 
did achieve the most stable serum concentration of CyA. Oral administration was
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poorest . Following on from this, Bain determined that a dose of 5mg/kg/day 
was the lowest effective dose in providing immunosuppression sufficient for 
peripheral nerve allografting in rats, thus reducing the risks of CyA toxicity . 
Histological features of an inlaid nerve allograft and the response to a mixed 
lymphocyte reaction immunological test were used to compare allogenic and non- 
allogenic groups. Both of these authors also noted that increasing harmful effects 
were associated with higher CyA doses and concentrations.
For short-term experiments using low doses, toxic effects were not a great 
problem, however as nerve regeneration takes time Midha expressed some 
concern over long-term CyA use in rats. His study identified a depot effect of using 
oral-type formulations of CyA subcutaneously (oil based CyA preparations) which 
resulted in greater toxicity from CyA . The best indicator of toxicity was the 
animals' weight gain which fell drastically following CyA administration and 
although recovering with time, failed to rise in line with normal rats’ weight. 
Farthings earlier work also defined weight as a good indicator of CyA toxicity , 
He also noted that failure to thrive and changes to liver and kidney (functionally 
and histologically) were related to dose and duration of CyA administration.
All of the above contributions have stressed the importance of achieving a safe 
therapeutic window for CyA use. In this project the dose of 5mg/kg/day was used 
and to prevent an excessive depot effect, the CyA was administered on alternate 
days after 12 weeks, which was in line with Midha’s work.
In Chapter 5, essentially no major differences were noted between the 
experimental groups regardless of immunosuppression or graft type. The reasons 
for this could relate to the use of oily CyA and to lack of sufficient genetic disparity 
between the rat strains. As Chapter 3 results did indicate poorer regeneration 
within the allografted nerve with loss of donor Schwann cells and an increased
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macrophage response, most likely as part of a rejection response, then there 
would appear to be sufficient evidence to discount genetic similarity between the 
strains i5i,162,246 However, further investigation is required to test whether the CyA 
preparations are truly adequate.
6.2 AIMS
To test the hypothesis that oily CyA(oCyA) may not provide sufficient 
immunosuppression for nerve allografts and sandwich grafts, oCyA had to be 
assessed compared to parenteral CyA (pCyA), which had been shown to be 
successful over the early regeneration period. Axonal regeneration, Schwann cell 
and macrophage staining were compared up to 21 days (see Chapters 3 & 4). 
Long-term results from pCyA groups were compared to results from oCyA (see 
Chapter 5) to complete the analysis.
As oCyA is hypothesised to be less bioavailable and more associated with depot 
effects than pCyA, this could be expected to affect CyA concentrations and 
therefore toxicity. A further aim of this project was therefore to determine any 
potential harmful effects which may have resulted from these experiments by 
measuring animal weights, serum CyA concentrations, hepatic transaminases, 
alkaline phosphatase and creatinine as indicators of hepatic and renal function 
respectively.
6.3 EXPERIMENTAL PROTOCOL
Within the early regeneration period of 21 days, simple graft procedures were 
employed as in Chapter 3. Ten millimetre grafts were transplanted orthotopically 
following resection of 10mm right sciatic nerve segments.
For 32 week long-term experiments the protocol was similar to that in Chapter 5. 
Ten millimetre sciatic nerve resections were repaired with 15mm grafts. In this
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situation autografting without sacrifice of an additional nerve is impossible, 
therefore isografts formed the main non-allogenic control group (Table 6.1).
Cyclosporin remained the sole immunosuppressant used. Results have already 
been reported on the parenteral preparation of CyA (pCyA) in Chapters 3 and 4, 
and on oily preparation of base powder CyA (oCyA) in Chapter 5. Therefore to 
complete the assessment of both CyA preparations in this experiment groups 
receiving oCyA and pCyA were undertaken and assessed over 21 days and 32 
weeks respectively.
Assessments involved analysis of axonal, Schwann cell and macrophage staining 
at 21 days, and myelinated fibre characteristics at 32 weeks. In addition 
comparisons were made of gastrocnemius muscle mass.
To assess the general effects of CyA administration, as well as daily observations, 
the animals receiving CyA were weighed weekly. They also had blood samples 
taken for analysis of CyA levels, serum creatinine (creat), alkaline phosphatase 
(alk phos), alanine-amino transferase (ALT) and aspartate-amino transferase 
(AST) as indicators of renal and hepatic function. Non-immunosuppressed animals 
were weighed at operation and at the end of the experiments.
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Table 6.1 
Group Code 
Simple grafts
Experimental Groups
Time (weeks) CyA Numbers
Allograft (Allo+oCyA) 3 32 oily 6
Allograft (Allo+pCyA) 3 32 parenteral 6
Allograft (Allo-CyA) 3 32 none 6
Isograft (Iso+pCyA) 3 parenteral 5
Isograft (Iso+oCyA) 32 oily 5
Isograft (Iso-CyA) 3 32 none 6
Sandwich grafts
Sand.Allo (SAIIo+oCyA) 32 oily 6
Sand.Allo (SAIIo+pCyA) 3 32 parenteral 6
Sand.Allo (SAIIo-CyA) 3 32 none 6
SandControl (SCon-CyA) 3 32 none 6
6.4 RESULTS
6.4.1 Early Regeneration -  21 days
6.4.1.1 Axonal regeneration
Macroscopically, the harvested allograft immunosuppressed with oily CyA 
(Allo+oCyA) had a yellower colour than the corresponding allograft segment from 
the group immunosuppressed with parenteral CyA (Allo+pCyA). However, the 
colour was not as obvious, nor the grafts as firm as the non-immunosupressed 
allografts (Allo-CyA).
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Table 6.2
21 day Percentage area of axonal staining -  Proximal Allograft
Mean (+/-SD), n=6
+pCya +oCya -CyA
Allograft 19.66* 14.13 11.89
(+/-1.79) (+/-4.14) (+/-4.64)
* p< 0.05 Allograft+pCyA vs Allograft-CyA
One way ANOVA to compare groups (p=0.008). Tukey multiple comparison procedure to compare 
every pair of group means.
Quantification of axonal regeneration within the proximal graft (Area G -  Figure
2.4) indicated similar findings to the macroscopic features. The Allo+oCyA group 
produced axonal regeneration values between those of the Allo-CyA and 
Allo+pCyA groups (Table 6.2). Comparisons were also made with the allogenic and 
non-allogenic grafts from Chapter 3 (Table 6.3). These show that the Allo-CyA and 
Allo+oCyA groups were significantly different from the Isograft control groups, while 
the Allo+pCya group was not.
Comparisons were also made with the sandwich graft groups from Chapter 4 
(Table 6.4). Although the sandwich grafts in these experiments are 5mm longer 
than the simple grafts, the analyses were all undertaken within the same proximal 
quantification zone (Area G) to allow comparative assessments. Within this 
comparison, the Allo+oCyA group and the Allo-CyA group showed consistently 
statistically poorer axonal regeneration than the Allo+pCyA group. However the 
Allo+oCyA group showed similar results to those of the sandwich graft groups, who 
in turn produce similar results to those from the Allo+pCyAgroup.
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Table 6.3
21 day Percentage area of axonal staining -  Proximal Simple Graft
Mean (+/-SD), n=6
+pCyA
+oOyA
-CyA
Allograft
19.66
(+/-1.79)
14.13**
(+/-4.14)
11.89*
(+/-4.66)
Autograft
18.37"
(+/-2.78)
28.84""
(+/-2.6B)
Isograft
25.88
(+/-3.24)
24.07
(+/-7.04)
* p<0.05 Allograft-CyA vs Allograft+pCyA, Autograft -  CyA & Isograft +/- CyA
**p<0.05 Allograft+oCyA vs Autograft -  CyA & Isograft +/- CyA
* p<0.05 Autograft+CyA vs Autograft-CyA, Isograft+CyA
”  p<0.05 Autograft-CyA vs Allograft+pCyA
One way ANOVA to compare groups (p<0.001). Tukey multiple comparison procedure to compare 
every pair of group means.
Table 6.4
21 day Percentage area of axonal staining -  Proximal Graft 
Mean (+/-SD), n=6
+pCyA
+oCyA
-CyA
* p<0.05
Allograft
19.66*
(+/-1.79)
14.13
(+/-4.14)
11.89
(+A4.66)
SandAllo
14.94
(+/-1.47)
SandControl
14.84
(+/-2.18)
10.75
(+A2.46)
Allograft+pCyA vs Allograft-CyA, Allograft+oCyA, SandControl
One way ANOVA to compare groups (p<0.001). Tukey multiple comparison procedure to compare 
every pair of group means.
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These results indicate that while oily CyA is associated with an improvement in 
axonal regeneration within an allograft model, the benefit is not as great as that 
conferred by parenteral CyA.
6.4.1.2 Macrophage Quantification
Analysis of macrophage staining (Tables 6.5) also indicates that oily preparation 
CyA produces results that are part-way between those of parenteral CyA and the 
non-immunosuppressed allografts. The Allo+oCyA group results were more 
variable than the other groups. Although, unlike the Allo+pCyA group, they show 
statistically increased macrophage staining compared to isograft controls (Table 
6 .6).
Table 6.5 
21 day Percentage area of macrophage staining -  Proximal Allograft 
Mean (+/-SD), n=6
+pCya +oCya -CyA
Allograft 17.11* 25.26 30.26
(+/-4.60) (+A7.72) (+7-2.99)
* p< 0.05 Allograft+pCyA vs Allograft-CyA
One way ANOVA to compare groups (p=0.003). Tukey multiple comparison procedure to compare 
every pair of group means.
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Table 6.6
21 day Percentage area of macrophage staining ~ Proximal Graft
Mean (+/-SD), n=6
Allograft Autograft Isograft SandAlloG
+pCyA 17.11
(+/-4.60)
18.95
(+/-6.73)
12.35
{+/-2.19)
10.99*** 
(+/-1.75)
+oCyA 25.26**
(+Z-7.72)
-CyA 30.26*
(+/-2.99)
21.30
(+/-2.66)
15.80
(+/-2.39)
18.17
(+/-4.32)
* p<0.05 Allograft-CyA vs Allograft+pCyA, Autograft+pCyA, SandAlloG+/-CyA,
lsograft+/-CyA
**p<0.05 Allograft+oCyA vs SandAlloG+pCyA, lsograft+/-CyA
***p<0.05 SandAlloG+pCyA vs Autograft-CyA
One way ANOVA to compare groups (p<0.001). Tukey multiple comparison procedure to compare 
every pair of group means.
Comparison with sandwich grafts indicates similar levels of staining to the non- 
immunosuppressed sandwich allograft, but higher levels than within the 
SandAllo+pCyA group. All groups receiving parenteral CyA had lower levels of 
staining than their non-immunosuppressed counterparts. This implies that, for 
allogenic graft segments, both administration of oily CyA and addition of the 
autologous graft segment within the sandwich graft construct lead independently to 
a similar reduction in the macrophage response. Administration of seemingly more 
potent parenteral CyA enhances this response, producing similar amounts of 
macrophage staining to that measured in non-allogenic grafts.
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6.4.1.3 Schwann Cell Quantification
Comparison of Schwann cell staining within the early graft groups indicates greater 
Schwann cell quantification within the Allo+pCyA group. Results from the 
Allo+oCyA group lie between its allogenic counterparts, although on this occasion 
differences between both groups are significant. Schwann cell staining within the 
Allo+oCyA group is also poorer than within the non-allogenic groups but remains 
significantly better than the Allo-CyA group.
When compared to Sandwich graft models (Table 6.8), the Allo+oCyA group 
results were similar to the allogenic sandwich graft groups.
Table 6.7
21 day Percentage area of Schwann cell staining -  Proximal Graft 
Median (25-75%), n=6
+pCyA
+oCyA
-CyA
Allograft
41.86
(31.91-49.66)
25.14**
(7.63-32.79)
9.94*
(4.39-11.19)
Autograft
38.63
(35.62-40,94)
45.56
(42.55-47.84)
Isograft
37.54
(36.07-40.67)
47.59
(46.02-49.95)
* p<0.05 Allograft-CyA vs All groups
**p<0.05 Allograft+oCyA vs All groups
One way ANOVA on ranks to compare groups (p<0.001). Student-Newman-Keuls multiple 
comparison procedure to compare every pair of group medians.
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Table 6.8
21 day Percentage area of Schwann cell staining -  Proximal Graft
Mean (+/-SD), n=6
+pCyA
+oCyA
-CyA
Allograft
40.92
(+7-9.69)
21.69
(+7-12.42)
8.30
(+7-4.55)
SandAllo
31.45
(+7-5.70)
28.04
(+7-8.62)
SandControl
41.16
(+7-6.69)
p<0.05 Allograft-CyA vs Allograft+pCyA, All sandwich graft groups.
** p<0.05 Allograft+oCyA vs Allograft+pCyA, SandControl.
One way ANOVA to compare groups (p<0.001). Tukey multiple comparison procedure to compare 
every pair of group means.
6.4.2 Long-term regeneration - 32 weeks
6.4.2.1 Myelinated axon analyses
Analyses for long-term results were undertaken on semithin sections of posterior 
tibial nerve using measurements taken from myelinated axons, as described in 
Chapters 2 and 5 (Figure 6.1).
Total axon counts for allograft and sandwich allograft groups immunosuppressed 
with parenteral CyA (Allo+pCyA and SandAllo+pCyA) show lower results with 
narrower variability than the corresponding sandwich and allograft groups (Table 
6.9).
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Figure 6.1 Semithin sections of distal myelinated nerve at 32 weeks
Allo+pCyA X 40
SandAllo+pCyA x 40
w
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Table 6.9 Total Axon Counts in 3 Frames “ Mean +/- SD
Group n CyA Type No. Axons SD
Simple Grafts
Allograft 6 yes oCyA 1251 (+/-262)
Allograft 5 yes pCyA 1035 (+/-146)
Allograft 6 no 1274 (+/-330)
Isograft 5 yes oCyA 1062 (+/-214)
Isograft 5 no 903 (+/-4S4)
Sandwich Grafts
SandAllo 5 yes oCyA 998 (+/-305)
SandAllo 6 yes pCyA 704* (+/-184)
SandAllo 6 no 1338 (+/-359)
SandCon 6 yes oCyA 949 (+/-304)
SandCon 6 no 1145 (+/-96)
Controls
Normal 6 no 505 (+/-55)
Unrepaired 5 no 12 (+/-5)
Allo+vehicle 6 no 1279 (+/-683)
"p<0.05 for SandAllo+pCyA vs Allo+oCyA, Allo-CyA, SandAllo-CyA
One way ANOVA comparing Simple (including Alio + vehicle control) with Sandwich grafts 
(p=0.004). Tukey multiple comparison procedure comparing every pair of group means.
When compared with matching non-allogenic groups, only the SandAllo+pCyA 
group shows any significant difference with lower values than the Allo+oCyA, Allo- 
CyA and SandAllo-CyA groups. Normal and unrepaired groups have been shown 
for completeness but were uninvolved in this analysis.
When the Normal group was compared to the experimental groups (Table 6.10) 
results from Allo+pCyA and SandAilo+pCyA were similar to normal values.
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Table 6.10 Total Axon Counts in 3 Frames -  Median values
Group n CyA Type No. Axons (25-75 centiles)
Simple Grafts
Allograft 6 yes oCyA 1137 (1068-1508)
Allograft 5 yes pCyA 1011 (968-1125)
Allograft 6 no 1235 (931-1583)
Isograft 5 yes oCyA 1035 (929-1205)
Isograft 5 no 932 (721-1104)
Sandwicfi Grafts
SandAllo 5 yes oCyA 1125 (801-1222)
SandAllo 6 yes pCyA 679 (582-777)
SandAllo 6 no 1221 (1069-1760)
SandCon 6 yes oCyA 926 (755-1138)
SandCon 6 no 1184 (1087-1216)
Controls
Normal 6 no 526* (474-593)
Unrepaired 5 no 11 (8-15)
Ailo+vehicle 6 no 1129 (896-1664)
Comparing the Normal control to all other groups (except Unrepaired), Kruskal-Wallis One way 
ANOVA on ranks executed (p=0.001). Dunn’s multiple comparison procedure, *p < 0.05 Normal vs 
Allograft+oCyA, Allograft-Cya, SandAllo-CyA, SandControl-CyA.
Results from Unrepaired nerve were omitted from statistical analysis as gross difference and 
variability skewed analyses, results included in table to indicate this.
Axon and fibre diameter measurements also indicated larger fibres within the 
Allo+pCyA and SandAllo+pCyA groups compared to the other experimental 
groups. However, these results were not statistically different (Table 6.11). All 
groups were statistically thinner than normal nerve, but when compared to 
unrepaired nerve, the values from the Allo+pCyA and SandAllo+pCyA groups 
reached statistical significance. For fibre diameter, the Allo+oCyA, Iso+oCyA and 
SandAllo-CyA groups were also significantly better than axons within the 
unrepaired group.
173
Table 6.11 Myelinated Nerve Morphology -  Mean (+/- SD)
Group
Simple Grafts
n CyA Type Axon Diameter
fxm
Fibre Diameter
j im
Allograft 6 yes oCyA 1.78 (+/-0.14) 4.47 (+/-0.25)
Allograft 5 yes pCyA 2.20 (+/-0.17) 4.62 (+/-0.20)
Allograft 6 no 1.76 (+/-0.37) 4.21 (+/-0.44)
Isograft 5 yes oCyA 1.99 (+/-0.39) 4.55 (+/-0.54)
Isograft 5 
Sandwich Grafts
no 1.69 (+/-0.26) 4.29 (+/-0.37)
SandAllo 5 yes oCyA 1.97 (+/-0.26) 4.42 (+/-0.32)
SandAllo 6 yes pCyA 2.40 (+/-0.34) 4.94 (+/-0.49)
SandAllo 6 no 1.75 (+/-0.20) 4.42 (+/-0.29)
SandCon 6 yes oCyA 1.72 (+/-0.26) 4.28 (+/-0.26)
SandCon 6 no 1.63 (+/-0.20) 4.38 (+/-0.38)
Controls
Normal 6 no 4.70 (+/-0.48) * 8.39 (+/-0.62) ‘
Unrepaired 5 no 1.24 (+/-0.27) ** 3.13 (+/-0.34) "
Allo+vehlcle 6 no 1.87 (+/-0.35) 4.29 (+/-0.51)
Comparing Axon diameters One way ANOVA (p<0.001), Scheffé multiple comparison procedure, 
*p<0.001 Normal vs All groups; **p<0.04 Unrepaired vs Allograft+pÇyA, SandAllo+pCyA.
Comparing Fibre diameters One Way ANOVA (p<0.001), Scheffé multiple comparison procedure, 
’p<0.001 Normal vs All groups; **p<0.04 Unrepaired vs Allograft+oCyA, Ailograft+pCyA, 
Isograft+oCyA, SandAiio+pCyA, SandAllo-CyA.
Myelin thickness calculation indicates no differences between the experimental 
groups, although all were thinner than normal (Table 6.12). The results from G- 
ratio analysis show similar findings except that the higher levels recorded for the 
parenteral CyA groups were statistically similar to normal nerve values. 
Comparisons with SandAllo-CyA and SandControl groups also showed the 
Allo+pCyA and SandAllo+pCyA groups to be significantly better. Analysis of 
laciness indicated mainly similarities between the groups, with only the difference 
between SandAllo+pCyA and SandAllo-CyA reaching statistical significance.
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Table 6.12 Myelinated Nerve Morphology -  Mean (+/- SD)
Group n CyA Type Myelin G-ratio Laciness
Simple Grafts
Allograft 6 yes oCyA
Thickness (pm)
1.35 (+/-0.10) 0.34 (+/-0.03) 0.85 (+/-0.01)
Allograft 5 yes pCyA 1.22 (+/-0.06) 0.42 (+/-0.02) 0.84 (+/-0.01)
Allograft 6 no 1.22 (+/-0.08) 0.36 (+/-0.04) 0.84 (+/-0.03)
Isograft 5 yes oCyA 1.28 (+/-0.12) 0.38 (+/-0.04) 0.84 (+/-0.02)
Isograft 5 no 1.30 (+/-0.06) 0.34 (+/-0.03) 0.82 (+/-0.03)
Sandwich Grafts
SandAllo 5 yes oCyA 1.23 (+/-0.06) 0.37 (+/-0.02) 0.84 (+/-0.03)
SandAllo 6 yes pCyA 1.27 (+/-0.16) 0.42 (+/-0.04) 0.85 (+/-0.02)
SandAllo 6 no 1.34 (+/-0.09) 0.33 (+/-0.03) • 0.79 (+/-0.01)
SandCon 6 yes oCyA 1.28 (+/-0.05) 0.34 (+/-0.03) 0.83 (+/-0.02)
SandCon 6 no 1.38 (+/-0.12) 0.32 (+/-0.03) •* 0.83 (+/-0.03)
Controls
Normal 6 no 1.85 (+/-0.09) * 0.50 (+/-0.01) **0.85 (+/-0.02)
Unrepaired 5 no 0.58 (+/-0.48) 0.26 (+/-0.22) 0.51 (+/-0.42)
Allo+vehlcle 6 no 1.21 (+/-0.14) 0.39 (+/-0.05) (+/-)
Comparing Myelin Thickness One way ANOVA (p<0.001), Scheffé multiple comparison 
procedure, *p<0.001 Normal vs All groups.
Comparing G-ratio One way ANOVA (p<0.001), Scheffé multiple comparison procedure, **p<0.002 
Normal vs all groups, except Allograft+pCyA and SandAllo+pCyA. *p<0.05 SandAllo-CyA vs 
Allograft+pCyA, SandAllo+pCyA. ” p<0.02 SandCon-CyA vs Allograft+pCyA, SandAllo+pCyA.
Comparing Laclness One way ANOVA (p<0.001), Scheffé multiple comparison procedure, 
***p=0.041 SandAllo-CyA vs SandAllo+pCyA
Unrepaired group omitted from statistical analysis in view of gross difference and high variability, 
results included in table to indicate this.
The distribution of myelinated fibres within the groups identified no statistical 
differences between the experimental groups within the low, middle or high fibre 
size ranges (Table 6.13). All groups were however statistically different to normal 
nerve with regenerated fibres mainly being of small calibre. Comparison with 
results from unrepaired nerve only reached statistical significance for the Sand 
Allo+pCyA group. Within the experimental groups, this group produced the largest 
amount of thick fibres.
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Table 6.13
Frequency Distribution of Fibre Diameters ™ Mean Percentage +/- SD
Groups 
Simple Grafts
CyA Type % Small 
1-7pm
% Medium 
8-10]im
% Large 
11“20+jxm
Allograft yes oCyA 87.77
(+A2.73)
9.42
(+/-2.04)
2.80
(+/-0.84)
Allograft yes pCyA 87.32
(+/-1.96)
10.35
(+/-1.69)
2.33
(+/-0.74)
Allograft no 90.76
(+/-S.66)
7.63
(+M.22)
1.61
(+/-1.47)
Isograft yes oCyA 87.00
(+/-7.08)
9.98
(+/-4.65)
3.03 
(+/-2.81 )
Isograft
Sandwich Grafts
no 90.13
(+A3.73)
8.15
(+/-2.90)
1.72
(+/-0.85)
SandAllo yes oCyA 86.51
(+/-5.03)
10.23
(+/-3.15)
3.27
(+/-2.14)
SandAllo yes pCyA 81.77
(+/-6.01)
12.83
(+A3.44)
5.40
(+A3.73)
SandAllo no 87.48
(+/-4.47)
9.55
(+/-2.91)
2.97 
(+/-1.63)
SandCon yes oCyA 87.87
(+Z-2.87)
9.24
(+/-1.97)
2.89 
(+/-1.49)
SandCon
Controls
no 88.32
(+/-4.95)
9.26
(+/-2.98)
2.42
(+/-2.09)
Normal no 33.39 * 
(+A4.35)
31.56"
(+/-5.12)
35.05 "  
(+7-9.33)
Unrepaired no 98.00 ** 
(+/-4.47)
2.00
(+Z-4.47)
0.00
(+7-0.00)
Allo+vehlcle no 90.30
(+/-5.17)
8.06
(+A3.85)
1.64 
(+7-1.36)
Comparing % Small One way ANOVA (p<0.001), Scheffé multiple comparison procedure, *p<0.001 
Normal vs All groups; **p=0.024 Unrepaired vs SandAllo+pCyA.
Comparing % Medium One way ANOVA (p<0.001), Scheffé multiple comparison procedure, 
*p<0.001 Normal vs All groups.
Comparing % Large One way ANOVA (p<0.001), Scheffé multiple comparison procedure, 
**p<0.001 Normal vs All groups. However, omitting the Normal group Improves the assumption of 
homogeneous variances. Subsequent One way ANOVA, p=0,049 showing no significant difference 
between the remaining groups.
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e.4.2.2 Gastrocnemius muscle mass
Analysis of Gastrocnemius muscle mass from the experimental groups 
immunosuppressed with oily CyA and the non-immunosuppressed groups has 
been detailed in Chapter 5. Analysis of mass values for the groups 
immunosuppressed with parenteral CyA (Table 6.14) shows no statistical 
difference between groups, except that all groups had significantly improved 
muscle bulk to that recorded for the unrepaired nerve group.
Table 6.14
Gastrocnemius muscle mass -  Percentage operated side /  normal 
Median (25-75 centiles)
Group n CyA Type Median % 25-75 centiles
Simple Grafts
Allograft 6 yes oCyA 64.24 (53.98-70.90)
Allograft 5 yes pCyA 65.27 (63.32-71.98)
Allograft 6 no 68.21 (59.05-72.93)
Isograft 5 yes oCyA 58.91 (52.27-63.52)
Isograft 5 no 49.29 (35.62-59.40)
Sandwich Grafts
SandAllo 5 yes oCyA 65.00 (61.37-65.67)
SandAllo 6 yes pCyA 64.23 (62.44-67.11)
SandAllo 6 no 72.39 (69.91-74.69)
SandCon 6 yes oCyA 68.20 (60.23-75.42)
SandCon 6 no 67.75 (65.63-68.61)
Controls
Unrepaired 5 no 11.68* (9.69-13.11)
Ailo+vehicle 6 no 66.56 (51.83-74.68)
Kruskal-Wallis One way ANOVA on ranks executed using Median values.
Comparing Unrepaired to experimental grafts (including Allograft+vehicle), K-W ANOVA, p<0.002. 
Dunnett’s multiple comparison procedure, *p<0.05 Unrepaired vs All groups.
Omitting Unrepaired group, K-W ANOVA shows no significant difference between the remaining 
groups, p=0.061.
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The use of parenteral formulation CyA (pCyA) appears to have some benefit over 
oily CyA (oCyA) over long and short term experimental periods when comparing 
regeneration parameters. However, in the majority of cases the measured 
differences do not reach statistical significance. The extent of regeneration found 
within experimental groups was greatly improved from that seen in an unrepaired 
identical model.
6.4.3 Cyclosporin monitoring
As improved levels of immunosuppression with general methods are often 
associated with increased drug toxicity and side-effects, for these experiments 
evaluation of CyA, creatinine, and liver enzymes blood levels were measured, 
along with the animals’ weights.
6.4.3.1 Cyclosporin levels
Assessments of CyA levels measured pre- and 4 hours post-dose indicate that 
levels were satisfactory following drug administration (Figure 6.2) and agree with 
other reported levels . The highest levels were associated with parenteral 
formulation CyA. Unfortunately within the biochemistry laboratory carrying out the 
analyses concentrations greater than 1500p,g/l were often reported as such and not 
as absolute values, therefore no statistical analysis of these results was possible, 
as results would have been meaningless.
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Figure 6.2
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Trough CyA concentrations were measured from blood samples obtained from the 
relevant groups at weeks 12 and 32 during the long-term (32 week) experiments 
(see Chapter 2 for methods). At 12 weeks, analysis of specimens from the 
Allo+oCyA and SandAllo+oCyA groups showed no significant differences in trough 
CyA levels 24 hours following the last CyA dose (Table 6.15).
At 32 weeks, specimens were analysed from groups receiving oily and parenteral 
CyA. Comparisons within the oily CyA groups showed similar trough values (Table 
6.15). These were significantly higher than levels recorded at 12 weeks. Results 
from the parenteral CyA groups were lower than for oily CyA groups. The 
Allo+pCyA and SandAllo+pCyA groups produced vastly different mean levels. The 
reason for this, as determined from the experimental protocol diary may be that 
over 48 hours had elapsed following the last dose to the SandAllo+pCyA group 
compared to 24 hours for the Allo+pCyA group. The SandAllo+pCyA group would 
usually have had CyA but it was omitted as the group was due for harvest.
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however this low level could also represent a laboratory based fault or a spurious 
finding.
Table 6.15 
Blood Cyclosporin Concentration - Mean (+/-SD)
Group n CyA type Trough levels (jxg/f)
12 weeks 32 weeks
Simple Grafts
Allograft 6 oCyA 340.17** 660.33
(+/-108.84) (+/-144.45)
Allograft 5 pCyA 245.17)*
(+/-12.45)
Isograft 5 oCyA 486.60
(+/-157.09)
Sandwich Graft
SandAllo 5 oCyA 315.60** 645.83
(+/-S7.24) (+/-200.75)
SandAllo 6 pCyA 40.00
(+/-11.58)
One way ANOVA comparing CyA levels In groups receiving oCyA at 32 weeks (p=0.16).
K-W ANOVA on ranks comparing groups receiving oCyA and pCyA at 32 weeks (p=0.002). 
SandAllo+pCyA omitted. Dunn’s multiple comparison procedure *p<0.05 Allo+pCyA vs Allo+oCyA, 
SandAllo+oCyA.
t-test comparing CyA levels In the 2 groups receiving oCyA at 12 weeks (p=0.662).
One way ANOVA comparing groups receiving oCyA at 12 and 32 weeks (p<0.001). Tukey multiple 
comparison procedure, **p<0.05 All 32 week oCyA groups vs All 12 week oCyA groups.
These results suggest a depot effect was present within this model for the 
subcutaneous route of CyA administration, but that the depot effect was mainly 
associated with the oily CyA preparation.
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6.4.S.2 Hepatic and renal function
Measurements of plasma concentrations of creatinine, alkaline phosphatase, AST 
and ALT are shown in Table 6.16. In the isograft group, all of the specimens were 
haemolysed and analysis could not be conducted on them (Haem).
For creatinine and alkaline phosphatase, the mean levels from every group are 
within the upper reference range used by the laboratory undertaking the analyses 
(Guy’s Hospital Biochemistry Dept. -  Chapter 2). Likewise, ALT levels are within 
the range, with only the Allo+pCya group being just outside. The AST levels are, 
however, much higher than expected. As the laboratory reference values relate to 
human blood samples, blood was taken from 28 non-immunosuppressed groups at 
the end of the experiment to be used to determine rat control concentrations for the 
substances under investigation. These values are reported as Rat Controls within 
Table 6.16.
Comparison with the Rat Controls indicates that the lower values for creatinine are 
probably normal for these rats. Creatinine concentration relates to muscle mass, 
therefore rat levels would be expected to be lower than human. Also the levels of 
Alkaline phosphatase and ALT appear normal for these rats. While there were no 
statistical differences between Controls and experimental groups in the creatinine 
and ALT groups, the Iso+oCyA and Allo+pCyA groups were significantly lower than 
the control value for alkaline phosphatase. However it is unlikely that this difference 
has any relevance in real terms in so much as it is low and CyA toxicity is 
associated with high levels.
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Table 6.16 Creatinine, Alkaline Phosphatase, AST, ALT Blood Levels
Group n CyA
Type
Creat
(pmoi/i)
AikPhos
(iu/i)
AST
(iu/i)
ALT
(iu/i)
Simple Grafts
Allograft 6 oCyA 40.5
(+M.93)
76.17
(+/-17.31)
295.5
(+7-68.85)
40.33
(+7-15.97)
Allograft 6 pCyA 42.67 
(+/-1.63)
55.17
(+/-8.50)
256.33
(+7-39.37)
59.83
(+7-12.81)
Isograft 5 
Sandwich Graft
oCyA Haem 47.60*
(+/-8.17)
Haem 51.80
(+7-4.97)
SandAllo 6 oCyA 40.67
(+/-4.08)
79.17
(+/-26.31)
332.5
(+7-57.58)
39.00
(+7-21.40)
SandAllo 5 pCyA 38.8
(+/-2.68)
83.00
(+/-10.79)
281
(+7-70.70)
40.80
(+7-23.84)
Rat Controls none 40.87
(+/-13.96)
117.61**
(+/-79.S4)
174.76
(+7-89.67)
61.54
(+7-59.57)
Human Ref. Values 65-101 38-126 0-35 0-55
Creatinine K-W ANOVA on ranks comparing experimental groups (p=0.13): no significant 
differences. No difference compared to Control Creatinine (p=0.309).
Aik Phos One Way ANOVA comparing experimental groups (p=0.004). Tukey multiple
comparison procedure: *p<0.05 Iso+oCyA vs SandAllo+oCyA and pCyA. 
Compared to Control Alkaline Phosphatase, **p<0.05 Iso+oCyA and Allo+pCyA vs 
Control.
AST K-W ANOVA on ranks comparing experimental and control groups (p<0.001).
Dunn’s multiple comparison procedure, p<0.05 SandAllo+oCyA vs AST Control.
ALT One Way ANOVA comparing experimental groups (p=0.197): no significant
difference. No difference compared to Control ALT (p=0.518).
Haem: Haemolysed samples.
Regarding AST measurement, when compared to Rat Control values, only the 
SandAllo+oCyA produced significantly higher levels of AST. All other groups, 
although recording high concentration, may have to be regarded as normal within 
anaesthatised Lewis rats.
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6.4.3.3 Weight gain
Groups receiving CyA were weighed weekly, to determine the dose of CyA to 
administer and also as a monitor of general health (Figure 6.3). Non- 
immunosuppressed groups were weighed at the start and end of the experiments 
(Figure 6.4).
Figure 6.3
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starting Weight One Way ANOVA comparing groups (p<0.001 ). Tukey multiple comparison
procedure: *p<0.05 Iso+oCyA and SandAllo+oCyA vs All other groups.
Final Weight Similar findings to above.
All animals gained weight whether immunosuppressed or not. In the 
immunosuppressed groups, the graph of weight gain plotted over four weekly 
increments identifies two distinct populations. Statistical analysis identifies that this
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difference is related to the different mean starting weights of these groups but 
generally the rate of weight gain was similar between all groups (Table 6.17). The 
rate of weight gain was greatest within the Normal group but this also did not reach 
statistical significance (Figure 6.4 and Table 6.17). From this we can conclude that 
as far as this parameter is concerned, CyA administration did not appear to have a 
detrimental effect on the rats’ general health, any more so than the operative 
procedure itself.
Figure 6.4
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Table 6.17 Mean Rate of Group Weight Gain over 32 Weeks
Simple Grafts Rate(g/week)
Iso-oCyA
Iso+oCyA
Allo-CyA
Allo+oCyA
Allo+pCyA
Normal
2.46
2.32
2.56
2.48
2.42
3.30
Sandwich Grafts
SandCon-CyA
SandAllo-CyA
SandAllo+oCyA
SandAllo+pCyA
Rate(g/week)
2.40
2.90
2.62
2.28
One Way ANOVA comparing experimental groups (p=0.843): no statistical difference. Comparison 
with Normal also non-signIflcant (p=0.159).
6.4.4 Morbidity and Mortality
There were nine unexpected deaths during this project. The majority were 
associated with general anaesthesia. These numbers include two rats who 
underwent euthanasia in the early stage of the project following prolonged and 
inadequate post-operative recovery despite standard anaesthetic precautions and 
recovery room practices, as per veterinary advice and Home Office regulations. As 
female rats were used in these experiments, it was felt that the temperature of the 
post-operative recovery room may have been inadequate for recovering these rats. 
Other experiments in the same facility used mainly male rats which are much 
larger than females of the same age. Following an increase in recovery room 
temperature, along with the provision of subcutaneous saline already being 
practiced, further preoperative deaths were prevented.
Two further rats required euthanasia. Both belonged to long-term experimental 
groups receiving oily CyA. One developed sudden onset left hind limb paralysis at 
30 weeks (Allo+oCyA), while the other developed a middle ear infection 
(Iso+oCyA). The former rat had no evidence of infection and appeared to have had
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a CVA (cerebrovascular accident), while the latter rat’s death could be related to 
CyA administration because of its infective nature.
One other unexpected death was attributed to CyA. This long-term experimental 
animal was receiving daily oily CyA within the first 12 weeks of the experiment. The 
animal had been noted to have developed a soft non-tender scruff swelling (see 
later) which was thought to be related to CyA administration. This animal was 
found dead. Post mortem findings noted cloudy oily fluid within the scruff 
subcutaneous swelling which grew Staphlococcus aureus on bacteriological 
culture. All other organs appeared normal. The death was therefore attributed to 
septicaemia, secondary to infection of a collection of oil based CyA preparation. No 
cage mates became unwell.
Morbidity within the experimental groups fell into four main groups: autoamputaton, 
scruff subcutaneous fluid collections, cutaneous pressure effects and rashes.
Two animals had autoamputated toes within three weeks of denervation. Both 
animals were not immunosuppressed and both injuries involved lateral right toes (3 
in one rat and 1 in the other rat). The animals belonged to short and long-term 
experiments respectively. Three rats had right footpad skin changes, which 
included a 2mm dry, healing ulcer, a small granuloma which healed and a keratin 
horn at the base of the fifth metatarsal. Neither of these animals were 
immunosuppressed. Rats from four groups had skin rashes which produced a few 
dry scaling spots within the coats on the main corporeal parts of the animals. 
Fourteen animals out of a possible 24 were affected, all within long-term groups 
receiving CyA, irrespective of the formulation. There was no evidence of infection 
or infestation. All the rashes were noted towards the end of the experiment 
therefore no comment can be made about the long-term prognosis of this condition
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but within the confines of the experiment the animais continued to behave normally 
and gain weight while affected by the rash.
Ten animals, mainly from two groups were noted to have developed scruff 
subcutaneous swellings towards the end of the experiment although a few were 
noted from as early as six weeks into the long-term experiments. All of the groups 
were receiving oily CyA. The injection sites for CyA administration were varied to 
try to avoid any drug accumulation and tissue reaction, however in the small 
female rat inevitably the scruff area appeared to have been a favoured site. A 
coalescent effect from injections appeared to produce these soft, fluid, oily 
collections of a few millilitres in volume. None of the animals appeared distressed 
by the collections although one death was attributed to infection of such a 
collection (see above). To avoid causing further problems, following discovery of a 
collection, the whole scruff area was avoided for drug administration and to prevent 
the introduction of potential pathogens. For this reason the collections were not 
drained electively.
Therefore for the whole project, from 12 deaths, two may have been associated 
with CyA, and out of 29 animals with noted morbidity, 24 were associated with CyA 
use. The vast majority of animals had no decernable problems.
6.5 DISCUSSION
Results from Chapter 5 indicate no significant difference in the long term 
regeneration potential of simple or sandwich allografts irrespective of 
immunosuppression following repair of a 10mm sciatic nerve defect with 15mm 
grafts. Indeed, results from both nerve graft types were similar to controls. 
However, while all fell short of normal sciatic nerve in terms of myelinated axon 
morphology and gastrocnemius muscle mass, all groups produced significantly
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improved regeneration than that of an unrepaired nerve defect. Based on these 
findings, the question remained as to whether or not the oily formulation of CyA 
being used in Chapter 5 was providing adequate immunosuppression.
To assess the efficacy of oCyA and pCyA further experiments were undertaken 
using oCyA in the short term and pCyA in the long term so that these additional 
groups could be compared with those already reported in Chapters 3 and 5.
Against a background of some resistance to clinical nerve allografting on ethical 
grounds, additional assessments were made to determine any undesired effects of 
CyA that may also be influential in future decision making regarding nerve 
allografting.
The efficacy of any drug relates to its bioavailability in sufficient concentration to 
produce the desired effects while minimising any negative effects in any individual 
recipient. Cyclosporin is poorly water soluble ^^ 8,200,202 although delivery orally 
in humans is a major benefit, in small animals the oral route has been associated 
with highly variable bioavailability . The provision by Sandoz of base powder 
CyA has meant many authors have used this prepared in oil and alcohol as 
undertaken here. Wasseff, Bain and Midha have contributed important information 
on the use of CyA in rat models 206.213,254,262 p f o m  their work, although higher 
doses were associated with greater bioavailability more pronounced 
immunosuppression, a dose of 5mg/kg/day was the minimum required to maintain 
satisfactory immunosuppression with this dose Bain showed total
suppression of a mixed lymphocyte reaction. With this dose equivalent to 
syngeneic controls while side effects were minimised. In a rat model incompatible 
at both MHC I and II loci . The same administration route and does were 
subsequently used in a peripheral nerve allograft study where at 14 weeks 
regeneration in an immunosuppressed PNAG was equivalent to the autograft
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controls . Midha however also demonstrated with subcutaneous delivery of CyA 
that a depot effect was evident secondary to fat binding . If overlooked this 
could result in higher levels of circulating drug than expected with a greater risk of 
toxicity. Beneficial effects of a depot effect mean that reduced drug dosing is 
required while maintaining steady-state circulating drug concentrations. This 
minimises toxicity associated with gross concentration fluctuations. The use of an 
oil based CyA formulation in the long-term experiments (see Chapter 5) was 
suspected to produce such a depot effect and to beassociated with poorer 
bioavailability. The development of subcutaneous fluid connections provided visual 
evidence that this may be occurring , therefore the decision to reduce dosage 
interval during the experimental period appears justified, provided a steady state 
has been reached.
Axonal regeneration described in Chapter 3 for simple allografts 
immunosuppressed with pCyA was equivalent to that in non-allogenic control 
nerves. Associated with this were findings of reduced macrophage infiltration and 
greater Schwann cell presence than that identified in the non-immunosuppressed 
allografts. The administration of oCyA to the same model in the same dose 
produced effects midway between those seen in the non-immunosuppressed and 
pCyA groups. However the beneficial effects of CyA were evident when compared 
with the same parameters measured from non-immunosuppressed nerve 
allografts. This indicates poorer efficacy of oCyA compared to pCyA which likely 
relates to poorer bioavailability of oCyA related to its reduced solubility.
Results of long term studies using both CyA formulations indicates no significant 
difference in outcome across morphological parameters or related to the 
restoration of muscle mass with reinnervation. The lower myelinated axon counts, 
approaching normal values, associated with pCyA administration and the higher 
values across other paramenters may, despite the lack of statistical significance 
indicate greater potential benefits with pCyA use.
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As indicated in Chapter 5, the interpretation of axon counts in isolation is difficult. It 
is understood that during regeneration greater numbers of smaller axons 
regenerate following injury than the numbers measured in normal nerve . Once 
distal connections are established “pruning” occurs . However the residual axon 
counts remain in excess of normal nerve axon counts although function does not 
reach normality implying some of these axon are inappropriately connected . 
Therefore, conclusions regarding adequacy of axonal regeneration long term are 
related to comparisons made with results obtained from the standard repair 
methods of grafting or direct coaptation, in Chapter 5 and here, axon counts were 
increased compared to normal. However, when other parameters were also 
considered, particularly for the pCyA groups, the lower axon counts are suggestive 
that this indicates a beneficial response.
Despite the evidence from early regeneration periods, the similarity of outcomes 
from long-term regeneration could still be interpreted as secondary to the 
ineffective action of CyA. Therefore circulating CyA concentrations were measured 
as is regularly undertaken for monitoring purposes in clinical transplantation. The 
Biochemistry department used here to measure CyA had reference values for 
trough CyA concentrations of 150p.g/l for renal and 300-400jig/l for cardiac and 
hepatic allografts.
Unlike adult humans, venepuncture is difficult in small animals and also only small 
volumes can be removed for testing without the animal experiencing negative 
effects. Therefore in these experiments regular monitoring of blood CyA levels was 
deemed inappropriate. Generally blood was taken at the end of the experiment 
along with the main specimen retrieval. This allowed larger volumes to be removed 
for tests of renal and hepatic functions.
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In the early phases of this project some animals did have peak and trough blood 
CyA levels analysed (Figure 6.3 and Table 6.15). These results indicate that 
satisfactory trough levels were achieved when compared to the reference values 
given above. Results from trough levels of oCyA at 12 and 32 weeks also appear 
satisfactory and increase throughout the time of the experiment. These findings 
agree with those of Midha regarding a depot effect developing from subcutaneous 
CyA administration which was beneficial in maintaining steady-state CyA 
concentration using alternate day administration . Taken in conjunction with 
peak levels, knowledge of suitable levels for solid organ transplantation and 
experience with the CyA used in these experiments, it could be argued that these 
measured levels could be reduced further without losing immunosuppression once 
a steady state has been achieved. However, as the study of CyA pharmacokinetics 
was not the aim of this project, provided immunosuppression appeared 
satisfactory, the dosage regimen was unaltered.
The greater fluctuation in concentration witnessed for pCyA relates to its greater 
bioavailability associated with its greater solubility . The greater the
bioavailability, then also, the greater the drug clearance. Higher peaks and lower 
troughs are expected with parenteral administration as identified by Wassef using 
the intramuscular and intraperitoneal routes of administration . In these 
experiments, parenteral formula CyA, although delivered subcutaneously also 
produced lower trough concentrations at 32 weeks than the oily preperation. This 
may explain the low CyA level measured for SandAllo+pCyA in Table 6.15, as 
animals due for CyA dosage in the morning but scheduled for harvest would not 
have received the CyA dose that morning therefore a maximum of 54 hours may 
have elapsed since their last dose.
Evidence from early nerve regeneration assessments indicates the dose of 
5mg/kg/day produces adequate immunosuppression to allow axonal regeneration. 
Reducing the dosage interval avoids producing excessively high peak and trough
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levels, which in turn will reduce the potential risk of drug toxicity . To protect the 
regenerating axons up to, and including target organ reinervation the dosage 
interval was not reduced until 12 weeks had passed. This time point was also used 
by MacKinnon and Hare following their studies monitoring functional recovery by 
calculation of Sciatic Function Index .
The majority of animals showed no signs of CyA toxicity although enough evidence 
has been accrued to indicate not insubstantial levels of morbidity.
Wasseff, Bain and Farthing all noted rat weight to be a useful indicator of well­
being while receiving therapeutic doses of CyA 206.213,253 young rats (8 weeks) 
gain weight to reach adult proportions. This maturation was occurring during these 
experiments. The female Lewis rats used here were mainly less than 200g in 
weight at 8 weeks of age. The average weekly rate of weight gain was similar 
between experimental groups irrespective of CyA. For rats receiving CyA, two 
distinct populations were noted. Both collections of groups gained weight similarly 
and had initial and final weights consistently different. The slope of the graph 
appears to be reaching a plateau as the rats reached maturity. Although 
observation of the raw data indicates that individual rats occasionally did loose 
weight, the general trend overwhelmingly shows satisfactory and equivalent weight 
gain between groups. This in keeping with the findings of Bain and Wassef using 
the same does and route of administration 206.213 _
Levels of creatinine, alkaline phosphatase, AST and ALT were reasonably 
consistent within the experimental groups. In view of likely differences between rat 
and human values a number of control blood samples were taken from Lewis 
donor and experimental animals not receiving CyA. These blood samples were 
taken under identical conditions to those in the immunosuppressed rats. Only the 
results for AST were higher than expected. This may be normal for rats as 
indicated by the control blood samples. However could relate to the administration 
of general anaesthetic agents or to muscle damage associated with surgery and
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cardiac-puncture for blood sampling. Farthing also noted this. Levels of AST from 
28 control group rats ranged from 231 to 410 iu/l. These animals also had an 
inhalational anaesthetic. Farthing attributed these wide ranging levels to cardiac- 
puncturing. For his longer term experiment ALT instead. In that experiment there 
was no difference between control and experimental rat ALT levels regardless of 
CyA administration. The same was found here although the levels here were 
higher, on the other hand Farthings levels for alkaline phosphatase were higher. A 
significant rise in alkaline phosphatase was found using 25 mg and 50mg/kg after 
10 days of administration. The lower results here are consistent with the low does 
CyA (Smg/kg) administered in this experiment. This does has been widely because 
it provides satisfactory immunosuppression with reduced risk of toxicity 206.213,254
There was some general morbidity recognised from animal observations related to 
CyA use. The most striking associations were skin rashes and subcutaneous fluid 
collections. This latter finding was exclusively related to oCyA administration. While 
neither of these conditions were widespread within the CyA groups, their 
association with the length of time of the experiment cannot exclude the potential 
risk of these problems becoming more widespread with time. Midha also 
experienced similar injection site problems which resolved spontaneously. He 
associated this with high ethanol concentrations used in the preparation of CyA 
solution . Ethanol was also used to prepare CyA in these experiments. The 
small amount of morbidity related to right hind limb denervation was not 
unexpected. From the small numbers affected no conclusions can be made as to 
whether this could have been influenced by CyA administration or not.
As mentioned previously the majority of mortality was per-operative. Although 
attributed to general anaesthesia and the operative procedure, it cannot be ruled 
out from the data presented here that some contribution may have been made to 
mortality rates by CyA administration. These small female rats appeared less 
robust than their male counterparts (witnessed undergoing experiments in same
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facility). These rats required maintenance subcutaneous fluid and a higher 
recovery room temperature than the male rats (GA is known to reduce ability to 
maintain homeostasis especially temperature). Add to this the development of high 
peak CyA concentrations in such susceptible animals and the risk of mortality 
could easily be increased.
While the majority of authors publishing research on experimental nerve 
allografting acknowledge the ethical dilema posed by Immunosuppressant 
administration none supply much detail regarding their experiences of morbidity 
and mortality in their models other than that related to the nerve injury itself. 
However for human cases, MacKinnon with nerve allografts and Dubernard for 
upper limb transplantation site immunosuppressant associated morbidity leading to 
the cessation or alteration of Immunosuppressant therapy 224,231
The most significant mortality associated with CyA in these experiments relates to 
Infective episodes. Whether suddenly, or as euthanasia, two rats' deaths appeared 
related to infection. The scruff “abscess” case is the most clearly related death. 
Infection is also.associated with significant morbidity and mortality in human 
allotransplantation .
Concerns regarding CyA and immunosuppressants generally have encouraged 
researchers to investigate the hypothesis borne from the knowledge that as axons 
are host derived, once through the nerve graft material, the conduit function may 
no longer be required. Immunosuppression could stop with subsequent rejection of 
the allograft, leaving the host axons. This frequently studied phenomenon has not 
delivered completely clear-cut results . The timing of the duration of CyA 
administration has to be determined and the effect on ultimate regeneration 
established. The majority prefer target organ innervation to be underway or 
complete 153,209,216,233,267,325,327 Using electrophysiology, morphology and
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functional testing, an axonopathic process does follow immunosuppressant 
withdrawal. This is associated with donor Schwann cell loss and demyelination. 
However while some note no or incomplete recovery following the rejection assault 
123,125,195,204,210,212,247  ^ Qthors ropoil a full rotum of outcome indicators to pre CyA 
cessation levels 124,196,209,216,213,230 ^
Clinically, MacKinnon has the largest reported human series within the CyA era. 
She has had one failure due to subtherapeutic immunosuppression in seven cases 
over 10 years. FK506 has replaced CyA in the most recent cases. All of the 
patients were young (<24 years) and were immunosuppressed for a mean of 18 
months with no significant loss of function following immunosuppressant 
withdrawal. Although recovery following these serious injuries is sub-optimal, the 
patients have retained limbs where salvage was debateable. These patients 
maintain protective sensation, and some can mobilise unaided and play sports
217,224,225
The similarity between immunosuppressed and non-immunosuppressed groups for 
these long term experiments indicate little role for testing temporary 
immunosuppression within these models for either the simple or the sandwich graft 
procedures.
In summary, analysis of the different formulations of CyA used in this project 
indicate that both formulations were providing sufficient Immunosuppression. 
Although oCyA appeared to provide lower levels of immunosuppression than pCyA 
in the short term, this difference was not significantly different as seen in the longer 
term experiment. However on balance pCyA was easier to administer with more 
predictable bioavailability and less associated morbidity, but because of its reduced 
capability of producing depot effects, its activity would benefit from more frequent 
monitoring and dose adjustment than oCyA. This would be practically easier in a
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larger model, and essential to minimise morbidity and potential mortality in human 
allograft recipients.
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CONCLUSIONS
Reported in this thesis are the results of experiments to determine whether the 
strategy of increasing the autologous Schwann cell complement within a peripheral 
nerve allograft (PNAG) model could improve the regenerative potential of host 
axons through PNAGs irrespective of immunosuppression.
Historically much research has sought to improve the abysmal results following 
neurological trauma. Function is best achieved following repair of transected single 
modality nerves and poorest following delayed repair of proximal mixed nerves 
where a structural defect exists. Local to the peripheral nervous system research 
effort has concentrated around identification and manipulation of the local 
environment and structures required for axonal regeneration. Many conduit 
materials have been proposed, some showing promise, but as yet, autologous 
nerve grafting remains the standard in clinical practice. The reason being that only 
nerve tissue satisfies all the criteria of an ideal conduit: the Schwann cell basal 
lamina scaffold containing supportive non-neuronal cells, especially Schwann cells. 
Unfortunately, the supply of expendable cutaneous nerves is limited and 
associated with donor site morbidity.
Allogenic nerve shares these ideal conduit components but its morbidity lies with 
immunological rejection and the side effects of immunosuppressants. Ethically, 
PNAG is viewed at best sceptically.
Immunosuppressed PNAGs are known to produce results similar to autografts. 
Advocates of PNAG have attempted to improve regeneration while minimising 
immunosuppressant requirements by a variety of strategies, including temporary
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immunosuppression, rendering the grafts acellular and inducing donor specific 
tolerance. The latter has no clinical bearing and acellular conduits are generally 
inferior to autografts. The rationale for temporary immunosuppression is that axons 
are host derived, therefore once regeneration is established, the conduit function 
provided by the PNAG may no longer be required. However, results from 
temporary immunosuppression have produced conflicting results often related to 
methodology, while all agree that an axonopathic process follows 
immunosuppressant withdrawal.
Neuronal cell death secondary to trauma is partly responsible for diminished 
regeneration outcome. Early repair and restoration of neurotrophic influences are 
neuroprotective. Therefore a second assault from immunosuppressant withdrawal 
would be expected to negatively influence regeneration. For this reason, an “all or 
nothing" approach to immunosuppression was used here.
Schwann ceils contribute to nerve antigenicity and in other acellular models have 
been shown to improve regeneration, whether inserted as nerve portions, cell 
cultures, or by the addition of the neurotrophic factors they produce. We 
hypothesized that by inserting a segment of autologous nerve into a nerve 
aiiograft, forming a chimeric structure of mixed antigenicity the depot of autologous 
Schwann cells would aid axonal regeneration by improving Schwann cell migration 
into the rejection PNAG. Also without immunosuppression, as allogenic Schwann 
cells are destroyed, repopulation with autologous Schwann cells will render the 
graft non-allogenic and reduce the delay period affecting regeneration with 
beneficial effects on target organ reinnervation.
Initial experiments assessed the early regenerative potential of non- 
immunosuppressed PNAG. Although poorer in terms of rate and amount of 
regeneration, the pattern of regeneration followed that of non-antigenic groups.
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Increased macrophage staining and decreased Schwann cell staining were not 
witnessed in the immunosuppressed allografts group, indicating the poorer 
regeneration was reiated to an immunological response to allogenic Schwann 
cells.
Experiments using Sandwich allografts showed similar regeneration between 
groups regardless of immunosuppression and improved regeneration compared to 
simple non-immunosuppressed allografts. Schwann cells were qualitatively and 
quantitatively improved and macrophage staining reduced.
Long-term experiments further validated the use of Sandwich allografts. 
Assessment parameters were similar between all experimental groups. Neither 
lack of immunosuppression nor the extra neurorrhaphies appeared significant. 
While these results appeared to satisfy the aims and hypothesis of the thesis, they 
also raised some concerns regarding the project design, which have to be 
addressed before final conclusions can be drawn.
The rat strains empioyed were incompatible based on previous experience and 
evidence of rejection produced here. However, to further test the hypothesis 
comparing models of greater and lesser genetic disparity especially with larger 
defects requiring reconstruction would be beneficial and raise the chances of 
possible clinical application.
Two formulations of CyA were used in the project and both appeared to provide 
adequate immunosuppression. The parenteral CyA (pCyA) was associated with 
slightly improved results compared to the other groups. In view of the similarities in 
findings between groups, not only would use of a larger model make monitoring of 
immunosuppression simpler, but would also allow the Sandwich graft to be tested 
within iarger reconstructions. Also repeating the experiments using the newer 
generation immunosuppressants, whose use is suggested to positively influence
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axonal regeneration, may increase the difference in the regeneration achieved by 
immunosuppressed and non-immunosuppressed models, thus providing a more 
testing environment for the Sandwich graft.
Finally, since this project was completed the technology now exists to label 
Schwann cells so that their position and origin can be tracked. The ability to 
distinguish between host and donor Schwann cells directly is a major advance. 
Further work comparing the empirical, clinically achievable Sandwich graft with 
other conduit materials containing nerve segments and cultured autologous and 
allogenic Schwann cells would provide further evidence on Schwann cell function 
and antigenicity while allowing more opportunities to test the regeneration potential 
of allogenic nerve tissue.
While the unethical label attached to peripheral nerve allografting is difficult to shift, 
the recent advent of limb allotransplantation indicates that investigation of 
peripheral nerve allografting is still required if this surgical advance is to achieve 
any greater potentiai than just the technical feat.
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APPENDICES
Appendix 1 - Solutions
Zamboni's Solution
Solutions are mixed in the following proportions:
85ml 2% paraformaldehyde in 0.1% phosphate buffer (see below)
15ml saturated picric acid
For 2% paraformaldehyde, 20g paraformaldehyde is dissolved in 800ml 0.1% 
phosphate buffer with heat (max. 60°C), stirring until solution is clear. The volume 
is then adjusted to 1 litre and left to cool.
Saturated picric acid is added to make Zamboni’s solution which is stored at 4°C 
until use.
0.01 M Phosphate Buffered Saline (PBS)
Makes 10 litres
The following are added to 5 litres of distilled water, stirring until dissolved:
NaCl 87.9g
KH2PO4 2.72g
Na2HP0 4 (H2 0 ) 12 23.9g
Or Na2HP0 4  11.35g
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The resulting solution is then left for a few hours before adding the remaining 5 
litres of distilled water. After standing for at least 8 hours, the pH is checked and 
adjusted to pH 7.3 (NaOH/HCI).
PBS -  Sucrose
15% sucrose + 0.1% sodium azide in PBS (as above)
For 1 litre, dissolve the following in 700m! PBS:
Sucrose 150g
Sodium azide 1g
When dissolved, make up to 1 litre with further PBS.
0.1M Phosphate Buffer
Solution A 31.2g NaH2P0 4 .2 H2 0  dissolved in 800ml distilled water and
made up to 1 litre
Solution B 28.4g Na2HP0 4  dissolved in 800ml distilled water and made
up to 1 litre
Approximately 23ml of Solution A are added to 77ml of Solution B until the pH is 
7.2-7.4. The pH can be adjusted by adding small volumes of either solution as 
required. The solution is then diluted 1:1 with distilled water to give a 0.1M 
solution.
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2.5% Glutaraldehvde
25% electron microscopy grade glutaraldehyde is diluted with 0.1M phosphate 
buffer in a ratio of 1:9.
PBS + 0.2% Triton X
Mix 2ml of 0.2% Triton X-100 with 1 litre PBS
GIvcerol/PBS mountant
1g of 1,4-diaza bicyclo[2.2.2]octane is added to 4ml PBS and then mixed with 35ml 
glycerine.
0.05% Hydrogen Peroxide
Mix 0.175ml of hydrogen peroxide (AnalaR™, BDH Laboratory Supplies, U.K.) with 
99.825ml of distilled water, stir thoroughly.
0.1 M Sodium Acetate buffer
82.03g of sodium acetate is dissolved in 700ml of distilled water. The solution is 
made up to 1 litre then the pH is adjusted to 6 using NaOH or acetic acid.
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Antibody Diluent
For 100ml solution. Dissolve the following in 100ml of PBS:
Bovine serum albumin (BSA) 0.1 g
Sodium azide 0.1 g
Triton X-100 30ml
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Appendix 2 -  Glass microscopy slide preparation
Vectabond Coated Slides
Glass microscopy slides were treated in the following manner to enhance adhesion 
of the longitudinal tissue sections utilised here and prevent loss during the multiple 
steps and rinses involved in the staining techniques employed.
1. Slides were cleaned in dilute chromic acid and thoroughly rinsed in water.
2. Slides were immersed in acetone for 5 minutes, removed and thoroughly 
drained.
3. VECTABOND™ reagent was prepared by mixing 7ml with 350ml of acetone.
4. Slides were then placed in VECTABOND™ reagent treatment solution for 5 
minutes.
5. Finally slides were dried thoroughly at 37°C.
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Appendix 3 -  Semi-thin section staining
Acridine orange and thionin staining of semi-thin sections
Stain preparation:
Thionin 0.05g thionin is dissolved in 22.5ml absolute alcohol. 22.5ml 
of distilled water Is added plus 5ml of 0.1 M sodium hydroxide, 
and then filtered.
Fresh stain should be prepared for each staining run.
Acridine orange Prepare in a fume cupboard
Add 0.25g acridine orange to 20ml distilled water and 5ml 
0.1 M sodium hydroxide solution and heat gently to dissolve. 
Filter before use.
Staining method:
Dry glass mounted 1pm semi-thin sections on a hot plate. 
Flame the underside of the glass slide through a Bunsen 
burner flame to fix the section to the slide.
Stain with thionin for 45-60 seconds at 65-70'"C on the hot 
plate.
Wash well with distilled water.
Stain with acridine orange for 30 seconds at 65-70°C on the 
hot plate.
Wash well with distilled water and dry on the hot plate.
Mount in DPX mountant
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Appendix 4 -  Presentations to Learned Societies
British Association of Plastic Surgeons - Summer Meeting 2001
Sandwich Grafting: An Assessment of the Long-term Effects of this technique on 
Regeneration through Peripheral Nerve Allografts 
F.J. Hogg, C.J. Green, G. Terenghi.
British Association of Plastic Surgeons - Summer Meeting 1998
Sandwich Grafting: Can host Schwann cells improve regeneration through 
peripheral nerve allografts?
F.J. Hogg, C.J. Green, G. Terenghi.
British Association of Plastic Surgeons - Winter Meeting 1996
Is immunosuppression for peripheral nerve allografts necessary?
F.J. Hogg, G. Terenghi, C.J. Green.
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